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QUILL ON SCALPEL
This section provides a medium through which Canadian
surgeons can declare themselves, briefly and informally, on
the day-to-day affairs of surgery.

Important Modification of the Jejunoileal Bypass
Procedure for Morbid Obesity
The surgical management of the morbidly
obese patient has been the subject of often
bitter debate over the last 30 years. The
jejunoileal bypass, championed by Payne,
by Scott and by Salmon, has been
associated with high morbidity and the
occasional death. This has prompted a
renewed interest in gastric procedures for
such patients, procedures that also have
had their share of failures and complica
tions.
A novel approach to preventing bac
terial overgrowth in the defunctioned
loop, presented in this issue (pages 114 to
116) by Cleator and Gourlay, introduces
an innovation that may solve the
problems related to the major morbidity
of traditional jejunoileal bypass surgery.
In his m onograph on intestinal
bypass1 Mason stated, in 1981, “ If the
bypassed bowel could be emptied into
some sterile area so that it would not
become a receptor for bacterial over
growth, these problems would not arise.”
He was referring to the effects of bacterial
overgrowth in the bypassed segment

which resulted in excessive weight loss and
diarrhea, and hepatic, joint, skin and
electrolyte abnormalities. Cleator and
Gourlay present a well-studied series of
50 patients in whom the bypassed segment
was drained through the anterior wall of
the stomach, thus avoiding the bacterial
environment Mason described. The
weight loss in their series, together with
the lack of major side effects, is a stimu
lus to others interested in surgery for mor
bid obesity to duplicate their results.
When I arrived in Vancouver to head
the Department of Surgery at St. Paul’s
Hospital and found that jejunoileal
bypass procedures were still being done
in my department, my initial impulse was
to ask Dr. Gourlay to stop performing the
operation forthwith! But after observing
some of these patients on the wards and
the end results in others, I was quickly
convinced that the procedures, as modi
fied, had considerable merit. Dr. Gourlay
was encouraged to study a consecutive
series of cases thoroughly in order to
justify his enthusiasm for the procedure.
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Prophylactic Treatment of Stress Ulcers: First Do No Harm
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Just when we thought we understood
how to prevent stress ulceration in the
stomach without unpleasant side effects
in severely injured and septic patients,
nagging doubts have arisen. In the past
decade, clinicians from various disciplines
have noted a marked decrease in the fre
quency of stress ulcers and now surgery
is rarely required.1 Large surgical serv
ices operate on fewer than one patient
annually for stress ulceration with bleed
ing.2 M ost agree that the effective
prophylaxis — antacids and H 2 blocking
agents — account for this decrease. There
has also been an improvement in general
supportive care, but better overall survival
of seriously ill patients in intensive care
units has not been documented during
this decade. In fact, the death rate may
be higher in those receiving antacids or
cimetidine.3
The routine use of antacids or cimeti
dine in the intensive care unit is based on
excellent studies4,5 that have implicated
ischemia, with breakdown of the normal
defence capability of the gastric mucosa,
as the most important cause. These inves
tigators have emphasized the need to raise
the pH of gastric contents above 4 to
avoid hemorrhage.6' 8 Randomized trials
have been designed to evaluate the rela
tive efficacy of antacids versus cimetidine.
These therapies appear to be equally effi
cacious in reducing the incidence of bleed
ing and the requirement for transfusion.2
What information is there that ques
tions our practice of neutralizing stomach
acid in critically ill patients? In 1982 du
Moulin and colleagues9 reported on 60
patients in an intensive care unit, 52 of
whom had the same organisms cultured
simultaneously from both the upper air
way and stomach. Pneumonia due to
gram-negative organisms developed in 31
patients, and in most instances the organ
isms had been cultured from the stomach.
No pneumonia developed in eight patients
whose gastric and upper airway flora were
different. The number of gram-negative
bacilli in gastric aspirates in this study
increased logarithmically as the pH rose.
All patients were receiving antacids,
which likely encouraged bacterial over
growth in the stomach with colonization
of the airway from that source. Over
growth of pathogenic organisms in the
76

stomach with later transmission to the
trachea and development of pneumonia
has been reported previously.10
Patients who likely would have bled to
death from stress ulcers 10 years ago will
now survive for prolonged periods in the
intensive care unit, but many will suc
cumb to multiple organ failure. It has
been known since the first descriptions of
multiple system organ failure that this was
related to infection — sometimes occult,
usually intra-abdominal. Recently, it has
become apparent that a focus of infection
is not always found at the time of explora
tory surgery in patients with bacteremia
and multiple organ failure. The source is
not always revealed even at autopsy. In
other patients, adequate management of
a septic focus does not necessarily reverse
the organ failure or halt the bacteremia.
The microbial flora cultured from
patients who died of organ failure in the
absence of persistent peritonitis differs
from the usual flora of bacterial perito
nitis,11 suggesting that the phenomenon
involves mechanisms more complex than
the simple persistence of inadequately
controlled infectious foci. Organ failure
can develop in patients who enter the
intensive care unit with peritonitis, for
example after ruptured diverticulitis, and
the infections are most commonly caused
by Escherichia coli, Bacteroides fragilis
and Enterococcus. On the other hand,
infection acquired in the intensive care
unit and organ failure, which occur later
and are frequently not associated with pus
in the abdomen, are due to quite a diffe
rent group of organisms: Staphylococcus
epidermidis, Candida albicans and Pseu
domonas aeruginosa." Most deaths due
to multiple system organ failure occur in
patients with the latter group of organ
isms. Cultures of the upper gastrointes
tinal tract likewise reveal an overgrowth
of these same organisms.12
Normal gastric acidity is an important
component of the antibacterial defence of
the upper gastrointestinal tract. Loss of
this defence permits overgrowth of bac
teria and fungi and has now been shown
to predispose to pneumonia9 and multi
ple organ failure.12 The magnitude of the
overgrowth may cause translocation of
viable organisms across the mucosal
barrier.13

Altered proximal gastrointestinal flora
and translocation of organisms may also
contribute to the development of an
abnormal systemic immune response and
abnormal liver function. Marshall and
colleagues14 have shown that gram
negative pathogens entering the portal cir
culation from the gut can suppress the
immune response, rendering these infec
tions potentially more lethal. This appears
to be due to a direct stimulation of Kupffer cells.14 In a related experiment, a
Kupffer-cell preparation, when stimu
lated by endotoxin, markedly inhibited
hepatocyte protein synthesis.15
Is there any way we could avoid neu
tralizing acid in the stomach but protect
it in other ways to see if this might
decrease the frequency of ICU-acquired
multisystem organ failure? The most
promising avenue is the use of sucralfate,
which acts through pepsin absorption,
mucosal binding and cytoprotection, but
leaves acid production by the stomach
unimpaired.
Two prospective randomized trials on
the use of sucralfate in the intensive care
unit have now been completed. In the
first,16 patients receiving mechanical ven
tilation were randomly assigned to receive
sucralfate or antacids. The investigators
found that nosocomial pneumonia
occurred in 3 of 29 patients (10%) treated
with sucralfate, compared with 11 of
34 (32%) treated with antacids. In a
recent paper, Driks and colleagues17
studied the rate of nosocomial pneumo
nia in an intensive care unit among 130
mechanically ventilated patients who were
receiving as prophylaxis for stress ulcer
either sucralfate (61) or conventional
treatment with antacids or H2 blockers,
or both (69). The two groups were simi
lar in age, underlying disease and severity
of acute illness. Patients in the sucralfate
group had a significantly higher propor
tion of gastric aspirates with a pH less
than 4 and a significantly lower concen
tration of gram-negative bacilli in gastric
aspirates, pharyngeal swabs and tracheal
aspirates than did patients in the
antacid/H 2 blocker group. The rate of
pneumonia was twice as high in the
antacid/H 2 blocker group as in the
sucralfate group. Gram-negative bacilli
were isolated more frequently from the
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tracheal aspirates of patients with pneu
monia who were receiving antacids or H2
blockers and the death rate was signifi
cantly higher in this group.
Sucralfate may be given prophylactically (1 g every 6 h), suspended in 20 ml
of sterile water and administered by
nasogastric tube, which is then flushed
with 10 ml of sterile water to prevent clog
ging. Heating the water may aid in this
form of administration.
Pneumonia can occur in patients on
sucralfate medication. Gastric pH above
4 can also occur in this group and be
associated with bacterial overgrowth. One
of the reasons for this is enteral feedings
which can increase gastric pH and thereby
increase the risk of nosocomial pneumo
nia or translocation of bacteria, even
though the patient is not on antacids
or H2 blockers.18
The beneficial effects of sucralfate in
the intensive care unit have been
documented by randomized trial only in
respirator-dependent patients. Whether
this encouraging result will hold for all
patients in the surgical intensive care unit
remains to be proven, but the results to

date strongly suggest that this break
through will have wide application in the
treatment of seriously ill patients.
L loyd D. M ac L ean , m d , frcsc
Coeditor
Canadian Journal of Surgery
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Blood Is Thicker (and More Dangerous) Than W ater
The interesting observation that blood
transfusion enhances tumour growth was
first reported in 1955 in a mouse sarcoma
model.1 Recently, many studies, includ
ing that by Arnoux and colleagues in this
issue (pages 121 to 126), have examined
retrospectively the relation between blood
transfusion and survival in various groups
of cancer patients. The adverse effect of
blood transfusions on survival after resec
tion of rectal cancers is reported and the
effect is found to be dose-related. The
authors have previously demonstrated the
same effect in patients with colorectal
cancer, but the numbers in the previous
study were insufficient to permit separate
conclusions for those with cancer of the
rectum.
The evidence must be examined criti
cally, as important decisions for clinical
management must be made. Readers will
note the mounting evidence of the
deleterious effect of blood transfusion on
survival described in the literature review.
Arnoux and colleagues note the evidence
for decreased survival in patients with
colorectal cancer, breast cancer, softtissue sarcomas and cancer of the lung.
They could also have added similar evi

dence for patients with renal adenocarci
noma.2,3 In retrospective studies of this
kind, one is heavily dependent on confir
mation and consistency from study to
study to raise the credibility of the
hypothesis. In the case of colorectal
cancer, multiple consistent studies are
available as described by Arnoux and col
leagues, but in the case of breast cancer,
two other studies4,5 have failed to
demonstrate any deleterious effect of
transfusion on survival. The overall pat
tern, however, is of lower survival rates
in cancer patients receiving blood trans
fusion perioperatively than in those not
transfused. Transfusion has also been
shown to increase the risk of postopera
tive septic complications. The only good
news is the improvement of kidney sur
vival in patients given blood transfusion
before renal allograft transplantation. All
of these effects are consistent with the
hypothesis of immune suppression.
The mechanisms are not clear, but the
currently favoured hypothesis relates to
a general suppressive effect on cellmediated immunity. It has been shown
that blood group antigens are present
throughout the fetal colon, are usually

absent in distal colon in adults, but are
frequently re-expressed by cancers o f the
distal colon.6 The indictment of blood
transfusion makes biologic sense in this
framework, but the major criticism of all
the existing evidence is that those patients
who were transfused may have had more
aggressive disease or tumours that were
technically more difficult to resect. These
factors could be associated with increased
risk o f tum our spread during and after
surgery. This criticism cannot be laid to
rest without better stratification and
choice o f controls in the case control
design of studies. It is common for
authors to end with a plea for randomized
prospective studies, but that is simply not
a realistic option in trying to answer this
particular question. It would be unethi
cal and inappropriate to consider a ran
domized prospective design to investigate
the effect of blood transfusion on survival
following resection for colonic cancer. It
would be ethical and appropriate (but
clinically impossible) to carry out a study
comparing the effect of homologous and
autologous blood. It is not unusual,
however, to have a clinical question in
which the use of a randomized controlled
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trial is impossible. Further retrospective
case control studies are required, designed
to eliminate bias as much as possible. A
consistent trend in further studies would
eventually lead to general acceptance of
the hypothesis.
There are several reasons for the
progressive reduction in the amount of
blood transfused in surgery. We know
now that in patients with healthy cardi
ovascular systems hemodilution to a
hematocrit as low as 20% to 25% can be
tolerated as long as the blood volume is
adequately maintained. Transmission of
hepatitis virus is an ever-present risk and
there is now a high level of anxiety con
cerning transmission of the virus respon
sible for the acquired immune deficiency
syndrome (AIDS). Fear of AIDS has
reached the point at which many patients
make it clear that blood transfusion will
not be accepted under any circumstances.
We now have an additional reason to

minimize the amount of blood transfused
in surgery, namely the probable adverse
effect on survival from cancer. The
association is not yet proven beyond the
shadow of a doubt, but the evidence is
strong enough to make us review our
transfusion orders carefully. The extent
of the blood loss in relation to the
patient’s cardiovascular status may
demand transfusion, but before reaching
for the requisition, let us ensure that the
indications are strong.
C harles
FRCSC

J.

W

r ig h t , m b , c h

b, m sc,

Member,
Editorial Board,
Canadian Journal o f Surgery
Department o f Surgery,
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SESAP V Question
116.

Which of the following statements about severe pelvic fractures is NOT true?
(A)

Open pelvic fractures have a mortality of at least 50%

(B)

Peritonitis due to perforation of the colon or rectum is the major cause of death

(C)

A t least two major fractures or ligamentous disruptions will generally be present

(D)

When death results from hemorrhage, the usual bleeding source is from branches of the hypogastric arteries

(E)

Blood at the penile meatus associated with pelvic fracture should be evaluated with urethrography

For the critique of Item 116 see page 109.
(Reproduced by permission from SE SA P VSyllabus; Surgical Education and Self-Assessment Program No. 5. For enrol
ment in the Surgical Education and Self-Assessment Program No. 5, please apply to the American College of Surgeons,
55 East Erie St., Chicago, IL 60611.)
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To the editors.—Dr. Kuusk in this issue
of the Journal (pages 133 and 134) reports
an interesting and rare case of multiple
successive fibroadenomas that developed
in the left breast of a 14-year-old adoles
cent. In her discussion, she rightly stresses
that for patients with giant or multiple
fibroadenomas, local excision is usually
adequate and there is no recurrence of the
excised tumours. This is what is usually
seen in clinical practice.
In this particular case there were mul
tiple successive fibroadenomas represent
ing the ultimate expression of this dis
order where virtually all breast tissue is
transformed into massive yet benign
fibroadenomas.
I would like to emphasize that the need
for total mastectomy is not only because
of the large size of the lesions or in order
to remove all the lesions, but mostly
because if any breast tissue is left behind,
the condition will recur.

Luc Deschenes,

md, frcsc

tion to remove the main core with
attached side cores intact. Angiographic
studies also showed that branches were
not occluded by atheromatous debris and
intimal flaps.1
In an attempt to verify this histologi
cally, autopsy was performed on 45
patients who had recently undergone
coronary endarterectomy and bypass
grafting. The study did confirm the
absence of ostial occlusion by the “ snow
plough” effect in most cases. However,
we did encounter one interesting case in
which the ostium of a major side branch
of a recently endarterectomized right
coronary artery was obstructed by a typi
cal large residual intimal-medial flap (Fig.
1). The contribution of the side branch
occlusion to the patient’s early postoper
ative death of acute myocardial infarction
was, however, thought to be minimal in
the presence of a thrombosed distal right
coronary artery and graft.
Although early authors were correct in
predicting the possible occurrence of
occlusive intimal-medial flaps at the ostia
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of major coronary artery side branches,
the extremely low incidence, as shown in
this autopsy study, demonstrates that it
is not a major problem.

To the editors.—Manual endarterectomy
of the coronary system is a technique that
is used to improve blood flow in diffusely
atheromatous arteries that are to receive
aortocoronary vein grafts. It also pro
vides a better vessel wall for the graftartery anastomosis.1
Initial reports were concerned that the
removal of the atheromatous core from
the main artery would result in shearing
and occlusion of smaller side branches,
much as a snow-plough blocks side streets
while clearing main thoroughfares.2 Sub
sequently, this was not found to be a
problem, as it is possible by a combina
tion of careful dissection and gentle trac-

'.iA *

b ,A
■BPu .....

/

FIG. 1—Occlusion of ostium of side branch of right coronary artery by large intimal-medial
flap (arrow). Circumferential recent mural thrombus is present in artery. Inset shows flap at
higher magnification (Movat’s pentachrome stain, original magnification x 35, inset x 60).
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What's new in surgery is the subject of this column. The short items are designed to let readers know
who's doing what and why. Surgeons are interested in what other surgeons are doing in
research, education, practice and administration. Surgery is a vibrant specialty, and, as
its practitioners, you must be the source as well as the readers of this column.
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Heart Research in Ottawa
Surgeons at the University of Ottawa’s
Heart Institute recently performed the
world’s first coronary endarterectomy
using an excimer laser. The laser was
developed by Lumonics Inc., an Ottawabased laser manufacturer, with technical
and financial assistance from the National
Research Council of C anada. An
ultraviolet laser beam, transm itted
through a fiberoptic delivery system, cuts
away plaque deposits that have accumu
lated in the coronary arteries. An on-line
helium-neon laser that does not change
the properties of the excimer laser aids the
surgeon in threading the fibre through the
arteries and locating plaque.
An excimer laser is also being deve
loped that could be used for angioplasty.
An optical fibre contained in a catheter
would be inserted into a major artery
(such as the femoral artery) and threaded
to the coronary arteries and then used to

transmit a pulse of ultraviolet energy that
would destroy the plaque deposit. The
pulses of ultraviolet energy would allow
precision in cutting away plaque deposits
and a cooling time to prevent heat
damage to surrounding tissues.
Refinement of the laser’s use will be
one of the areas of study at the new heart
research centre at the University of
Ottawa’s Heart Institute. Other areas will
include further testing of the Jarvik-7
artificial heart and development of more
efficient power sources for it, develop
ment of a portable electromechanical
artificial heart and clinical trials of new
cardiovascular drugs. Two-hundred and
fifty researchers, technicians and support
staff will be employed in the 48 research
labs. Construction is expected to be com
pleted by December 1988.

Research Centre in Hamilton
Contributions to this column are welcome.
Please send your material to: Miss Laurel
Williamson, Canadian Journal o f Surgery,
PO Box 8650, Ottawa, Ont. K1G 0G8.

The creation of the Hamilton Civic
H ospitals Research Centre was

announced recently. The Centre was
developed jointly by the Hamilton Civic
Hospitals, the Hamilton Regional Cancer
Centre and the Faculty of Health Sciences
at McMaster University and will initially
be situated at Henderson General Hospi
tal. Dr. J. Hirsh, Professor and Chair
man of the Department of Medicine at
McMaster will assume the position of
Director of Research in July 1989. Dr. G.
Browman, Associate Professor of Medi
cine, will be the interim director.

Toronto’s Trauma Care
Capacity Increased
St. Michael’s Hospital, which now
treats approximately 150 trauma cases
annually, will, over the next 2 to 3 years,
be able to treat 300 to 350 trauma victims
a year. This is the latest step in the
development of Toronto’s integrated
trauma care system, a system that the
Metropolitan Toronto District Health
Council advised Ontario’s Ministry of
Health was required due to the size and
complexity of the Toronto area.
L aurel W illiamson
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NOTICES
Conference on Shock
Fontana, Wisconsin will be the site of the
Shock Society’s 11th annual conference
on shock, June 5-8, 1988. Symposia
include such topics as “ Organ Blood
Flow and Metabolism in Shock” and
“ The Effects of Endotoxemia in Humans
and in Experimental Septic Shock” . The
keynote speaker will be John J. Spitzer
of the Louisiana State University Medi
cal Center and workshops entitled
“ Animal Models That Simulate Circula
tory Shock in Humans: Fact or Fan
tasy?” and “ Use of Hypertonic Solutions
80
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for Shock Resuscitation” are planned.
For further information, contact: Dr.
Sherwood M. Reichard, Shock Society,
Medical College of Georgia, Augusta,
GA 30912, USA.

School of Medicine, Room 569-U, San
Francisco, California 94143 or calling:
(415) 476-4251.

Extended Programs in
Medical Education

Paris is the location of a symposium on
therapeutic progress in urological cancers
scheduled for June 29-July 1, 1988. For
details contact: Dr. Gerald P. Murphy,
Professor of urology, School of Medi
cine, State University of New York at
Buffalo, 139 Parker Hall, Buffalo, NY
14214; telephone: (716) 831-2338.

The University of California in San Fran
cisco is sponsoring a postgraduate course
in general surgery, Apr. 14-16, 1988.
Further information can be obtained by
writing: Extended Programs in Medical
Education, University of California

International Symposium

continued on page 104
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1987 Gallie Lecture. Quality Control in Surgical Research:
Importance to the Patient
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One of the deficiencies in surgical
scholarship is the rarity of timely, wellcontrolled research to evaluate new
operative procedures. The invasive
aspect of surgery makes randomized
studies more difficult to initiate, and in
studies with large numbers of participat
ing surgeons, the impact of unsatisfac
tory surgical expertise (craftsmanship) is
a major variable. In an effort to improve
surgical research, the use of quality con
trol data for early assessment of the
effectiveness of the operative procedure
is strongly recommended. Early postoper
ative studies of stimulated gastric acid
secretion have led to improved surgical
performance during trials of operations
using vagotomy for control of peptic
ulcer disease. Similar, early, quality con
trol studies have been effective when
investigating selective shunts for control
of variceal bleeding; necessary data
include shunt patency, portal perfusion
of the liver and obliteration of major portoazygous collaterals. Failure to incor
porate objective tests for surgical quality
control can lead to erroneous assess
ment of operations. Carefully planned
prospective studies of well-performed
operations are urgently needed.
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Une des carences de la science en chirurgie reside dans la rarete des projets de

* Whitehead Professor and Chairman,
Department o f Surgery, Emory University
School o f Medicine, Atlanta, Ga.
Presented at the 56th annual meeting o f the
Royal College o f Physicians and Surgeons
o f Canada, Winnipeg, Man., Sept. 13,
1987
Accepted f o r publication Nov. 26, 1987
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Reprint requests to: Dr. W. Dean Warren,
Department o f Surgery, Emory Univer
sity School o f Medicine, 1364 Clifton
Rd. N E, Atlanta, GA 30322,
USA

recherche bien controles et opportuns
visant a evaluer les nouvelles techniques
operatoires. Le cote sanglant de la chirurgie rend plus difficile la mise en route
d'etudes randomisees et, dans les etudes
necessitant la participation d'un grand
nombre de chirurgiens, I'influence d'une
expertise chirurgicale deficiente constitue
une variable majeure. Si Ton veut ameliorer la recherche en chirurgie, il est fortement recommande d'utiliser des donnees
de controle de la qualite afin d'effectuer
une evaluation precoce de I'efficacite de
la technique operatoire. Des etudes postoperatoires precoces de stimulation gastrique ont permis d’ameliorer I'execution
de I'acte chirurgical lors d’essais de tech
niques ayant recours a la vagotomie pour
traiter I'ulcere gastro duodenal. De meme
des etudes precoces de controle de la
qualite ont ete efficaces lors de recherches sur le choix des derivations destinees a soulager les hemorragies variqueuses; les donnees requises portent
sur la permeabilite des derivations, sur la
perfusion porte du foie et sur I'obliteration des principales collaterals porteazygos. Le defaut d'inclure des tests
objectifs de controle de la qualite de
I'acte chirugical peut entraTner une eva
luation erronee des interventions chirurgicales. Des etudes prospectives soigneusement planifiees d'actes chirurgicaux
bien faits sont requises de toute
urgence.

One of my concerns for the generic field
of surgery is the rarity of prompt,
accurate assessment of new operations
designed to extend or improve the qual
ity of life in our patients. There is cer
tainly no dearth of testimonials for new
procedures, often reporting a low opera
tive mortality and early improvement in
symptoms, comparing them to other
therapeutic modalities. However, most of
these papers present retrospective, uncon

trolled and incompletely reported data
from a group of selected patients.
In nonsurgical fields, recognition of the
need for intensified clinical science has
been extensively documented. The crucial
role of the controlled prospective ran
domized trial has received general accep
tance, and any current debate centres
around ethical considerations and metho
dology for implementing such studies.
The New England Journal o f Medicine
has played a major role in stimulating
interest in clinical trials, and there are now
several textbooks devoted wholly or in
part to this general field. There are,
however, few references to surgical trials
and the complex factors that are unique
to surgery. An illustration of the paucity
of such data is found in Fundamentals o f
Clinical Trials.1 There is but one indexed
reference to surgery and that is on a sin
gle page. It relates to difficulties in obtain
ing good data in relation to the efficacy
of coronary bypass surgery, one of the
most frequently performed operations in
the United States. This glaring defect in
the fundamental structure of surgical
science needs to be examined. As I have
considered these problems, three primary
difficulties have seemed to me most evi
dent: (a) disinterest of the surgeons, (b)
ethical questions specific for surgery and
(c) methodologic problems unique to
surgery.
I shall not consider the first two points
in detail today. There is little doubt that
threatened loss of income is a major fac
tor in inhibiting such studies. Cardiac sur
geons whose personal income is generated
largely from coronary bypass procedures
are rarely enthusiastic about randomiza
tion with a nonsurgical therapeutic inter
vention. The period of randomization
itself often results in reduced surgical
volume, and the ultimate analysis of data
could indicate the need for a permanent
realignment of the role of surgery in the
care of patients with coronary artery dis
ease. It should come as no surprise that
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most such trials will come from health
care systems in which surgical income is
unrelated to surgical volume or patient
entry into the system is through nonsurgical physician participants. An exception
to this rule is the recent exemplary effort
initiated and designed primarily in
Canada.2 Although the subject of heated
debate,3 this example should be of great
value in stimulating further work in all
surgical disciplines. Several papers in the
Mar. 27, 1987 issue of the New England
Journal o f Medicine address this issue.
The major ethical concern that tends
to inhibit investigations in which a surgi
cal procedure is randomly allocated is
rooted in the inability to “ correct” for
an inferior outcome. Drug trials are
usually readily managed with the placebo,
double blinding and crossover techniques.
In most instances, all patients in such
studies can look forward to receiving the
superior product once the results are
clear. Such is usually not the case with
surgical procedures, for obvious reasons.
Virtually all carefully considered analyses
of these issues have concluded that ran
dom surgical trials are not only ethical,
but sorely needed.
The focus of this paper will be on the
third impediment to excellent surgical
trials, methodologic factors unique to the
surgical disciplines that inhibit optimal
design.
Basic Scientific Methodology
Not Applicable in Surgery

There are several factors inherent in the
surgical discipline that prevent the utili
zation of some of the classic tools of clin
ical investigations.

Randomization o f the First Patient
The premise behind this concept is to
avoid the difficulty with which true scien
tific studies are initiated once seemingly
spectacular results are achieved with early
uncontrolled interventions.4 This is a
much debated issue in all fields of clini
cal study but in surgery is not really moot.
One must first learn how to do the oper
ation (laboratory animals are not the
same) and, second, determine if the
desired physiologic goals are achieved
(e.g., a marked reduction in stimulated
gastric acid secretion following vagot
omy). The point at which to institute con
trolled trials of new surgical procedures
versus older, standard ones, continues to
be a valid question. The technical require
ments of most new operative procedures
must be elucidated by experience and any
physiological changes sought by the new
procedure confirmed by objective test
ing whenever possible. If early studies
show that the operation fails to produce
the desired physiologic result, the opera
tion needs to be redesigned or abandoned,
not randomized. One frequently cited
example of an excellent and rapid analy
sis of a new procedure was that of gas
tric freezing for duodenal ulcer disease.
Appropriate studies confirmed dimin
ished gastric acid secretion in the period
immediately after freezing. Controlled
trials demonstrated failure to achieve
long-term control of the ulcer diathesis
and complications that rendered the
procedure useless if not harmful. Gastric
freezing for duodenal ulcer was quickly
abandoned.
Unique Requirements for
Definitive Surgical Trials

Placebo
Use of the placebo is well documented
in the clinical investigation of pharmaceu
ticals and a “ response” rate of about
20% to 25% is often quoted. The use of
a sham operation would be its equivalent
in surgical trials. A few such studies have
been done in the past but are neither prac
tical nor defensible for complicated, risky
surgical procedures.
Blinding
Here again a sound fundamental tech
nique to lessen the impact of bias is sim
ply not feasible for most surgical studies.
When certain aspects of “ quality of life”
are important end-points (e.g., severity of
dyspepsia), an independent observer can
be helpful. However, most surgical inter
ventions require specific knowledge of the
procedure by the patient and physicians
involved in postoperative care. Patient
safety as well as appropriate therapy for
symptoms and potential complications
rule out effective use of blinding.
82

Surgical Expertise:
Surgical Quality Control
A specific problem in the design and
evaluation of surgical trials is the varia
ble of surgical expertise (skills, craftsman
ship) possessed by individual participat
ing surgeons. This issue has clouded
interpretation of surgical studies for a
long time,5 but has been elucidated more
clearly by the excellent work of Johnston
and colleagues,6'7 Adami and colleagues8
and van der Linden.9 The basic question
concerns the validity of surgical trials
in which operative procedures are
improperly performed or do not achieve
reasonable standards. An excellent and
pioneering effort in this regard has been
the careful analysis of surgical perfor
mance in trials of vagotomy for duodenal
ulcer disease.6-8'10 In these patients
objective data can be obtained that make
feasible the early assessment of the effec
tiveness of the operation. Using insulinstimulated gastric acid secretion as an
indicator of the completeness of vagot

omy, several studies have addressed the
question of the importance of expertise
(craftsmanship) in surgical controlled
trials. The data provide convincing evi
dence that (a) substandard surgical per
formance is an important variable affect
ing the results of a trial, (b) failure to
achieve the surgical goals of the study
grows as the number of surgeons included
in the study increases, (c) training and
increased experience in a specific tech
nique improves operative performance
and (d) the knowledge that early testing
can identify an inadequate operation
improves the performance of the surgeon
and the quality of the study. From my
own experience, as well as study of the
efforts of others, I believe these observa
tions are correct and important in both
planning and evaluation of surgical trials.
The term “ surgical quality control” con
veys the essence of this Gallie Lecture.
The importance of such efforts to
upgrade surgical science, when doing clin
ical trials, has become more apparent in
recent years.
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When to Randomize:
Selection o f Participating Surgeons
There has been a good deal of debate
on this subject in reference to all clinical
trials, but I believe it is a much more cru
cial issue for operative (including radiologic and endoscopic interventions) than
nonoperative trials. As noted in studies
cited earlier,6' 10 the attainment of the
physiologic goal of an operation is more
certain when the surgeons are carefully
selected from those with real expertise in
the particular field of surgery and for the
specific operation being tested. Those
who oppose this approach cite the “ res
trictive” nature of the study and empha
size its lack of wide applicability or exter
nal validity. I believe the logical first step
in the evaluation of a new procedure is
to determine if there are significant
improvements in therapy when the new
operation is tested by “ experts” . If nega
tive findings are forthcoming (no
improvement or even harmful effects,
even with a high-quality control score),
there is obviously no need for wide appli
cation and a useless or dangerous
approach can be terminated. On the other
hand, if the new operation provides
superior results, its use should be
expanded with additional controlled trials
at different sites, with different patients
and different surgeons. This approach is
in agreement with that espoused by
Bunker and associates.11 The opposite
approach (trials with large numbers of
surgeons in many different hospitals) has
a confounding effect if no quality con
trol is instituted and the results are poor
or equivocal. Some randomized trials of
the selective-shunt concept to control
variceal bleeding illustrate this point.
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There are three primary goals inherent
in the selective distal splenorenal shunt
(SDSRS) design. The first is to prevent
variceal bleeding by decompression of the
varices in the gastroesophageal area. This
requires a patent shunt. The second fun
damental goal of the procedure is to
preserve portal venous perfusion of the
liver. The underlying hypothesis is that
continued portal perfusion of the liver
ameliorates the incidence and severity of
hepatic encephalopathy when compared
with operations that shunt all portal flow
around the liver. Effectiveness in this
regard requires (a) a patent portal vein
with a pressure high enough to perfuse the
liver and (b) obliteration of major col
laterals (portal azygous disconnection);
such collaterals divert portal flow away
from the liver. The third desired effect is

to maintain high intestinal venous pres
sure, which has been shown to ameliorate
encephalopathy further. This goal also
requires closure of the major collateral
veins.
There are, then, definitive early qual
ity control tests for selective shunt surgery
that include at least angiographic assess
ment of shunt patency, portal perfusion
of the liver and obliteration of the portalazygous collateral. Other important end
points include operative mortality, he
patic encephalopathy, rebleeding, ascites,
long-term survival and quality of life.
Two rigorous random trials testing this
hypothesis were carried out early, one at
Emory University12 and one at the
University of T oronto.13 A group of
three surgeons in each city carried out the
surgery, and the quality of the surgery
was high. Figures 1 and 2 show the results
of these two studies in assessing the rela
tive risk of encephalopathy between the
SDSRS and the total shunts. The similar
ity in the findings is striking. There was
a steadily progressive impact of encephal
opathy in the total shunt patients in each
study; there was a clear protective effect
in the SDSRS patients with a markedly
lower rate of encephalopathy. Note the
early rise followed by a pronounced flat
tening of the curve in the SDSRS groups.
This was present in each study and appar

FIG. 1—Emory University randomized trial
of selective distal splenorenal shunt (S) versus
mesocaval interposition shunt (NS). Note
markedly increased incidence of encephalopa
thy with patient nonselective shunt (p < 0.01).
Of great interest is shape of selective-shunt
curve, with steady increase for 2 years and then
long-term stabilization. Published by permis
sion from: M illikan WJ jr , W arren WD,
H enderson JM, et al: Ann Surg 1985; 201:
712-722, with minor modifications.
FIG. 3—Survival curve from Emory study
at median of 10 years. Published by permis
sion from: M illikan W J j r , W arren W D ,
H enderson JM , et al: Ann Surg 1985; 201:
712-722, with minor modifications.

FIG. 2—Toronto randomized trial of distal
splenorenal shunt (solid line) versus nonselec
tive end-to-side portacaval shunt (dashes).
Again, significant protection is seen with selec
tive shunt and both curves are almost identi
cal to those in Fig. 1. In addition, Toronto
group presented data showing encephalopathy
was less severe and quality of life higher in dis
tal splenorenal shunt group. Published by per
mission from: Lancer B, T aylor BR, M ack
enzie DR, et al: Gastroenterology 1985; 88:
424-429, with minor modifications.

FIG. 4—Toronto survival curve. Note cross
ing of survival curves in each study around 5
to 6 years. Solid line = selective distal
splenorenal shunt, dashes = portacaval shunt.
Published by permission from: L ancer B,
T aylor BR, M ackenzie DR, et al: Gastroen
terology 1985; 88: 424-429, with minor modifi
cations.

ently relates to an important physiologic
feature of even a well-performed SDSRS;
in patients destined to lose portal perfu
sion, this usually occurs within the first
postoperative year and frequently after
only a few months.
In contrast, a third trial, carried out in
six hospitals with 12 surgeons participat
ing, reached the opposite conclusion, that
no protection was provided against
encephalopathy by the selective shunt.14
With such a large number of surgeons
attempting to study a new and complex
operation, good surgical quality control
should have been an integral part of the
study but was not. In that study,
■documentation of shunt patency, portal
venous perfusion of the liver and col
lateral venous pathway occlusion was not
regularly obtained. Great emphasis was
given to a low operative mortality as the
validator of surgical quality, an errone
ous concept. I agree with Rutstein15 and
others16 in believing the most lamentable
human studies are those in which ran
domization is employed but the design of
the study makes the results uninterpreta
ble. A “ negative study” (no difference in
outcome between groups in a high-quality
trial) is a legitimate scientific achieve
ment!
Randomization o f New or Complex
Procedures
An additional role of surgical quality
control includes a more accurate assess
ment of a new, more complex procedure
versus a standard technique. Again, the
Toronto study13 has been an excellent
example of how to approach this type of
problem. In Toronto, the end-to-side por
tacaval shunt had long been the standard
approach for management of bleeding
varices when the controlled surgical trial
of the distal splenorenal shunt (DSRS)
versus portacaval shunt was initiated. The
first remarkable achievement of the
Toronto group was the performance of
all 40 portacaval shunts without any oper
ative deaths. In contrast, in the first 20
DSRS procedures there were five deaths,
a significantly higher operative death rate.
In the next 18 patients, however, there
were no deaths in the DSRS group,
emphasizing the principle that even excel
lent surgeons go through a learning phase
with new and complicated operations. Of
equal importance, and deserving special
note, the potential impact o f this
phenomenon on the results and interpre
tation of the study was discussed fully.
In the analysis by the authors, it was
pointed out that three of the early deaths
were due to learning-phase technical
problems; there were no operative deaths
in the last 31 patients randomized to
DSRS. Figures 3 and 4 show the survival
data of our two studies.
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A different approach was taken at the
University of Rome, when a trial of por
tacaval shunt versus a modified Sugiura
procedure was in stitu ted .17 Long
renowned in the portacaval shunting
field, the Rome group had limited
experience with nonshunting procedures.
The results in the nonshunt group were
so poor that the study was quickly termi
nated. In the discussion of this paper, it
was clear that the authors believed an
important problem was the superior sur
gical expertise they had in the shunt arm
of the study compared with the new non
shunt technique. The importance of
experience in a specific operation even for
highly trained and skilled surgeons has
been emphasized by van der Linden.9
Failure o f Therapy - Crossover
The question of crossover designs is
prominent in the current literature and is
a vital component of many clinical trials.
In surgery, the crossover technique is
usually not a planned step in the investi
gation; it is an option for use when
needed for patient safety. Often this is not
possible in surgery versus surgery trials,
but a potential impact is inherent in trials
such as sclerotherapy versus shunt sur
gery. There are now good data showing
that sclerotherapy is superior to simple
medical therapy (without sclerosis) for the
management of the acute variceal hemor
rhage. A continuing question of great
clinical importance is the effectiveness of
sclerotherapy in long-term control of
variceal bleeding when compared with
operative or other nonoperative tech
niques. To illustrate the use of a crossover
design — a method that requires deter
mination of failure of therapy and an
option offering another technique of
management — I will briefly present and
comment on some recent trials.
First is the Kings College trial18 of
sclerotherapy versus usual medical man
agement, which demonstrated the clear
superiority of the sclerotherapy technique,
with improved survival and greatly
reduced rates of death from rebleeding.
However, death from rebleeding con
tinued to be an important factor in each
group, with 25 in the control group and
5 in the sclerotherapy group dying as a
direct consequence of bleeding. In this
trial there was no option for shunt sur
gery, which was thought to be of little or
no value.
The second study is that of Rikkers and
associates,19 initially in Utah and now in
Nebraska, comparing the efficacy of
sclerotherapy versus shunt surgery for the
control of variceal bleeding. Rikkers, an
excellent surgeon, performed the opera
tions himself and achieved a good surgi
cal quality control rating. Survival in the
failed sclerotherapy group, however, was
not substantially enhanced by surgical
84

crossover. Ten of the 30 patients ran
domized to the sclerotherapy group failed
that therapy, but only 2 were managed
successfully by surgical intervention. This
appeared to be due, at least in part, to
severity of the liver disease, long distances
from a medical centre (patients entered
into the study could reside as far away as
500 miles) and the critically ill nature of
the patient when again seen by the sur
geon. This was a valid study with good
surgical quality control. It raises the ques
tion of the appropriateness of sclerother
apy when urgent return to the medical
centre, if needed, is not possible.
A third study is from Emory Univer
sity. Sclerotherapy (plus surgery when
needed) was randomized versus sur
gery.20 Those patients randomized to
sclerotherapy had a clearly superior sur
vival (Fig. 5). The major difference in our
results is summarized in Table I. Twelve
patients failed sclerotherapy and 11 were
crossed over (operated upon for bleed
ing); all 11 survived the operation and left
the hospital and 7 are still alive. Among
the important findings of our controlled
trial, not anticipated before the study, are
improved hepatic function in the
sclerotherapy group, safe return to the
medical centre and an operative death rate
no higher in sclerotherapy failure than in
patients originally randomized to surgery.
These important clinical events con
tributed to the superior survival in the
sclerotherapy group.
Some recently published data from the
Barcelona sclerotherapy versus shunt

FIG. 5—Emory University sclerotherapy
(EVS) versus distal splenorenal shunt (DSRS)
study. Survival is clearly enhanced in the EVS
patients (p < 0.01). Eleven patients crossed
over to surgery and 8 were still surviving
(arrows, Table I). Reproduced by permission
from: Warren WD, H enderson JM, M il
likan WJ, et al: A nn Surg 1986; 203:
454-462, with minor modifications.

Table l-Emory Randomized Sclerotherapy Group
Result
Rebleeding
Rebleeding to failure
of therapy
Death without surgery
Crossover to surgery

No. of patients
(n = 37)

%

21
12

57
32

1
11

3
29

study21 highlight a different point related
to the crossover principle. This study
experienced numerous exclusions from
the trial after randomization that were
primarily in the surgical group. The
authors concluded, from analysis of the
exclusion data, that sclerotherapy was a
simpler technique and must have much
wider applicability. Therefore, in the
absence of unequivocal superiority of the
shunt, it seemed reasonable to start with
sclerotherapy. From analysis of all these
trials, one could conclude that an excel
lent regimen for management of cirrhotic
variceal bleeding is sclerotherapy when
backed by accessible, and expert, surgery.
In concluding, I would like to consider
some important factors for analysis of all
clinical trials.22 First is the reliability of
the data. Is there a personal and institu
tional record of accurate publication of
data from well-designed and controlled
studies? Second, is the time period long
enough to experience most of the impor
tant events secondary to the intervention?
Third, are all the patients entered into the
study accounted for? Significant numbers
of patients lost to follow-up or refusing
treatment after randomization cast doubt
on the basic strength of the investigation.
Fourth, are there enough patients in each
arm of the study to allow identification
of real differences? One analysis of this
question (power) used 10 patients in each
study group as minimal, a surprisingly
small num ber.16 Finally, population
differences account for many of the
apparent contradictions in data between
high-quality trials. An illustration of this
point is seen in the greatly increased sur
vival of the nonalcoholic in the Atlanta
study, while this was not found in
Toronto. The small number of nonalco
holics in the trials could be important, but
in our evaluation of controlled surgical
trials, the pertinence of the patient popu
lation is always carefully considered.
In the final analysis, there are few sur
gical studies that meet all the desirable
goals of randomized trials. However,
increasing awareness of the vital nature
of such data should hasten this evolution.
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1. Injuries to the Urethra and Urinary Bladder Associated
With Fractures of the Pelvis
The posterior urethra or urinary bladder
may be injured in patients who sustain
fractures of the bony pelvis.
It is important to assess the urethra
radiologically by retrograde urethrogra
phy before introducing a urethral
catheter to avoid missing a urethral
injury or causing further damage. The
author's approach to the immediate
management of urethral injury is supra
pubic cystostomy. The urethra may be
repaired later after other injuries have
healed. With this approach the incidence
of permanent impotence and inconti-
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nence will be low and the stricture cure
rate high.
If the urethra has not been injured, a
catheter is introduced and cystography
performed to rule out bladder injuries. If
the bladder is ruptured, the area is
explored, the perivesical space drained
and urinary drainage is provided by either
a suprapubic cystostomy or a urethral
catheter.
Une blessure de I'uretre posterieur ou de
la vessie peur survenir chez les patients
qui subissent une fracture du bassin.
II est done important de faire I'examen
radiologique de I'ur&tre par uretrographie
retrograde avant d'y introduire une sonde
uretrale, et ceci afin d'eviter de manquer
une lesion uretrale ou de causer des
dommages supplementaires. L'auteur
aborde le traitement immediat des
lesions uretrales par une cystostomie
suprapubienne. L'uretre peut etre repare
plus tard, apres la gu£rison des autres
blessures. De cette facon, I'incidence de
I'impuissance et de I'incontinence permanentes est faible et le taux de guerison
des retrgeissements est eleve.
Si I'uretre n'a pas ete touchy, un
catheter est introduit et une cystographie
est effectuee afin d'eliminer la possibility

de lesions vesicales. S'il y a rupture de
la vessie, on explore cette region,
I'espace perivesical est draine et on
assure le drainage urinaire, soit par
cystostomie suprapubienne, soit par
cathetyrisme uretral.

Approximately 5% of patients who sus
tain fractures of the pelvis will have
associated injuries to the bladder, and a
similar percentage will have injuries to the
posterior urethra.
In this paper we outline our diagnostic
and therapeutic approaches to the
management o f these injuries.

Injuries to the Posterior Urethra
Posterior urethral injury is one o f the
most serious and challenging problems a
urologist is required to manage. Initial
mismanagement can incapacitate the
patient for life. The potential com plica
tions include severe strictures, repeated
lower urinary tract infections, recurrent
pyelonephritis, lithiasis, periurethral
abscesses and fistulas, urinary inconti
nence and sexual impotence. Some
patients may suffer renal failure if the
problem is not corrected.
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It is important to suspect this injury in
all patients with pelvic fracture. It occurs

more frequently when the anterior por
tion of the pelvic ring is involved. There
is often blood at the external urinary ure
thral meatus, but this is not a constant
finding. The bladder may be distended if
the patient has not voided for a few
hours. The patient is usually unable to
void and should be discouraged from try
ing to do so. It is important to rule out
injuries to the rectum and the possibility
of bony spicules projecting into its lumen.
The classic boggy mass described on rec

tal examination and the marked upward
displacement of the bladder and prostate
cannot always be relied upon as an indi
cation of urethral transection. It is pos
sible for the urethra to be markedly
stretched without disrupting. A retro
grade urethrogram is the final and most
important step in confirming the diagno
sis. The most suitable contrast is
intravenous urographic medium as it is
not uncommon for the fluid to enter dis
rupted vascular channels. Figure 1

FIG. 1—Retrograde urethrogram showing
loss of urethral continuity.

FIG. 4—Use of male sounds shows actual gap between severed ends of urethra. Although
ends are in close contact there is slight malalignment. Reconstruction in this case is easy through
short midline perineal incision.

FIG. 2—Combined cystogram and retro
grade urethrogram demonstrates complete
transection of posterior urethra.

FIG. 3—Combined cystogram and retro
grade urethrogram demonstrating length of gap
between severed urethral ends.
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FIG. 5—I Jrethroscope passed through suprapubic cystostomy opening to demonstrate exact
length of gap between severed urethral ends. Combined cystogram and retrograde urethrogram
indicates artificially long gap extending from bladder neck to proximal bulbar urethra. In fact,
gap is short, and although there is some malalignment, anastomosis is not difficult.
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demonstrates complete transection of the
posterior urethra with contrast medium
entering a vascular channel. The retro
grade urethrogram shows the urethral
injury but does not determine whether
there is complete or incomplete transec
tion of the lumen. Generally, however,
some contrast medium will pass into the
urinary bladder when the transection is
incomplete.
There are several alternatives in the
management of this injury. Because most
of these patients have sustained multiple
injuries, attention to higher priority sys
tems must be considered initially. The
urethral injury may be handled by
primary anastomosis of the severed

FIG. 6—Edges of proximal and distal ure
thra have been trimmed and spatulated.

FIG. 7—End-to-end anastomosis.

ends,1 primary realignment over a Foley
urethral catheter with traction to the
catheter to maintain the severed urethra
in continuity until healing occurs2 or the
severed ends may be held in contact by
the use of perineal sutures placed through
the prostate and tied over gauze in the
perineum.3 We have tried all the above
techniques and were not entirely satisfied
with the results. In a high percentage of
the patients, strictures developed and
some patients were incontinent and impo
tent. For these reasons, in 1965, we
changed our therapeutic approach.
Current Management
Once the diagnosis is confirmed by
retrograde urethrography, a suprapubic
cystostomy tube is placed in the dome of
the urinary bladder. Three months later,
elective urethral reconstruction is done for
complete transections. If the injury has
involved only part of the urethral circum
ference, the patient will usually void spon
taneously within 3 weeks and further
reconstructive surgery may not be neces
sary, but in some patients who have stric
tures an internal urethrotomy may be
required.
A suprapubic cystostomy at the time of
injury has the advantages of being easy
to perform and being a technique well
known to all urologists. The short oper
ating time required is important in the
patient with multiple injuries who may
require the services of several other
specialists. By avoiding manipulation of
the urethra it is possible to avoid the
danger of converting a partial rupture
into a complete one. Since the area is not
explored and infection is avoided, the
hematoma is usually absorbed with
minimal scarring, permitting urethral
Table 1-Results With Johanssen Technique4
(119 Patients)
No. (%)
Result
Complete rupture
105 (88)
14 (12)
Partial rupture
8
Healed without stricture
Successful internal urethrotomy
5
1
Urethral reconstruction
113 (95)
Continent without stricture
Stress incontinence
6 (5)
Reoperation for stricture
7 (6)
10 (8)
Impotence

Table I I - Results With Single-Stage Perineal
Spatulated End-to-End Anastomosis
(26 Patients)*
Result
No. (%)
Stricture cure
23 188)
Incontinence
0 (0)
Impotence
3 (1 1 .5 )
* All were complete disruptions; 3 patients in
whom procedure failed were cured by internal
urethrotomy.
FIG. 8—Completed anastomosis.
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reconstruction to be performed without
much difficulty. This approach also
results in a low incidence of permanent
impotence and urinary incontinence. In
addition, the external sphincter mechan
ism is not destroyed or bypassed.
Patients who have sustained a complete
transection of the posterior urethra are
generally suitable for urethral reconstruc
tion 3 to 4 months after injury. In some
cases this may be delayed because of other
injuries. When the patient is readmitted
for urethral reconstruction, combined
cystography and retrograde urethrogra
phy is done (Fig. 2). The bladder is filled
to capacity with urographic contrast
medium through the suprapubic cys
tostomy tube which is then clamped. With
the patient in the oblique position, con
trast medium is injected into the urethra
through the external meatus. During the
procedure the patient is instructed to bear
down in an attempt to void. This enables
some patients to open their bladder neck
and reveal the exact length o f the gap
between the severed urethral ends (Fig. 3).
Many patients, however, cannot open the
bladder neck to demonstrate the prostatic
urethra. In such cases, the length of the
gap between the severed urethral ends can
be determined by passing a male sound
(Fig. 4) or urethroscope (Fig. 5) through
the suprapubic cystostomy and gently
guiding it through the bladder neck down
the prostatic urethra until it meets the
point of obstruction. Another sound is
passed proximally along the urethra until
it meets the obstruction. A composite film
(Fig. 4) will demonstrate the gap between
the severed ends.
The urethroscope permits visualization
of the bladder neck and is the procedure
of choice if any difficulty is encountered
in introducing the male sound into the
prostatic urethra.
Figures 6 to 8 demonstrate the tech
nique of end-to-end spatulated anastomo
sis. The edges of the proximal and distal
urethra are trimmed and spatulated on
opposite sides, approximately 180° apart.
The anastomosis is accomplished (Fig. 7)
using 4-0 Dexon suture. An indwelling
urethral catheter is left in position for
approximately 2 weeks.
From 1965 to 1983 we performed a
two-stage scrotal flap urethral reconstruc
tion using mostly the technique of
Johanssen.4 In a few cases the TurnerWarwick method5 was used.
Table I shows the results using the
Johanssen technique of suprapubic
cystostomy4 followed approximately 3
months later by a two-stage urethral
reconstruction. This technique was used
in 119 consecutive cases. Of these, 105
were complete and 14 were partial ure
thral transections. After the two-stage
urethral reconstruction, 95% of the
patients were continent and cured of their
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strictures. Six patients complained of
stress incontinence. Because of restricturing, seven required repeat first-stage ure
thral flap reconstruction, which must
always be done before a second stage if
there is any narrowing. Of these 119
patients, 109 were sexually potent. The
follow-up ranged from 3 to 21 years.
Since 1983 we have managed all
patients with complete urethral transec
tion by a one-stage perineal end-to-end
spatulated anastomosis. Other techniques
described for the management of this
injury are the transpubic reconstruction
using a one-stage anastomosis6 or some
times a combined transpubic and perineal
one-stage repair.7 The latter two proce
dures are generally unnecessary and have
the potential to increase the complication
rate.
Table II shows the results using a onestage perineal spatulated end-to-end
anastomosis. They are similar to those
using the two-stage scrotal flap technique.
The one-stage method is technically less
demanding and requires one less opera
tion. We believe, therefore, it is the proce
dure of choice for reconstruction of com
plete urethral transection associated with
pelvic fractures.

Intraperitoneal rupture may also occur
with fracture of the bony pelvis, as in
18% of the 181 pelvic fractures with blad
der rupture studied by Prather and
Kaiser.8 In their series it was impossible
to determine whether the pelvic injury was
responsible for the bladder rupture. Prob
ably the traum a produced two indepen
dent effects — distension of the bladder,
producing intraperitoneal rupture, and a
crushing of the bony pelvis. Extraperitoneal rupture (Fig. 10) is usually seen in
association with fracture of the bony
pelvis. The urine escapes into the perives
ical tissues but not into the peritoneal
cavity.

Bladder Injuries

Contusion is an unimportant, non
penetrating injury of the bladder not
requiring treatment. Intraperitoneal rup
ture (Fig. 9) usually follows a blow to the
lower abdomen when the bladder is dis
tended. The peritoneal surface, not being
supported by bony or muscular struc
tures, is the weakest part, so these inju
ries occur in the posterior wall or fundus.

FIG. 10—This cystogram shows extraperitoneal rupture of bladder with contrast
medium in perivesical tissues. Smooth outline
of urinary bladder is obscured by escape of
contrast.

In the study of Prather and Kaiser,8
embracing 1798 patients with fractured
pelvis, 181 patients (10%) had associated
rupture of the bladder, 141 (82%) being
extraperitoneal, twice the rate of our
experience.
Bladder injury is unusual with isolated
fractures of the sacrum, coccyx, ileum or
acetabulum. It is seen more frequently
with fractures below the pelvic brim, par
ticularly the pubic rami and symphysis,
although sometimes severe distortion of
these bones may not cause injury to the
bladder.
Most extraperitoneal injuries to the
bladder occur on the anterolateral wall,
close to the vesical neck, and urine
extravasates to the prevesical space.
Combined intra- and extraperitoneal
rupture is relatively rare but may be seen
in patients with pelvic fractures. The diag
nosis is confirmed by a retrograde cysto
gram if the intravenous urogram is incon
clusive. With intraperitoneal rupture of
the bladder, dye accumulates in the
dependent portions of the peritoneal
cavity and in the paracolic gutters. With
extraperitoneal rupture, the opaque
medium should be evident in the pre- and
perivesical spaces (Fig. 11). The injury is
serious and treatment should be prompt
after the required attention, where neccesary, for shock, hemorrhage and higher
priority systems. The surgery is relatively
straightforward. At laparotomy, bladder
drainage is more important than precise
suturing of a laceration, but tears should
be closed if possible. Urine should be
aspirated, blood clots evacuated and
involved areas liberally drained. The
prognosis is excellent if the injury is
treated without delay.
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2. Hemorrhage and Pelvic Fractures
Hemorrhage is the major cause of death
in pelvic fractures. In closed pelvic
fractures the bleeding is usually self
limited. In the small number of patients
with continuing hemorrhage there may
be disruption of a major iliac vessel,
which will require immediate exploration
and repair. In a few patients continuing
hemorrhage is due to disruption of a
branch of the hypogastric artery, which
may be identified by angiography and
controlled by embolization. A manage
ment protocol is suggested for these
patients.
L'hemorragie est la principale cause de
deces dans les cas de fracture pelvienne.
Le saignement est habituellement contenu lors des fractures pelviennes fermees. Chez un petit nombre de patients
chez qui l'hemorragie persiste, il peut y
avoir rupture d'un vaisseau iliaque
majeur exigeant une exploration et une
reparation immediates. Chez certains
patients, l'hemorragie est due a la rup
ture d'un tronc de I'artere hypogastrique.
On peut en faire I'identification par
angiographie et on peut juguler I'hemorragie par embolisation. On propose un
protocole de traitement pour ces
patients.

sion. Eight patients had disrupted major
iliac vessels, usually the iliac veins. With
open pelvic fracture there is a greater
propensity for bleeding because there is
no tamponade effect from a closed
retroperitoneal space.
In recognizing the seriousness of
hemorrhage in pelvic fractures one must
consider methods of control. Most
patients with an undisturbed retro
peritoneal hematoma will have spontane
ous control of bleeding. External com
pression with the military antishock
trousers (MAST) as reported by Flint and
colleagues2 may contribute to this con
trol. This remains controversial, and seri
ous complications with the MAST have
been identified. The patient who con
tinues to bleed after initial resuscitation
and the exclusion of other possible causes

The importance of hemorrhage associated
with pelvic fractures as a major cause of
death has been emphasized by Rothenberger and colleagues,1 who reported a
12% death rate in 604 patients. Of the 72
who died, pelvic fractures were the
primary cause in 26, and 18 of these
patients died of exsanguination from their
pelvic injury shortly after hospital admis-

poses a major problem in management.
Ligation of the hypogastric arteries
enjoyed a period of popularity, but its
ineffectiveness was reported by Patterson
and M orton3 in 1973.
More recent reports4-6 have demon
strated the effectiveness of angiography
and catheter embolization for arterial
bleeding. The problem of timing of the
angiographic assessment remains con
troversial. Some aggressive investigators
such as Panetta and colleagues5 sug
gested that all unstable patients with a
negative peritoneal lavage and who
require more than four units of blood in
24 hours should be subjected to pelvic
angiography with a view to embolization.
The trauma unit at the Health Sciences
Centre in Winnipeg recommends angiog
raphy after 12 units of blood or continued
transfusion requirement after 18 hours
(Burns CM: Personal communication,
1986). We have had experience with
embolization in four patients and success
fully controlled the bleeding in three. An
example of arterial bleeding from the
internal pudendal artery with control by
embolization is shown in Fig. 1.
Occasionally, especially in open frac
tures, packing may be necessary to con
trol venous bleeding, but the packing
should be removed as early as possible to
reduce the likelihood of pelvic sepsis.
External or internal fixation may reduce
persistent venous bleeding from the frac
ture sites.
The rare case of major vessel injury
usually presents as exsanguinating hemor
rhage necessitating early laparotomy
without angiography. Repair of the iliac
arteries or veins may be life-saving.
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FIG. 1—(a) Selective angiogram of left inter
nal iliac artery demonstrates contrast extrava
sation (arrow), (b) Angiogram after success
ful embolization of internal pudendal artery
(arrow).
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Any institution receiving traum a
patients with pelvic fractures should have
a treatment protocol in place. The follow
ing is recommended for management of
hemorrhage associated with pelvic frac
tures (Fig. 2).
A patient with multiple injuries will ini
tially require general resuscitation. If the
patient remains stable after resuscitation,
the pelvic fractures can be treated as
required for orthopedic stabilization.
If, however, the patient remains unsta
ble after the initial volume replacement,
supraumbilical peritoneal lavage should
be performed. If the lavage contains
blood, celiotomy will be necessary and
appropriate treatment will be apparent.
The retroperitoneal hematoma should not

N

be disturbed unless it is pulsatile or there
is obvious disruption of major vessels
which require repair. If there is continued
blood loss after all other mechanical
bleeding has been appropriately managed,
angiography should be carried out. When
an arterial branch of the hypogastric
artery is identified as the bleeding site, dis
tal embolization with autologous clot or
Gelfoam should be performed. Usually,
this will control the bleeding. Only occa
sionally will bleeding continue, in which
case continued transfusions and replace
ment of clotting agents will be necessary.
External fixators or internal bony fixation
may be necessary to control bleeding.
Rarely will direct vessel ligation or pack
ing for venous bleeding be required.

ic o l a s
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3. Infectious Problems in Pelvic Trauma
Pelvic injury provides a challenge to the
trauma surgeon. Acute awareness of the
possibility of associated hollow-viscus
damage must be maintained to identify
these injuries and steps must be taken to
correct them. This article reviews the
current thinking concerning infectious
problems in pelvic trauma. With the
development of new and more-powerful
antibiotics, plus immunomodulators that
may correct the suppression of host
defences seen after pelvic trauma, there
may be an improvement in the number
and severity of septic complications that
occur following such injuries.
Les blessures pelviennes represented un
defi pour la chirurgie des traumatismes. II
faut savoir garder un sens aigu du risque
de retrouver des dommages associes aux
organes creux, si I'on veut reconnaftre
ces blessures et les traiter correctement.
Cet article fait le point de la situation sur
les problemes infectieux relie aux trau
matismes pelviens. Avec I'arrivee de
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nouveaux antibiotiques plus puissants,
d'immunomodulateurs capables de corriger la suppression des defenses immunitaires consecutive £ un traumatisme pelvien, il y a possibility d'une amelioration
du nombre et de la gravite des complica
tions infectieuses qui accompagnent ces
blessures.

Infectious complications of major pelvic
trauma relate to the type of trauma. Blunt
or “ crushing” pelvic trauma results from
motor vehicle accidents or falls from great
heights, and penetrating trauma from
sharp instruments or missiles. Combina
tions of the two types can occur and this
form of pelvic trauma is associated with
the highest morbidity and mortality.
The infectious sequelae of major pel
vic trauma are of two types — superfi
cial soft tissue and deep tissue. Superfi
cial infections, such as those of skin,
subcutaneous tissues, muscle and bone
(with open pelvic fractures) are usually
caused by exogenous pathogens. Deep tis
sue infections are usually due to endo
genous pathogens, secondary to rupture
of the bowel or the infected urinary tract.
Pelvic trauma may lead to breakdown of
environmental defence barriers such as
the skin and bowel mucosa. The trau
matic event also causes suppression of
both nonspecific and specific hostdefence mechanisms.1 If, in addition,
bacterial contamination of the wounds
occurs, the stage is set for infectious com
plications. Crushing pelvic trauma with
major disruption of the pelvic ring can
lead to severe retroperitoneal hemorrhage
and a high death rate in the period
immediately after trauma. If the patient

survives, the blood loss further com
promises host defences,2 again augment
ing the chance of infection.
The development of soft-tissue infec
tion caused by exogenous organisms in
major pelvic trauma depends on the
degree of skin breakdown and bone
exposure and also on the location of the
accident which can dictate the degree of
bacterial contamination. For example, an
open pelvic fracture sustained when the
patient is crushed by a tractor at a farm
carries a higher risk of infection than a
fracture sustained in a cleaner environ
ment. Sound surgical principles of trau
matic wound care must be applied to
reduce the chance of infection. Foreign
bodies, particularly bits of clothing,
should be removed. Dead skin should be
excised but not extensively as there may
be a need to cover exposed deeper tissues.
Dead muscle must be debrided until fresh
contractile bundles are encountered. Bone
is left alone unless there are small frag
ments in the wound that have lost their
blood supply. The following couplets can
be useful to the young surgeon who may
treat such wounds.
Of the edge o f the skin
take a piece very thin
The tighter the fascia
the more you should slash’er
O f muscle much more
till you see fresh gore
And bundles contract
at the least impact
Leave intact the bone
except bits quite alone
— Sir James Learmonth.
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Tetanus toxoid should be administered
to these patients. If there has been no
previous history of tetanus immunization,
human tetanus immune globulin (500 to
1500 units) may be given in addition.
Antibiotics against Clostridium tetani do
not prevent the infection; local initial
wound care is more beneficial. A booster
dose of tetanus toxoid vaccine must be
given. The development of the disease
itself does not provide immunization. The
neurotoxin is very powerful and the
amount required to cause the disease is
not enough to stimulate the host immune
system to synthesize antitetanus anti
bodies.
Antibiotics given prophylactically for
superficial wounds that do not involve
bone are of no benefit unless a dirty
wound is present, in which case the issue
is not prophylaxis but treatment. The
work of Miles and colleagues,3 elabo
rated later by Polk and Lopez-Mayor,4
has shown that prophylactic antibiotics
are effective in reducing wound infections
if given during “ the golden period” (i.e.,
adequate tissue levels of antibiotic must
exist before the infectious challenge).
Thus, in pelvic trauma the prophylactic
use of antibiotics is impractical. The
issues of routine antibiotic use in open
pelvic fractures, the mode of administra
tion (systemic versus topical), the type of
antibiotic and the dosage have not been
resolved.
With open and dirty pelvic fractures the
concern is to prevent osteomyelitis and its
subsequent morbidity and mortality.
Rothenberger and colleagues5 reported a
series of 604 patients with pelvic fractures,
22 (4%) of whom had open fractures. The
death rate for those with open fractures
was 50% compared with 10.5% for
closed fractures. The higher rate was due
to increased hemorrhage immediately
after trauma or to later infection. Perry6
also found that 31 (4%) of 738 patients
with pelvic trauma had open pelvic frac
tures, and of these, 13 (42%) died as a
result of hemorrhage or late sepsis. A cul
ture taken from the wound at the time of
initial assessment is most likely to yield
the organisms that will subsequently
infect the wound,7 usually a penicillinresistant Staphylococcus aureus. Antibi
otic use in open, dirty fractures is ther
apeutic. The antibiotic should be bacteri
cidal and should provide broad-spectrum
coverage against both gram-positive and
gram-negative bacteria. It should be capa
ble of producing suitable antibiotic con
centrations in the blood, the extracellu
lar fluids and the joint fluids. It should
be given immediately after the initial
assessment of the patient. The antibiotic
should be administered for 2 to 14 days
after trauma, depending on the clinical
situation and the surgeon’s preference.
Cefazolin, a first-generation cephalospo

rin, or cefoxitin, a second-generation
broad-specti um cephalosporin with bet
ter gram-negative and anaerobic bacterial
coverage, would be good choices.
Viscus injuries with blunt pelvic frac
tures are rare. Awareness will prevent
some of the serious infectious sequelae of
endogenous bacterial contamination and
subsequent abscess formation, which can
lead to fatal disseminated sepsis.
Penetrating injuries of the pelvis fre
quently involve pelvic organs such as the
bladder, urethra, vagina or rectum, the
last being the most lethal. Three thousand
years ago the Chinese used impalement
as an effective method of execution. Since
the latter part of World War II, the
accepted management of major rectal
wounds has been fecal diversion by a
completely defunctioning colostomy,
closure of the rectal wound when possi
ble, dependant drainage of the retrorec
tal space, irrigation of all feces from the
rectum, and systemic administration of
antibiotics. The improved results with
irrigation removal of retained stool in the
rectum were proven in the Vietnam con
flict.8 Associated urethral injuries have
usually been repaired primarily. More
recently, Cass9 suggested that the
management of posterior urethral injuries
is changing from primary realignment of
the rupture to suprapubic cystostomy
alone, followed later by surgery for the
resulting stricture. The main move in
preventing infectious consequences is the
provision for drainage of urine from the
bladder. Though the urinary tract may be
sterile initially, especially in men,
undrained urine collections contribute to
infectious complications.
The majority of related papers in the
medical literature state that “ systemic
antibiotics” should be given to patients
with penetrating or blunt pelvic injuries
that involve penetration into a pelvic
viscus. The type of antibiotic, the route
and especially the duration of administra
tion are as controversial as with open pel
vic fractures that do not involve a pelvic
organ. The type of antibiotic to be
administered directly after injury, in order
to reduce infectious complications, is
based on empiric therapy and should pro
vide adequate coverage against a broad
spectrum of organisms. Penetration of
the rectum will allow contamination with
bowel flora, most notably gram-negative
anaerobes such as Bacteroides fragilis and
other Bacteroides sp, aerobes such as
Escherichia coli and other Enterobacteriaceae, as well as gram-positive organisms.
In a woman with involvement of the
vagina, Clostridium sp, Bacteroides
bivius, Bacteroides disiens, Chlamydia
trachomatis and Neisseria gonorrhoeae
must also be covered. Cefoxitin, 2 g
intravenously every 6 hours for 5 days
after injury, provides coverage against

most of these organisms and has proven
effective in preventing these infections in
patients sustaining penetrating injuries of
the colon and rectum. This regimen pro
vides equal efficacy when compared with
the gold standard for broad-spectrum
coverage (i.e., an aminoglycoside plus
clindamycin).10 No randomized study of
prophylactic antibiotics in patients with
isolated pelvic trauma has been reported
in the literature. A recent study by Del
linger and colleagues11 has provided evi
dence that a shorter course of antibiotics
after penetrating colorectal injuries might
suffice. They randomized 116 patients
with confirmed penetrating injuries of the
colon or small bowel to receive either 12
hours or 5 days of antibiotics. Age, sex,
weapon, severity of injury and other risk
factors were evenly distributed between
groups. Infection developed in 28 (24%)
of the patients and it was trauma-related
in 21 (18%); 3 of the patients died. There
were no significant differences between
groups in any category of outcome. For
patients with penetrating intestinal or
colonic injury, a 12-hour course of antibi
otics was found to be as effective as a
5-day course and had the advantage of
lower cost and, theoretically, fewer side
effects.
If subsequent pelvic or systemic infec
tions occur, definitive treatment is based
on culture and sensitivities of the isolated
pathogens. Until such results are availa
ble, treatment Of life-threatening sepsis
from pelvic injuries is based on empiric
therapy. The most common organisms
Table I—Common Organisms in
Established Pelvic Infection
Aerobes
Gram positive
Enterococcus sp
Staphylococcus aureus
Staphylococcus epidermidis
Gram negative
Acinetobacter sp
Escherichia coli
Enterobacter sp
Klebsiella oxytoca
Klebsiella pneumoniae
Klebsiella sp
Lactobacillus sp
Pseudomonas aeruginosa
Pseudomonas fluorescens
Pseudomonas maltophila
Pseudomonas sp
Proteus m irabilis
Serratia sp
Anaerobes
Bacteroides bivius
Bacteroides disiens
Bacteroides fragilis
Bacteroides sp
Clostridium sp
Corynebacterium sp
Eusobacterium sp
M icrococcus sp
Peptostreptococcus sp
Others
Candida albicans
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found in established infections of pelvic
origin are set forth in Table I.
Single-organism bacteremias occur in
approximately 64% of cases, two or more
organisms in 33% and three or more
organisms in 11% of patients. The gold
standard of empiric broad-spectrum
antibiotic coverage is an aminoglycoside
such as tobramycin for the gram-negative
organisms such as Enterobacteriaceae and
clindamycin for the anaerobes and some
staphylococci. New third-generation
cephalosporins can be used in place of the
aminoglycoside, especially in cases of
renal failure. Cephoperazone, ceftazidime
or cefotaxime plus clindamycin or
metronidazole for Bacteroides sp can also
be used. Most of these regimens are now
undergoing efficacy trials against
aminoglycoside-clindamycin combina
tions. None of the above regimens covers
Enterococcus. Since the role of
enterococci as pathogens is not clear, they
should be covered if found in the blood
or as the only organism grown from pus
of an abscess cavity. A new antibiotic of
the carbapenam class, im ipenam cilastatin (Primaxin) has recently received
approval for use in the United States.
Trials are on-going in Canada and

approval for use is pending. This antibi
otic alone provides excellent coverage
against all of the organisms listed in Table
I, including Enterococcus, except for
Pseudomonas sp such as Pseudomonas
maltophila and Pseudomonas cepaciae.
Until culture findings and sensitivities are
available it may prove useful for empiric
broad-spectrum coverage in a patient in
whom the septic focus is the pelvis.
In summary, pelvic injury provides a
challenge to the trauma surgeon. Acute
awareness of the possibility of associated
hollow viscus damage must be maintained
to identify these injuries and take steps
to correct them. With the development of
new and more powerful antibiotics, plus
immunomodulators that may correct the
suppressed host defences seen after pel
vic trauma, we may see improvement in
the septic complications that occur fol
lowing such injuries.
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Presidential Address, 1987:
the Future of General Surgery in Canada
Manpower studies carried out by the
Canadian Association of General Sur
geons revealed a need for approximately
70 new general surgeons to enter prac
tice each year to replace those who will
discontinue practice for various reasons.
The Royal College of Physicians and Sur
geons of Canada certifies about 70
general surgeons each year; however,
two-thirds of these pursue further
specialty training, leaving only 20 to 25
to continue in general surgery. Training
programs in Canada are of variable
length and content. Less than half the
trainees have substantial research
experience. Programs designed to train
the comprehensive community general
surgeon are lacking in Canadian medical
schools and reductions in residency
training posts and other governmental
constraints may worsen the anticipated
shortage of general surgeons.
Strong leadership is needed to bring
together organized medicine, the surgical
specialties, universities and government
to address the training and manpower
requirements for general surgeons in
Canada.

Les etudes d'effectifs effectuees par
I'Association canadienne des chirurgiens
generaux revelent qu'environ 70 nou-
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veaux chirurgiens generaux devraient
joindre la pratique chaque annee pour
remplacer ceux qui quittent pour diverses raisons. Le College royal des medecins et chirurgiens du Canada agree
environ 70 chirurgiens generaux
annuellement; toutefois les deux-tiers
poursuivent leur formation en specialite,
de sorte que seulement 20 a 25 continuent en chirurgie generate. Les pro
grammes de formation au Canada sont
de teneur et de duree variables. Moins
de la moitie des stagiaires possedent une
experience de recherche appreciable. Les
facultes de medecine manquent de pro
grammes destines a former des chirur
giens generaux complets; les coupures
de postes de residents, ainsi que les
autres contraintes gouvernementales
sont susceptibles d'aggraver la penurie
anticipee de chirurgiens generaux. Une
direction forte devra etre exercee afin de
rallier medecine organisee, specialites
chirurgicales. universites et gouvernements afin de repondre aux besoins de
formation et d'effectifs de la chirurgie
generate au Canada.

program, the Royal College of Physicians
and Surgeons of Canada (Royal College).
On behalf of the CAGS, Dr. Ted
Mullens was asked to propose a defini
tion of general surgery that would reflect
the position of the association. He
reviewed the various definitions previ
ously prepared by other organizations and
sent a questionnaire to program directors,
chairmen of departments of surgery and
community surgeons in Canada. He
presented his report to the Education
Committee on Feb. 19, 1983, and the fol
lowing definition was adopted.
General Surgery is that field of surgical skill
that includes surgery of the Head and Neck,
the Alimentary Tract, the Chest, the Breast,
the Endocrine system exclusive of the pituitary,
the Trunk, soft tissues and limbs, and vessels
exclusive of the Heart. It includes the manage
ment and direction of the care of multiple inju
ries. In some circumstances it includes the spe
cial designations of the general thoracic
surgeon, vascular surgeon or paediatric sur
geon, to indicate special training and compe
tence in a restricted field.
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Surgical Manpower

I received a telephone call from a senior
general surgeon in Toronto 5 years ago;
he had positions available for two sur
geons (one senior and one recent gradu
ate) and asked if we had any candidates
for these jobs. I mentioned that the
University of Toronto graduated six
young men from their residency training
program the year before and all were suc
cessful in obtaining a fellowship in
general surgery. His response was that
each one was pursuing specialty training
and not continuing in general surgery.
This conversation heightened my con
cern about the future of general surgery
and stimulated my interest in surgical
manpower. Immediately, I encountered
the problem of the definition of general
surgery, an exercise that has also
interested the Canadian Association of
General Surgeons (CAGS), the American
Board of Surgery, the American Surgical
Association and, through its accreditation

The Canadian Association of General
Surgeons has been active in manpower
studies. The Federal-Provincial Advisory
C om m ittee o f H ealth M anpow er
report,1 published in 1985, predicted an
annual outflow from the general surgical
pool of 88 general surgeons each year
between 1981 and 1990 and 96 general
surgeons each year between 1991 and
2000. The committee used the Southam
medical data base which was the best
available at the time but which had many
shortcomings. In 1986, under the direc
tion of Dr. Frank Turner, the CAGS,
with the Royal College and the Canadian
Medical Association (CMA), carried out
a validation of the Physician Resource
Data Bank. This data bank provided a list
of 2683 “ general surgeons” . The chief of
surgery or director of every hospital in the
country was contacted by members of
Dr. Turner’s committee with respect to
the surgical staff, and 1517 (56.5%) of the
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2683 were confirmed to be practising,
fulltime general surgeons. An additional
204 surgeons were identified, giving a
total for Canada of 1721. It is estimated
that 20% of these will retire during the
next 5 years, requiring an inflow of 344
new general surgeons (70/yr) to replace
them, but that only 38 general surgeons
(Canadian graduates) would enter prac
tice, leaving a net deficit of 154 by 1991.
The problem is further compounded by
the fact that 20% of Canadian residents
in a number of surgery programs are
women and for various reasons their
productivity in the field compared with
men is rated to be only 70%. Changes in
life-style and attitudes also have an
unpredictable impact on manpower.
Development of the Surgical
Specialties in Canada

To understand changing trends in man
power, I thought it wise to look at the his
tory of the surgical specialties in Canada.
The Royal College of Physicians and
Surgeons of Canada was incorporated by
an act of parliament and received royal
assent on June 14, 1929. Its charter was
to encourage and assess postgraduate
training and to grant suitable diplomas.
The first examinations consisted of a
T a b le 1 - R e s id e n t s G r a n te d F e llo w s h ip
in G e n e r a l S u r g e r y , 1 9 8 5 a n d 1 9 8 6
R e s id e n ts

1 9 8 5 , n o . (% )

M a le

1 9 8 6 , n o . (% )

5 8 (8 9 )

F e m a le
T o ta l

5 3 (7 8 )

7 (1 1 )

1 5 (2 2 )

6 5 (1 0 0 )

6 8 (1 0 0 )

primary, similar for medical or surgical
candidates, which was a basic science
written examination and an oral exami
nation. In surgery a final examination
covered all of the field as was then
known. Although certificates of special
competence were approved in ophthal
mology, otolaryngology and urology in
1937, fellowships were awarded only in
general surgery and general medicine until
1947. The first 15 years of Canadian
Royal College activities, therefore, were
dominated by internists and general sur
geons. Dr. Patch, a urologist from M on
treal, suggested in 1940 that a modified
form of fellowship be considered for
those in special branches of the profes
sion. The Committee on Educational
Standards made this recommendation in
1944, thus introducing recognition of the
specialties in medicine and surgery. Nine
surgical specialties were issuing certifi
cates of competence by the early 1950s.
Cardiovascular and thoracic surgery was
added during the 1960s and pediatric sur
gery in 1976. The flood gates for sub
specialization (fragmentation in the opin
ion of some) opened at the beginning of
the present decade. A certificate of vas
cular surgery was approved in 1980 and
awarded in 1983. There is agitation in the
surgical community for certification in
colorectal surgery, surgical oncology,
intensive care, head and neck surgery,
transplantation and biliary pancreatic
surgery.
In its wisdom the Royal College has put
the issuing of new subspecialty certificates
of competence on hold and is examining
a program of accreditation without cer

T a b le I I - - C a r e e r G o a ls ( 1 9 8 5 - 8 6

C o h o r t)

A r e a s o f in te r e s t

No.

%

G e n e ra l s u rg e ry

44

33

C a r d io v a s c u la r /t h o r a c ic s u rg e ry

25

19

V a s c u la r s u rg e ry

12

9

T h o r a c ic s u rg e ry

10

7

O n c o lo g y

10

7

C o lo r e c t a l s u rg e ry

9

7

In t e n s iv e c a r e

6

5

P e d ia tr ic s u rg e ry

5

4

T r a n s p la n t a t io n

4

3

P la s t ic s u rg e ry

3

2

L iv e r /b ilia r y s u rg e ry

3

2

H e a d a n d n e c k s u rg e ry

2

2
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1985
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G e n e r a l s u rg e ry

69

73

O b s t e t r ic s a n d g y n e c o lo g y

66

59

O r th o p e d ic s u rg e ry

44

50

O p h th a lm o lo g y

43

34

P la s tic s u rg e ry

22

22

U r o lo g y

20

16

V a s c u la r s u rg e ry

17

11

O to la r y n g o lo g y

17

24

C a r d io v a s c u la r /t h o r a c ic s u rg e ry

14

11

N e u ro s u rg e ry

8

11

T h o r a c ic s u rg e ry

4

2

P e d ia tr ic s u rg e ry

2

0

tification. In fact, Dr. Ronald V. Christie
suggested to the Royal College Council
in 1965 that the College did not want the
central core of general surgery and inter
nal medicine to be “ nibbled away until
there is nothing left” . This position is
strongly supported by the CAGS.
The American Board of Surgery
recently issued a policy statement relat
ing to this suggestion. In July 1985, at a
meeting in Denver, the following state
ment regarding specialization and frag
mentation was developed.
The American Board of Surgery recognizes
that with the evolution and advancement in
medicine, specialization within the art and
science of surgery will occur. The Board makes
a distinction between specialization, which
occurs under the continuing aegis o f general
surgery and articulates with the whole, and
fragmentation, which is a separation and dis
articulation from the surgical corpus. The
Board makes this distinction to emphasize the
importance of preserving the primary compo
nents of surgery and yet recognizes the contri
butions of specialization in the overall objec
tive of quality care and training. The Board
believes that this is best achieved by adding
qualifications to the surgery certificate and not
by creating separate certificates or boards.

With this background, in 1986 I sent
a detailed questionnaire to the directors
o f general surgical training programs in
the 16 Canadian medical schools. Not
only did all complete the questionnaire,
but most added editorial comment either
in the form of a letter or notes appended
to the questionnaire itself. The question
naire showed that 65 residents received
their fellowships in general surgery in
1985 and 68 in 1986. Of those in the 1986
cohort 20% were women (Table I). I was
not surprised to learn that two-thirds (45
[66%] in 1986, 44 [68%] in 1985) of those
receiving their general surgical fellowships
planned further certification, which
means that only one-third (21 [32% ] in
1985 and 23 [34%] in 1986) intend to con
tinue with general surgery.
Table II sets forth the career goals of
the 133 Canadian general surgeons receiv
ing fellowships during 1985 and 1986.
The certificates granted to successful
candidates by the Royal College in all
specialties appear in Table III. I have
listed the surgical specialties in numeri
cal order. There is a slight variance
between the results of my survey and that
of the Royal College, possibly because
Royal College figures include nonCanadian graduates.
If we substitute for the number of cer
tificates granted in general surgery in 1985
and 1986 (69 and 73), the number of resi
dents (fellows) planning to continue to
specialize in general surgery (21 and 23),
we find that the number is similar to those
entering urology, plastic surgery, vascu
lar surgery and otolaryngology.
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Training Programs in General Surgery

Training programs in general surgery
vary both in structure and content across
the country (Table IV).
Five programs offer 5 years of general
surgical training after internship and the
others offer 4 surgical years after either
a straight, rotating or comprehensive
internship. All program directors felt that
5 years of surgical training after intern
ship is desirable and I believe this will be
recommended — however, problems of
funding will inevitably arise.
Research Experience in
Training Programs

Fraser Gurd has written a stimulating
and challenging essay entitled “ Scholar
ship and science, and the Royal Col
lege” .2 The Council of the Royal College
has decided to increase its commitment
to involve trainees in biomedical research
and to place more emphasis on science in
training programs. This approach is to be
highly commended, since in this age of
rapidly advancing technology we must
graduate true professionals who have the
intellectual tools to seek new knowledge
and incorporate it into their professional
activities.
Current resident research experience in
our 16 programs indicates that in 1985
and 1986, only half our general surgical
trainees had research exposure (Table V).

The Future of General Surgery
in Canada

We will soon enter our third decade of
universal health care in this country.
There has been a slowly progressive and
inevitable increase in government control
of our training programs and in the way
Table IV—Training Programs in
General Surgery in Canada*
Comprehensive (6)
Rotating (5)
R1
R1
R2
R2
R3
R3
R4
R4
R5
Rotating (4)
Straight (1)
R1
R2
R2
R3
R3
R4
R4
R5
'Numbers in brackets indicate no. of medical
schools.
Table V—Residents' Exposure to
Research Experience
Exposure
1985, no. (%)
1986, no. (%)
1 yr
26 (401
28 (41)
6 mo
4 (6)
5 (7)
None
35 (54)
35 (51)
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we practise. Most provinces have reduced
the number of residency posts available,
some quite severely. The amount of
research money available from the Med
ical Research Council of Canada has been
eroded to the point where only 10% of
the applications for new research grants
were funded last year. University hospi
tals in some provinces are grossly under
funded and a formula recognizing that
these tertiary care teaching institutions are
important health care resources, requir
ing a premium of their budgets, is not
universal. In Quebec, the government has
attempted to control the distribution of
health care professionals by reducing the
income of young surgeons in urban areas
while augmenting it in rural areas. Limit
ing billing has been used in British
Columbia to control the numbers of phy
sicians practising in a given area. Health
care planners have determined the opti
mum number of practitioners for institu
tions and have thus limited the positions
available. They unfairly blame physicians
for the high cost of health care and would
further limit our ability to provide stateof-the-art care to patients. Hospital
deficits are being met by the closure of
hospital beds while administrative staff
and bureaucracy seem to expand. In Que
bec, 20% of beds in some acute-care
hospitals must be occupied by chroniccare patients. Our numerous medical
associations seem disorganized, frag
mented and complex, and react to rather
than participate in the planning of events
that have an impact upon us all. Data on
surgical manpower lack guidelines and
there is no specific body charged with
overall planning and development.
Although for the profession the picture
seems gloomy, surgeons do have an
opportunity to influence change and to
some degree control their destiny — if
aggressive leadership is shown. The
general surgeon must survive because his
strength is his comprehensive training and
approach to patient care. It is clear that
further subspecialization will occur but it
must do so within general surgery, so that
those who obtain additional training in
specific areas will remain general surgeons
in concept and in outlook. Residency
training program committees, under
suitable directors, should design our pro
grams for the educational needs of the
candidates. These committees should
recognize that it is more advantageous to
preserve surgery in general than to des
troy it with increasing fragmentation. If
the foundation and pillars of surgical
training in general are weakened, the tem
ple will collapse. The following three
training programs might be offered by a
large university department:
• Two core years of surgery in
general, to include urology, obstetrics and
gynecology, otolaryngology, and possibly
orthopedics and neurosurgery.

• Two core years of surgery in
general, 1 year of research and 2 more
years of general surgery, to include cardi
ovascular and thoracic surgery, plastic
surgery, vascular surgery, thoracic sur
gery, colorectal surgery, pediatric surgery,
oncology, head and neck surgery, inten
sive care procedures and academic general
surgery.
• Two core years of surgery in
general, 1 year of research, 2 years general
surgery and 1 comprehensive year for
community general surgery.
The specialty should select residents
before they enter training, and the pro
gram should be designed and tailored to
the needs of the trainee for his future
specialty. The academic general surgeon
would require 2 additional years of
research at the end of his surgical train
ing. The community surgeon, if he knew
by the final year where he intended to
practise, could tailor his training during
that year to meet the surgical problems
he would likely encounter there.
In the future, I think, a network of
hospitals and health care facilities should
be developed, with a major tertiary care
centre (a university teaching hospital) at
the core of the organization. Residents
going out to practise in a community
would establish and maintain contact with
the university hospital for consultation,
transfer of tertiary care patients and con
tinuing medical education. They would be
encouraged to return to the university
hospital to acquire skills they lacked or
to upgrade existing skills. If they wished,
they could participate in the care of their
patients with complex problems at the
health care centre. In some cases, the ter
tiary care staff might spend periods of
time at the outlying hospitals.
I think there are exciting challenges for
general surgery in the future. Sub'specialization is a good thing for patient care, for
teaching and for stimulating research.
Our challenge is to stop fragmentation
while encouraging specialization. Most of
all we must have an organizational struc
ture that allows us to examine these
problems, to react to them, to anticipate
future needs and to show leadership.
In my view and my experience, the
CAGS from its inception has reduced
fragmentation while encouraging speciali
zation and continues to grow in influence
and strength. We should actively cooper
ate with the Canadian universities, the
Royal College and governments in this
regard. I thank you for the honour of
being your president. I thoroughly
enjoyed my tenure.
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Prevention of Intra-abdominal Abscesses
With Fibrinolytic Agents
Fibrin deposition during secondary perito
nitis predisposes to abscess formation by
protecting bacteria from host-defence
mechanisms. To test the hypothesis that
local fibrinolytic therapy can prevent the
formation of intra-abdominal abscess,
daily injections of the fibrinolytic
enzymes trypsin and tissue plasminogen
activator (t-PA) were administered
intraperitoneally to Wistar rats inoculated
intraperitoneally with infected fibrin
clots. After 5 days, trypsin (1 mg/ml)
had significantly Ip < 0.001) reduced
abscess formation in animals inoculated
with monomicrobial Bacteroides fragilis
clots (2 0 % versus 8 7 % ) or mixed
Escherichia coii-B. fragilis clots (1 1 %
versus 9 1 % ). Bacteroides fragilis
abscesses were also completely
prevented with t-PA (0.25 mg/mi). The
number of B. fragilis organisms present
in residual abscesses in the trypsintreated group was significantly (p <
0.05) lower than in the control group
(8.2 ± 0 .2 , n = 7 versus 5.7 ± 1.4, n
= 4, log CFU/g abscess). In-vitro studies
demonstrated that trypsin had no bac
tericidal effect on B. fragilis. suggesting
enhanced clearance of bacteria. From
these studies it appears that controlled
fibrinolysis at operation may be a useful
adjunct to surgery and systemic antibi
otics in preventing abscess formation
postoperatively.
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Durant une peritonite secondaire, le
depot de fibrine cree un terrain favorable
a la formation d'abces en protegeant les
bacteries contre les defenses immunitaires de I'hote. Dans le but de verifier
I’hypothese voulant qu'un traitement
fibrinolytique localise puisse prevenir la
formation d'abces intra-abdominaux, des
injections quotidiennes d'enzymes fibrinolytiques, trypsine et activateur du plasminogene tissulaire (t-PA) ont ete administrees par voie intraperitoneale a des
rats Wistar a qui on avait inocule dans le
peritoine des caillots de fibrine infectes.
Apres 5 jours, la trypsine (1 mg/mL)
avait reduit significativement (p < 0.001)
la formation d'abces provoques par des
caillots monomicrobiens de Bacteroides
fragilis (2 0 % contre 8 7 % ) ou des caillots
mixtes de Escherichia coii-B. fragilis
(1 1 % contre 9 1 % ). Les abces a B.
fragilis ont aussi ete completement
prevenus par le t-PA (0.25 mg/mL). Dans
le groupe traite a la trypsine, le nombre
de B. fragilis present dans les abces residuels etait significativement (p < 0.05)
inferieur a celui du groupe temoin (8.2 ± 0.2,
n = 7 contre 5.7 ± 1.4, n = 4, log VCF/g
d'abces). Des etudes in vitro demontrent
que la trypsine ne possede aucun effet
antibacterien contre B. fragilis, ce qui
indique une augmentation de I'extraction
des bacteries. Ces etudes indiquent
qu'une fibrinolyse controlee durant I'operation peut etre, avec les antibiotiques
systemiques, un appoint therapeutiques
utile a la chirurgie pour prevenir la forma
tion postoperatoire d'abces.

The deposition o f fibrin after bacterial
soiling o f the peritoneal cavity is an
important defence mechanism, as it
entraps bacteria, thereby preventing sep
ticemia and death.1'2 As a consequence
o f this containment, however, the protec
tion from host defences afforded by the
fibrin mesh predisposes to abscess forma
tion.2-3 Clinically, postoperative intra
abdominal abscesses frequently represent
a source o f continued sepsis that may ulti
mately lead to multisystem failure and
death. In combination with modern sur
gical techniques and antibiotics given

intravenously, an agent capable o f
preventing residual abscess formation
could potentially improve the morbidity
and mortality associated with peritonitis.
The purpose o f the present study was to
determ ine whether in trap eriton eal
fibrinolysis, accomplished with fibrino
lytic enzymes, could prevent intra
abdominal abscesses from forming in a
clinically relevant infection model.

Materials and Methods
Growth and Culture o f Microorganisms
A clinical isolate o f Escherichia coli has
been used repeatedly for experiments by
one o f us (O .R .).3'4 It is maintained at
- 7 0 ° C in brain-heart infusion broth
(B H I; Difco Laboratories, Detroit, Mich.)
in 10% glycerol. Daily preparations o f E.
co li were made by inoculating 30 ml o f
B H I with a loop sample from a stock
plate. A fte r incubation at 37°C for 18
hours in a shaker bath, the bacteria were
washed three times by centrifugation at
1600 g for 10 minutes and resuspended
in sterile isotonic saline. Approximate
numbers o f bacteria were estimated by
densitometry and exact enumerations
were established by viable colony count
ing on nutrient agar plates (Difco Labora
tories). Bacteroides fragilis V P I 9032 was
provided by Dr. Tracy Wilkins, Virginia
Polytechnic Institute, Blacksburg, Va.
Stock cultures o f this bacterial strain were
maintained at - 7 0 ° C in thioglycolate
broth (BBL Microbiology Systems, Cockeysville, M d.). Frozen cultures were
thawed and 0.5-ml aliquots were inocu
lated into tubes containing 30 ml o f
minimal growth media as described previ
ously.5 The tubes were incubated for 18
to 20 hours at 35°C in an anaerobic
chamber (Forma Scientific, Marietta,
Ohio), which maintained an atmosphere
o f 85% nitrogen, 10% hydrogen and 5%
carbon dioxide.
For inoculation into fibrin clot, the
B. fragilis culture was removed from the
anaerobic chamber, pelletted by centrifu
gation (1600 g for 10 minutes) and
resuspended in prereduced H ank’ s
balanced salt solution (HBSS; Gibco,
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Grand Island, NY), supplemented with
0.05 mg/dl cysteine hydrochloride (Sigma
Chemical Company, St. Louis, Mo.). To
quantitate viable bacteria, resuspended
B. fragilis were surface-plated on sup
plemented BHI agar and counted after 48
hours of incubation at 35°C.
Incorporation o f Bacteria
into Fibrin Clots
Human fibrinogen (Sigma Chemical
Company) was dissolved in calcium-free
Dulbecco’s phosphate-buffered saline
(PBS; Irvine Scientific, Irvine, Calif.) and
pore-limit dialyzed with 10 000 MW
cutoff overnight to remove sodium
citrate. The fibrinogen was sterilized by
ultraviolet irradiation and the concentra
tion adjusted to 100 m g/dl with PBS.
Thrombin (Parke-Davis, Morris Plains,
NJ) was suspended in distilled water to
a concentration of 30 IU/ml. In the
anaerobic chamber, 1.4 ml of fibrinogen
was added to the 75 x 12 mm polysty
rene tube. Either B. fragilis (2 x 109
CFU) alone or a mixture of B. fragilis (2
x 108 CFU) and E. coli (2 x 106 CFU)
were added to the fibrinogen solution. A
0.2-ml aliquot of thrombin was then
added to each tube to clot the mixture.
The final volume of the fibrin clot was
2 ml.

Fibrin Clot Rat Peritonitis Model
Male Wistar rats, weighing 200 to 250
g each, were inoculated intraperitoneally
(ip) with infected clots as described previ
ously.6 Beginning at surgery, daily 5-ml
injections of PBS, trypsin in PBS (Sigma
Chemical Company, 0.25 to 1.0 mg/ml)
or 4 ml injections of tissue plasminogen
activator (t-PA, 0.25 mg/ml) were
administered ip. The t-PA was kindly
provided by Dr. Michael Shepherd,
Genentech Inc., San Francisco, Calif.
Animals were weighed daily and deaths
monitored.
Quantitation o f Viable Bacteria
in Abscesses
On day 5, rats were killed by carbon
dioxide asphyxiation. The peritoneal
cavity was inspected for the presence of
abscesses, characterized in this model by
the presence of a single walled-off collec
tion of purulent material. The abscess was
aseptically excised, weighed and carefully
minced into a tube (containing prereduced
HBSS and sterile glass beads) held under
a VPI anaerobe apparatus.7 The tube
was stoppered, vortexed and transferred
to the anaerobic chamber. The tube con
tents were serially diluted in prereduced
HBSS and surface-plated in duplicate on
supplemented BHI agar and nutrient
agar. The supplemented BHI agar plates
were incubated anaerobically at 35°C for
48 hours and the nutrient agar plates were
incubated aerobically at 37°C for 24
hours. The number of viable bacteria
(CFU) were quantitated and these num
bers were transformed to log 10 values.
Statistics

FIG. 1—Effect of trypsin on abscess forma
tion induced by clots infected with Bacteroides fragilis. Starting at surgery, animals were
injected intraperitoneally each day with
phosphate-buffered saline or trypsin at various
concentrations. On day 5, animals were killed
and peritoneal cavity was inspected for abscess
formation. T-I - combined injection of
trypsin inhibitor (1 m g/m l) plus trypsin (1
mg/ml) *p < 0.001 versus control.

Mortality and abscess formation data
were evaluated by a Fisher’s exact test.
Data comparing abscess weights and via
ble bacterial numbers in abscesses were
analysed using a one-way analysis o f var
iance.
Results
In-Vitro Fibrinolysis o f Sterile
Fibrin Clots by Trypsin
Sterile fibrin clots were incubated in

Table 1-Effect of Trypsin on Death Rate and Abscess Formation
Induced by a Mixed Escherichia coli-B acteroides fra g ilis Inoculum

Treatment3
Phosphate-buffered saline (PBS)
Trypsin, mg/ml
1.0
0.5
0.25

Deaths, no.1
total no. (%)

Abscess formation
in survivors,
no./total no. (%)

1/12 (8.3)

10/11 (91)

3/12 (25)
2/12 (16)
0/4 (0)

1/9 (11)b
1/10 (10)b
3/4 (75)
“Animals were injected intraperitoneally with 5 ml of the indicated solution beginning at surgery, then
daily for 5 days.
bp < 0.01 versus PBS control.

various concentrations of trypsin at 37°C
to determine the time required for the clot
to dissolve. At 1.0 m g/m l, the clot dis
solved within 10 minutes and at 0.5
mg/ml, by 30 minutes. Lower concentra
tions (0.25 mg/ml) failed to dissolve the
clot over the 30-minute examination
period. These studies formed the basis for
the trypsin concentrations used in vivo.
E ffect o f Fibrinolysis on Abscess
Formation Induced by Bacteroides
fragilis-Th/ectec? Clots (Fig. 1)
Intraperitoneal inoculation with fibrin
clots containing B. fragilis (2 x 109
CFU/clot) resulted in abscess formation
in 87% of animals (n = 15) when injected
simultaneously with PBS. Trypsin signifi
cantly (p < 0.001) decreased the incidence
of abscess formation at a concentration
of 1 mg/ml (n = 20) and was progres
sively less effective as the concentration
was reduced. To support the concept that
trypsin was acting through its proteolytic
effect, trypsin inhibitor (Sigma Chemical
Company, 1 mg/ml) was injected with the
trypsin. Trypsin inhibitor completely
reversed the ability of trypsin to prevent
abscesses (n = 4).
Another potential mechanism by which
trypsin might exert its effect was through
a direct microbicidal effect. In fact, via
ble bacteria (log CFU /g abscess) in
B. fragilis abscesses were 8.2 ± 0.2 (n =
7, mean ± SEM) in the PBS group and
5.7 ± 1.4 (n = 4) in the trypsin (1 mg/ml)
group (p < 0.05). In-vitro studies demon
strated no direct microbicidal effect of
trypsin on B. fragilis or E. coli, suggest
ing that enhanced bacterial clearance was
responsible for reduced abscesses and
bacterial numbers.
Tissue plasminogen activator, which
acts by converting the zymogen plasmino
gen to the fibrinolytic enzyme plasmin,
completely prevented abscess formation
at the single concentration tested (0.25
mg/ml). In B. fragilis-induced abscesses,
no deaths occurred.
Effect o f Trypsin on Mortality
and Abscess Formation Induced
by a Mixed Bacterial Inoculum (Table I)
Trypsin significantly (p < 0.01)
reduced abscess formation at concentra
tions of 1.0 mg/ml and 0.5 mg/ml but not
at 0.25 m g/m l. Although the death rate
was slightly higher in the trypsin groups,
the difference was not significant. Tryp
sin alone (1 mg/ml) had no gross adverse
effect on the animals.
Discussion
Peritonitis and its complications are
associated with a high death rate, partic
ularly among the elderly (range from 60%
to 80%),8 in whom management should
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include adequate fluid resuscitation,
administration of broad-spectrum antibi
otics and appropriate surgical therapy.
The goals of surgery are to control the
source of the bacterial spillage and to pre
vent septic complications postoperatively.
With present techniques, patients usually
survive the first week after surgery for
peritonitis. Death is invariably associated
with infection leading to multisystem
organ failure and progressive deteriora
tion despite aggressive therapy.
Therapy aimed specifically at prevent
ing late postoperative infection might pre
vent the development of multisystem
organ failure and subsequent death. One
approach has been to reduce fibrin depo
sition associated with peritonitis. Fibrin
deposition occurs during the early inflam
matory stage of peritonitis when the
fibrinogen-rich exudate in the peritoneal
cavity is converted to fibrin by tissue
thromboplastin activity.8 Fibrin acts to
wall off and contain bacteria, thereby
forming a nidus for residual infection.
The purpose of our study was to deter
mine the effect of local fibrinolytic ther
apy on abscess formation using a welldefined intra-abdominal infection model.
The hypothesis that fibrinolysis might
prevent infection is well founded and
based on experimental studies of infec
tions at other sites. Thrombolysis was
used successfully by Durack9 to prevent
endocarditis in a rabbit model. Rodeheaver and colleagues10 used fibrinolytic
agents to reduce the number of wound
infections induced by infected plasma
clots in guinea-pig skin incisions.
Both trypsin and t-PA reduced the fre
quency of abscesses in animals infected
with monomicrobial B. fragilis clots.
Similarly, trypsin prevented abscesses
induced by E. coli-B. fragilis clots.
Several lines of evidence support the con
cept that abscesses were prevented
through fibrinolysis. First, the concentra
tion of enzyme required to prevent
abscesses correlated well with those
needed for in-vitro clot lysis. Second,
trypsin inhibitor reversed the ability of
trypsin to prevent abscesses. Finally, tryp
sin demonstrated no direct microbicidal
activity, thereby making it unlikely that
its effect was due to an antimicrobial
property. These data suggest that reduced
bacterial numbers in residual abscesses in
the trypsin group were due to enhanced
clearance of bacteria (probably due to
partial fibrinolysis) rather than to a
microbicidal effect. One further possible
mechanism was that trypsin may have
stimulated cellular host defences, result
ing in enhanced bacterial clearance. Low
concentrations of trypsin have been
shown to enhance superoxide production
by m acrophages.11 In contrast, our
previous studies3 have shown that tryp
sin slightly impaired the neutrophil
100

respiratory burst in response to particu
late stimuli.
Based on the presumed bacterial trap
ping function of fibrin in the defence of
the peritoneal cavity, fibrinolysis would
be expected to result in bacteremia and
increased mortality, which would be
unlikely in monomicrobial B. fragilis
clots, since high inocula of B. fragilis,
even if administered systemically, are
rarely lethal.12 With mixed E. coli-B.
fragilis clots, the death rate was only
slightly increased. It is not clear whether
failure to demonstrate an increased death
rate was owing to the fact that a sublethal
inoculum of E. coli was initially present
in the clot or that fibrinolysis resulted in
a slow release of bacteria into the circu
lation that the host defences were able to
handle.
Previous studies13' 16 examining those
agents that may prevent intra-abdominal
abscesses have focused on the prevention
of fibrin deposition using anticoagulants.
Experimental studies in several animal
models have demonstrated that heparin
and low-molecular-weight dextran can
prevent abscess formation. In those
studies, anticoagulants were usually
adm inistered when peritonitis was
initiated (i.e., before fibrin deposition).
The present model more closely mimics
the clinical setting in that fibrin is present
when the infection is initiated, just as
infected fibrinous exudates are found
in patients with diffuse peritonitis.
Anticoagulants may be less effective in
these circumstances. Indeed, heparin did
not prevent abscess formation when
tested in the rat fibrin clot model.17 The
use of fibrinolytic agents may represent
an enzym atic m eans o f “ radical
peritoneal debridement” , which has been
advocated as a method of preventing
postoperative sepsis.18
The present study reports initial
experience with the use of t-PA to pre
vent intra-abdominal abscesses. Several
of its properties make it an attractive
fibrinolytic agent for use in the peritoneal
cavity.19 Its high molecular weight and
affinity for fibrin tend to confine its
activity to the peritoneal cavity, thereby
enhancing its potency and reducing side
effects. In addition, plasmin, formed by
the action of t-PA on plasminogen, is
rapidly inactivated by circulating antiplasmins should it escape into the systemic cir
culation. Further studies are presently in
progress examining the potential use of
t-PA in intra-abdominal sepsis.
We thank Miss Christina Wareham for
preparing the manuscript.
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Percutaneous Endoscopic Gastrostomy
by the “Pull” and “Introducer” Methods
After 28 patients, studied prospectively,
underwent percutaneous endoscopic gas
trostomy (PEG) by the Ponsky "p u ll"
technique, another 28 patients under
went PEG by the Russell "introducer"
method. These two groups were com
pared retrospectively with 28 patients
who had previously undergone Stamm
gastrostomy as an independent operation
performed by the same group of sur
geons. All procedures were done within
a 5-year period. The major indication for
gastrostomy was the inability to swallow
due to neurologic diseases; a similar
number of patients in each group also
had pharyngeal blockage, cachexia,
respiratory failure and inhalation burns.
Percutaneous endoscopic gastrostomy
could be done most appropriately under
local anesthesia, the "introducer"
method requiring less time than the
"pull” method, which in turn required
less time than the Stamm gastrostomy.
Feeding was generally instituted success
fully 24 hours after PEG compared with
3 days after Stamm gastrostomy.
"Introducer" PEG was not associated
with peristomal infection, and the
authors postulate that the peristomal
infections in the "p u ll" PEG group were
due to oropharyngeal bacteria brought
through the abdominal wall by that tech
nique.

Apres qu'un premier groupe de 28
patients eut subi, dans une etude pros-
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pective, une gastrostomie endoscopique
percutanee (GEP) par la technique de
"traction" de Ponsky, 28 autres patients
furent soumis a une GEP par la techni
que "d'introduction" de Russell. Ces
deux groupes furent ensuite compares a
28 autres patients qui avaient subi auparavant une gastrostomie de Stamm aux
mains du meme groupe de chirurgiens.
Toutes les interventions ont ete pratiquees a I'interieur d'un intervalle de 5
ans. La principale indication de gastros
tomie etait I'incapacite d'avaler consecu
tive a un probleme neurologique; dans
chaque groupe, un nombre similaire de
patients souffrait de blocage pharynge,
de cachexie, d'insuffisance respiratoire
ou de brulure par inhalation. La GEP peut
etre pratiquee de facon adequate sous
anesthesie locale, la technique par
"introduction" exigeant moins de temps
que la methode de "traction" qui, en
retour, peut etre faite plus rapidement
que la gastrostomie de Stamm. L'alimentation a generalement pu etre reprise 24
heures apres une GEP, comparativement
3 jours pour la gastrostomie de Stamm.
La GEP par "introduction" n'a pas ete
reliee a des infections du stoma et les
autres emettent I'hypothese que les
infections de ce type dans les GEP de
"traction" sont dues a des bacteries de
I'oropharynx qui sont ramenees a travers
la paroi abdominale par cette technique.

In 1980, Ponsky’s group1 described a
percutaneous method of passing a suture
into the stomach. The suture was pulled
out through the mouth using a gastroscope and tied to a tube which was then
pulled back through the stomach and
abdominal wall. Subsequently, Preshaw2
described a method of insufflating the
stomach and introducing a Stamey cys
toscopy catheter percutaneously as a gas
trostomy tube; this technique did not have
endoscopic control. In 1984, Russell and
colleagues3 reported a percutaneous gas
trostomy made by pushing an introducer
contained in a pacemaker lead peel-away
sheath over a guidewire into the stomach.
We have com pared percutaneous
endoscopic gastrostomy (PEG) by the

Ponsky “ pull” and Russell “ introducer”
techniques and the standard operative
Stamm gastrostomy.
Patients and Methods

Starting in 1983, patients who under
went the “ pull” PEG were studied
prospectively using a data collection
form. After 28 such gastrostomies we
became aware of the “ introducer” or
push technique, one that we had used for
10 years to insert long-term hyperalimen
tation catheters and pacemaker elec
trodes; accordingly, the next 28 patients
underwent PEG by the “ introducer”
technique. For further comparison, we
reviewed 28 patients who had previously
undergone Stamm gastrostomies, per
formed by the same group of surgeons.
All gastrostomies in this study were
performed within a 5-year period. Proce
dures were performed in a surgical
endoscopy room, part of the operatingroom complex in which anesthesia was
usually available. Patients received
meperidine and atropine before the proce
dure and oropharyngeal lidocaine when
local anesthesia was used.
Techniques

The “Pull” Techinque
After an initial esophagogastroduodenoscopy, the stomach is insufflated
with air and the skin cleansed and
anesthetized at the site of puncture. With
the room lights dimmed, the endoscope
light is visualized, located high in the left
upper quadrant, and a no. 16 Medicut
(Sherwood Medical Industries, St. Louis,
Mo.) is passed into the stomach. A heavy
silk or Mersilene suture, rendered some
what rigid with collodion, is inserted
through the Medicut, snared and with
drawn in turn through the gastroscope.
Another suture, guided through a second
no. 16 Medicut, is threaded on a needle,
passed through the end of a no. 16F
mushroom catheter and brought back
through this Medicut; traction on the
suture impacts the end of the catheter into
the wide end of the Medicut.1 Into the
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side of a segment of the connecting end
of the catheter, previously cut off, a small
hole is made and the piece is threaded
down the shaft against the mushroom to
act as a flange. The entire assembly with
the tapered end of the Medicut leading is
pulled through the stomach and abdomi
nal wall. Gastroscopy verifies that the
flange is against the anterior gastric wall,
apposing gastric serosa to parietal
peritoneum without excess tension. A
second flange is then passed over the pro
truding shaft of the gastrostomy tube and
sutured in place against the abdominal
wall. The tube is placed on gravity
drainage for 24 hours.
The “Introducer” Technique
A 7-cm-long no. 18 needle is introduced
through the abdominal wall into the
stomach at the site where the endoscope
light is visualized in the left upper quad
rant and where the endoscopist can see
an indentation on the stomach made by
the surgeon’s finger. Air is aspirated for
confirmation, the syringe removed, and
a J-tipped guidewire introduced using a
straightener.3 A no. 16F introducer in a
peel-away sheath is then pushed over the
guidewire into the stomach, and when
definitely visualized by the endoscopist,
the introducer with the contained guidewire is removed. A no. 14F lubricated
Foley catheter is then inserted, the bal
loon inflated and the sheath peeled away.
The balloon is verified endoscopically to
be pulled against the anterior gastric wall
and is then sutured to the skin.
Stamm Gastrostomy
The classic operation or a modifica
tion of it4 is performed. A no. 18F to
22F Foley catheter is used.
Postoperative Care
All patients received a cephalosporin
intravenously 30 minutes before the
procedure and two further doses at
6-hour intervals thereafter. Patients
already on antibiotics continued on the
medication.
An orange plastic occlusive tape was

placed securely over a gauze square to
prevent the gastrostomy tube being pulled
out. This dressing was removed and the
wound inspected every 2 days or any time
the patient had fever or leukocytosis.
Ranitidine was added to the intravenous
fluids postoperatively to decrease volume
and increase pH of gastric contents while
adhesion of the stomach to parietal
peritoneum began.
Tube feeding was started 3 days after
the Stamm operation and 24 hours after
the PEG procedures. Initially a non
stimulating elemental diet (Vivonex TEN,
Flexical HN) was given, progressing to a
non-digested liquid diet (IsoSource, Isocal or Osmolyte) after 5 to 7 days. After
2 weeks, patients to be on a gastrostomy
for many years were started on a liquid
diet with fibre (Enrich), and ultimately
progressed to a blenderized diet. Tubes
were not changed before 2 weeks
postoperatively or after longer periods in
depleted, diabetic patients or those on
steroids. In the PEG patients, a larger
lubricated Foley catheter could later be
inserted at weekly intervals until a no. 18F
size was reached.
Results (Table I)
The major indications for gastrostomy
were neurologic problems including
stroke, dementia, brain trauma, anoxic
encephalopathy, Parkinson’s disease,
amyotrophic lateral sclerosis and Hun
tington’s disease. It was also used in
patients with pharyngeal or esophageal
blockage due to malignant or benign
disease, including those who had under
gone radiotherapy for hypopharyngeal
tumours. Indeed, one patient with a large
hypopharyngeal tumour underwent dila
tation, thus enabling a “ pull” PEG to be
accomplished. Other indications were
weakness due to cancer, failure to thrive
in the elderly, chronic respiratory failure
and inhalation burns.
The PEG methods were more easily
accomplished under local anesthesia than
the Stamm operation. Patients with
uncontrollable movements such as Hun
tington’s chorea or who were unable to
cooperate required general anesthesia.
The duration of the procedures, taken
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from operative records, was less with
PEG than the Stamm operation and least
with the “ introducer” technique (Table
I). Wound infections in the Stamm group
were within the subcutaneous tissues of
the abdominal incision, while those in the
“pull” group were peritubal. It is interest
ing that no peritubal infections occurred
with the “ introducer” method.
There was one death in the recovery
room after a Stamm gastrostomy. It may
have been related to the magnitude of the
procedure in this patient; no autopsy was
carried out. Other deaths within 30 days
were due to the underlying disease.
Abdom inal distension occurred
immediately after PEG in 20% of cases,
disappearing clinically within 18 hours
and indicating pneumoperitoneum that
had no sequelae. We were impressed by
the absence of pain after the PEG proce
dures, but three patients had problems
with gastroesophageal reflux despite ele
vation of the head of the bed and admin
istration of metoclopramide, so the feed
ing was changed to a jejunostomy. Two
of these had had “ pull” procedures in
which the tip of the mushroom catheter
had been cut off (as was our practice). In
such cases a no. 9.6F polyurethane feed
ing tube with a suture tied about the
weighted tip was passed through the gas
trostomy tube into the stomach. Through
a gastroscope the suture was grasped and
the weighted tip delivered to the second
part of duodenum. In the stomach suffi
cient slack was left in the tube to enable
progression to jejunum.5-6 In the third
patient, who had had the “ introducer”
PEG and episodes of aspiration, the
Foley catheter could have been changed
to a mushroom with a polyurethane tube
passed through its side.7 However, the
tract in this patient was well developed,
so a polyurethane feeding tube was passed
alongside the Foley catheter and success
fully negotiated endoscopically beyond
the pylorus.8
Discussion
Nasoenteral feeding has advanced
remarkably during the past 15 years, with
the development of fine nonirritating
tubes and improved diets. However, tubes
that traverse the gastroesophageal junc
tion can result in aspiration of stomach
contents. They may plug, dislodge,
require tape on the face and are not
accepted for feeding at some nursing
homes. Many debilitated patients with
severe dysphagia can regain their ability
to swallow and eat orally, if their nutri
tion can be maintained over a prolonged
period.
The use of gastrostomies, although
requiring meticulous technique, attention
and maintenance, has increased over the
past few years. Gastrostomies should not
be used to feed patients whose disease is
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rapidly progressive and who will shortly
die. However, there are many patients
who require nutritional maintenance,
whose gut is functioning, who cannot or
will not eat orally, and who no longer
have available peripheral veins for
intravenous infusion. In these patients, a
feeding gastrostomy can be beneficial.
Percutaneous endoscopic gastrostomy
is contraindicated in patients with ascites,
because the procedure could lead to infec
tion or leak because of a lack of sealing
against the anterior abdominal wall. Rela
tive contraindications are significant
coagulopathy, esophageal varices and a
nonfunctioning gut, and the procedure
cannot be performed if the patient has
complete esophageal obstruction or has
previously undergone a total gastrectomy.
Percutaneous endoscopic gastrostomy
must be used with caution in patients who
have had previous upper abdominal oper
ations, the light must clearly be seen high
in the left upper quadrant, with the tip
of the gastroscope palpable through the
abdominal wall. One of our patients with
a previous Stamm gastrostomy had the
tube removed after she regained her abil
ity to eat; 1 year later she suffered a
relapse and, with the stomach already
adherent to anterior abdominal wall,
PEG was done safely and easily. With a
large hiatal hernia, the surgeon should
confirm radiologically that it can be
reduced into the abdomen before PEG
is performed.9 With severe gastroeso
phageal reflux, a means of inserting the
tip of a tube endoscopically into the
duodenum for jejunal feeding must be
part of the PEG technique.10
The organisms in the “ pull” PEG
p eritu b al infections were m ainly
Staphylococcus aureus and /3-hemolytic
streptococci. These were associated with
the other multiple gram-positive and
gram-negative aerobic and anaerobic
microorganism s th at reside in the
oropharynx and had been introduced into
the subcutaneous tissues of these fre
quently debilitated patients. The value of
antibiotics given prophylactically in such
patients has not yet been proven prospec
tively, but we believe, in line with similar
surgical situations, that antibiotics here
are advantageous.11 Patients on H 2
blockers preoperatively, especially those
who are diabetic, atherosclerotic, mal
nourished or on steroids, warrant
prophylactic antibiotic therapy.12 There
are three reports o f necrotizing fasciitis
and myositis, which required extensive
abdominal wall debridement, following
the “ pull” PEG technique.13-15 The oral
cavity in debilitated or semicomatose
patients often contains thick crusting and
debris. When antiseptic gargles are not
possible preoperatively, the oral cavity
should be prepared with a povidoneiodine-m oistened packing before
introducing the gastroscope. Our data
104

suggest that peristomal infection is more
frequent with the “ pull” than the
“ introducer” method, likely because,
with the “ pull” PEG, the tube with the
flange is pulled through the orohypopharynx and the endoscope must be
passed a second time.
Kits for the “ pull” PEG are available
from a number of sources: Dumex, Scar
borough, Ont. M1V 2V4; R. Laborie,
Rexdale, Ont. M9W 6C8; Turdell (Glaser
PEG), London, Ont. N5Z 3M5; Ameri
can Endoscopy, Mentor, OH 44060; TriMed (E-Z PEG), Stanley, KS 66223;
Davol, Cranston, RI 02920. A variation
of the Ponsky “ pull” method is the
Sacks-Vine kit (BeeJay, Oakville, Ont.
L6L 5M1), in which a percutaneously
inserted, long guidewire is retrieved from
the stomach through the gastroscope and
a polyethylene mushroom tube with a
flange is pushed perorally over the guidewire and through abdominal wall.
Subsequent to our study, a kit for the
“ introducer” method has been marketed
(Cook, Markham, Ont. L3R 3B1); this kit
contained a Foley catheter found to have
a defective balloon that frequently
decompresses within 48 hours, leaving a
free gastric hole causing peritonitis and
infusion o f diet into peritoneal cavity.
The complication with this kit was
widespread across North America. We
had three such emergency occurrences
recently, two patients were treated by sur
gical gastrostomy and one by a repeat
PEG, with a successful outcome. To over
come the problem, Cook is now market
ing a kit that permits introduction of a
Malecot catheter through the peel-away
sheath’ an outer tube is slid over the inner
tube. However, we continue to have
greatest ease of performance with the no.
16F pacemaker lead introducer (Cook CPLI-16-38) and a no. 14F Foley catheter,
instead of a kit.
Percutaneous endoscopic gastrostomy
can generally be performed on patients
who are considered very high risks and
is less costly than the Stamm gastrostomy.
It appears that the “ introducer” PEG is
simpler, faster and safer than the “ pull”
PEG, but all three methods require
meticulous technique and proper surveil
lance. Percutaneous endoscopic gas
trostomy requires two experienced wor
kers — a skilled surgeon at the abdomen
and a skilled endoscopist at the head.
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University of Toronto —
Continuing Education
The Faculty of Medicine of the Univer
sity of Toronto has scheduled two courses
to be presented this spring. The first will
take place May 19 and 20, 1988, at the
Mount Sinai Hospital and is entitled
“ Allografts in Orthopaedic Surgery —
Banking and Clinical Applications” . On
May 31 and June 1 at the same location,
a course entitled “ Advances and Con
troversies in Vascular Surgery” will be
held. Further information on both of
these courses can be obtained by writing:
Continuing Medical Education, Faculty
of Medicine, University of Toronto, Med
ical Sciences Building, Toronto, Ont.
M5S 1A8 or by calling: (416) 978-2718.

Multiorgan Transplantation
Symposium
The first Canadian symposium on mul
tiorgan transplantation will be held at
University Hospital, London, Ont., Apr.
28-29, 1988. Further information can be
obtained by contacting: Continuing Med
ical Education, Faculty of Medicine, The
University of Western Ontario, London,
Ont. N6A 5C1; telephone (519) 661-2074.

Congres annuel de (’Association
des chirurgiens generaux
L’Association des chirurgiens generaux
du Quebec tiendra son congres annuel, 21
et 22 avril, 1988, a l’Hotel Le Quatre Saicontinued on page 109
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7 (Suppl 3): S518-S521, July-August
1985.

EFFICACY IN LOW ER RESPIRATORY TRACT
INFECTIONS

2

85% cure or
improvement
in 2 0 4 evaluable

\

patients
2. Acar, J.E: Therapy for lower
respiratory tract infections with
imipenem/cilastatin: A review of
worldwide experience, Rev Infect Dis
7 (Suppl 3): S513-S517, July-August
1985.

+Caused by organisms susceptible to PRIMAXIN* I.V.
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EFFICACY IN BACTERIAF SEPTICEMIA

90% cure or
improvement
in 135 evaluable
patients
3. Eron, L.J.:
Imipenem /cilastatin
therapy of bacteremia,
Am J Med 78 (Suppl 6A):
95-99, June 7, 1985.
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EFFICACY IN GYNECOLOGICAL
INFECTIONS4

97% cure or
improvement
in 72 evaluable
patients
4. Sweet, R.L.: Imipenem/
cilastatin in the treatment
of obstetric and gynecologic
infections: A review of
worldwide experience,
Rev Infect Dis 7 (Suppl 3):
S522-S527, July-August 1985.
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PREV1AXIN* I.V. offers management
advantages over combination therapy
that includes an aminoglycoside
Generally w ell tolerated safety profile
sim ilar to cefazolin3
*-

□ 1723 patients, including the severely ill, have received therapy in clinical trials.
The incidence of the most common adverse experience (nausea) was no greater
than 2%.
□ Avoids the potential nephrotoxicity or ototoxicity experienced with
aminoglycosides.
□ Avoids the potential hypoprothrombinemia and clinical bleeding experienced
with cephalosporins with MTT side chain.
H Avoids the potential disulfiram-like effect experienced with metronidazole and
cephalosporins with MTT side chain.

v
4
*

Convenience o f a single agent

The broadest spectrum single
agent antibiotic representing
a transformation of parenteral
antibiotic therapy

■y
¥

5. Calandra G.B., Ricci F.M., Wang C., Brown K.R.: Safety and
tolerance comparison of imipenem/cilastatin to cephalothin and
cefazolin. J Antimicrob Chemother 12(suppl D): 125-131,1983.
+ Certain antibiotics which possess, as part of their molecular structure, the l-methyl-5-thiotetrazole (MTT)
group have been associated with hypoprothrombinemia (and in some cases, clinical bleeding) and with
a disulfiram-like effect.
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PRIMAXIN*
(imipenem and cilastatin sodium
for injection)
Antibiotic
CNS adverse experiences such as myoclonic
activity, confusional states, or seizures have
been reported with PRIMAXIN* especially when
recommended dosages based on renal function
and body weight were exceeded. These exper
iences have occurred most commonly in patients
with CNS disorders (e.g., brain lesions or
history of seizures) and/or who have compro
mised renal function. However, there were rare
reports in which there was no recognized or
documented underlying CNS disorder. Close
adherence to recommended dosage schedules
is urged, especially in patients with known factors
that predispose to seizures.

Neisseria
• Proteus (indole positive and indole negative
•

strains) 1

Providencia
Pseudomonas aeruginosa
• Serratia marcescens
•
•

Gram-positive Anaerobes

Clostridium (excluding C. difficile)
• Peptococcus
• Peptostreptoccus
•

Gram-negative Anaerobes

•
•

Bacteroides fragilis
Bacteroides (non-fragilis)

CONTRAINDICATIONS
PRIMAXIN’ (imipenem and cilastatin sodium for
injection) is contraindicated in patients who have
shown hypersensitivity to either component of this
product.

ACTION

WARNINGS

Imipenem exerts a bactericidal action by inhibiting
cell wall synthesis in aerobic and anaerobic gram
positive and gram-negative bacteria.

PRIMAXIN* (imipenem and cilastatin sodium for
in je c tio n ) SHOULD BE ADMINISTERED WITH
CAUTION TO ANY PATIENT WHO HAS DEMONS
TRATED SOME FORM OF ALLERGY, PARTICULARLY
TO STRUCTURALLY-RELATED DRUGS. IF AN
ALLERGIC REACTION TO PRIMAXIN* OCCURS,
DISCONTINUE THE DRUG. SERIOUS HYPER
S E N S IT IV IT Y R EAC TIO N S MAY REQUIRE
E PIN E P H R IN E AND OTHER EMERGENCY
MEASURES.

P R IM A XIN * con sists o f tw o c o m p o n e n ts :
(1) imipenem , a derivative of thie nam ycin , a
carbapenem antibiotic; and (2) cilastatin sodium, a
specific inhibitor of dehydropeptidase-l a renal
enzym e w hich m etabolizes and in a c tiv a te s
imipenem. Cilastatin blocks the metabolism of
imipenem in the kidney, so that concom itant
administration of imipenem and cilastatin allows
antibacterial levels of imipenem to be attained in the
urine.
Inhibition of cell-wall synthesis is achieved in gram
negative bacteria by the binding of imipenem to
penicillin binding proteins (PBPs). In the case of
E s c h e ric h ia c o li and s e le c te d s tr a in s of
Pseudomonas aeruginosa, imipenem has been
shown to have highest affinity for PBP-2, PBP-1a
and PBP-1 b, with lower activity against PBP-3. The
preferential binding of imipenem on PBP-2 and
PBP-1 b leads to direct conversion of the individual
cell to a spheroplast resulting in rapid lysis and cell
death without filament formation. When imipenem
is removed prior to complete killin g of gram
negative species, the remaining viable cells show a
measurable lag, termed a "post-antibiotic effect"
(PAE), prior to resumption of new growth.

INDICATIONS AND CLINICAL USE
PRIMAXIN* (imipenem and cilastatin sodium for
injection) may be indicated in the treatment of
serious infections when caused by sensitive strains
of bacteria. Where considered necessary, therapy
may be initiated on the basis of clinical judgment
before results of sensitivity testings are available.
Continuation of therapy should be reevaluated on
the basis of bacteriological findings and of the
patient’s clinical condition.
Imipenem is active in vitro against a wide range of
gram-positive and gram-negative aerobic and
anaerobic bacteria, including most strains which
are beta-lactamase producin g. Patients have
responded while under treatment with PRIMAXIN*
for single or mixed infections of the following body
systems, when they were associated with a number
of pathogenic species and strains of the genera
listed:
1.
2.
3.
4.
5.
6.

Lower Respiratory Tract Infections
Urinary Tract Infections
Intra-Abdominal Infections
Gynecological Infections
Septicemia
Endocarditis caused by Staphylococcus

aureus
1.
8.

Bone and Joint Infections
Skin Structure Infections

Gram-positive Aerobes

Listeria monocytogenes
• Nocardia asteroides
• Staphylococcus (excluding many strains
•

•

which are methicillin resistant)
Streptococcus (excluding S. faecium)

Gram-negative Aerobes

•
•

•
•
•
•

•
•

Acinetobacter
Citrobacter
Enterobacter
Escherichia coli
Haemophilus influenzae
Haemophilus parainfluenzae
Klebsiella
Morganella morganii

Pseudomembranous colitis

Pseudomembranous colitis has been reported with
the use of PRIMAXIN*. Therefore it is important to
consider this diagnosis in patients who develop
diarrhea during or after therapy. This colitis may
range from mild to life threatening in severity.
Mild cases of pseudomembranous colitis may
respond to drug discontinuance alone. In more
s e v e re case s, m a n a g e m e n t m ay in c lu d e
s ig m o id o s co p y, a p p ro p ria te b a c te rio lo g ic a l
studies, fluid, electrolyte and protein supple
mentation, and the use of a drug such as oral
vancomycin, as indicated. Other causes of colitis
should also be considered.

PRECAUTIONS
General

Prolonged use of PRIMAXIN* (imipenem and
cilastatin sodium fo r injectio n) may result in
overgrow th of resistant organism s. Repeated
evaluation of the patient’s condition is essential. If
superinfection occurs during therapy, appropriate
measures should be taken.
CNS adverse experiences such as m yoclonic
activity, confusional* states, or seizures have been
reported with PRIMAXIN* especially when recom
mended dosages based on renal function and body
weight were exceeded. These experiences have
occurred most commonly in patients with CNS
disorders (e.g., brain lesions or history of seizures)
and/or who have compromised renal function.
However, there were rare reports in which there was
no recognized or documented underlying CNS
disorder. Close adherence to recommended dosage
schedules is urged especially in patients with
known factors that predispose to seizures (see
D O SAG E A N D A D M IN IS T R A T IO N ). A n ti
convulsant therapy should be continued in patients
with a known seizure disorder. If focal tremors,
myoclonus, or seizures occur, patients should be
evaluated ne urologically and placed on an ti
convulsant therapy if not already instituted. If CNS
symptoms continue, the dosage of PRIMAXIN*
should be decreased or discontinued.

and death) at doses equivalent to the average
human dose in pregnant rabbits and cynomolgus
monkeys that is not seen in non-pregnant animals in
these or other species. In other studies, PRIMAXIN*
was well tolerated in equivalent or higher doses (up
to 11 times the average human dose) in pregnant
rats and mice (see REPRODUCTION STUDIES
underTOXICOLOGY in the complete monograph).
Nursing Mothers

It is not known whether PRIMAXIN* is excreted in
milk. If the use of PRIMAXIN* is deemed essential,
the patient should stop nursing.
Pediatric Use

Efficacy and tolerability in infants under the age of
3 months have not yet been established; therefore,
PRIMAXIN* is not recommended in the pediatric
age group below the age of 3 months.
Drug Interactions

C oncomitant adm inistration of PRIMAXIN* and
probenecid results in only minimal increases in
plasma levels of imipenem and plasma half-life. It is
not recommended that probenecid be given with
PRIMAXIN*.
PRIMAXIN* should not be mixed with or physically
added to other antibiotics. PRIMAXIN* has been
administered concomitantly with some antibiotics,
such as aminoglycosides.
There is no evidence to suggest that association of
PRIMAXIN* with any other beta-lactam antibiotics
has any therapeutic advantage.

ADVERSE REACTIONS
PRIMAXIN* (imipenem and cilastatin sodium for
injection) is generally well tolerated. The following
adverse reactions were reported on 1,723 patients
treated in clinical trials. Many of these patients were
severely ill and had multiple background diseases
and physiological impairments, making it d ifficu lt to
determ ine causal re la tio n sh ip of adverse ex
periences to therapy with PRIMAXIN*.
Local Adverse Reactions

Adverse local clinical reactions that were reported
as possibly, probably or definitely related to therapy
with PRIMAXIN* were:
Incidence (%)

Phlebitis/thrombophlebitis
Infused vein pain
Vein induration
Infused vein infection

1.7
0.6
0.2
0.1

Systemic Adverse Reactions

Adverse clinical reactions that were reported as
p o ssib ly, p ro b a b ly , o r d e fin ite ly re la te d to
PRIMAXIN* were:
Incidence (%)
Gastrointestinal

nausea
diarrhea
vomiting
tongue papillar hypertrophy
pseudomembranous colitis
(see WARNINGS)
hemorrhagic colitis
gastroenteritis
abdominal pain
glossitis
heartburn
pharyngeal pain
increased salivation

2.0
1.7
1.6
0.2
0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

Use in Patients with Impaired Renal Function

Dosage in patients with impaired renal function is
based on the severity of infection but the maximum
daily dose varies with the degree of renal functional
im p a irm e n t (see DOSAGE AND A D M IN IS 
TR A TIO N - Dosage in P atien ts w ith Renal
Insufficiency).
Use in Pregnancy

CNS

fever
dizziness
seizures
(see PRECAUTIONS)
somnolence
confusion
myoclonus
vertigo
headache
encephalopathy
paresthesia

The use of PRIMAXIN* in pregnant women has not
been studied, therefore, PRIMAXIN* should be used
during pregnancy only if clearly needed. Use of this
drug in women of childbearing potential requires
that the anticipated benefits be weighed against
possible hazards.

Special Senses

Reproduction studies with bolus I.V. doses suggest
an apparent intolerance to PRIMAXIN* (including
emesis, inappetence, body weight loss, diarrhea

transient hearing loss in
patients with impaired hearing
tinnitus

0.4
0.3
0.2
0.2
0.2
0.1
0.1
0.1
<0.1
<0.1

<0.1
<0.1

Respiratory
dyspnea
hyperventilation
thoracic spine pain
Cardiovascular
hypotension
palpitations
tachycardia

0.4
0.1
<0.1

Renal
oliguria/anuria
polyuria

<0.1
<0.1

Skin
rash
pruritus
urticaria
skin texture changes
candidiasis
erythema multiforme
facial edema
flushing
cyanosis
hyperhidrosis
pruritus vulvae

0.9
0.3
0.2
0.1
0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

Body as a whole
polyarthralgia
asthenia/weakness

Dosage in Infants and Children

TABLE 1
0.1
<0.1
<0.1

<0.1
<0.1

Adverse Laboratory Changes
Adverse laboratory changes, without regard to drug
relationship, that were reported during clinical trials
were:
Hepatic: Increased SGPT, SGOT, alkaline phospha
tase, bilirubin and LDH.
Hemic: Increased eosinophils, positive Coombs
test, decreased WBC and neutrophils, increased
WBC, increased platelets, decreased platelets,
decreased hemoglobin and hematocrit, increased
monocytes, abnormal prothrombin time, increased
lymphocytes, increased basophils.

A D U LT DOSAGE OF PRIMAXIN*
I.V. Adm inistration
Dosage
Interval

D aily
D ose

250 mg

6h

1.0 g

Moderate

500 mg

8h

1.5 g

Severe (fully
susceptible)

500 mg

6h

2.0 g

C A U TIO N : CONTENTS OF VIALS NOT FOR
DIRECT INFUSION.

1000 mg
1000 mg

8h
6h

3.0 g
4.0 g

Each reconstituted 250 mg or 500 mg dose should
be given by intravenous infusion over twenty to
th irty minutes. Each 1000 mg dose should be
infused over 40 to 60 minutes. In patients who
develop nausea during the infusion, the rate of
infusion may be slowed.

Severity
of infection

Urinalysis: Presence of urine protein, urine red
blood cells, urine white blood cells, urine casts,
urine bilirubin, and urine urobilinogen.

TREATMENT OF OVERDOSAGE
There are no data available on overdosage.

Severe* infections
due to less
susceptible
organisms
or life threatening
conditions

* Primarily some strains of Ps. aeruginosa.

The dosage recommendations for PRIMAXIN*
(imipenem and cilastatin sodium for injection)
represent the quantity of imipenem to be ad
ministered by I.V. infusion only. An equivalent
amount of cilastatin is also present in the solution.
The dosage of PRIMAXIN* should be determined by
the severity of the infection, renal function, body
weight, the antibiotic susceptibility of the causative
organism(s) and the condition of the patient. Doses
cited are based on body weight of 70 kilos.
The median duration of treatment with PRIMAXIN*
in clinical trials for infections of the various body
systems ranged from 6 to 10 days except for
endocarditis and bone and joint infections for which
the median duration of treatment was 4 weeks.

Administration

RECONSTITUTION

The maximum daily dose should not exceed 4 g or
50 mg/kg, which ever is less.

Contents of the 13 mL vials must be suspended and
transferred to 100 mL of an appropriate infusion
solution.

Dosage in Patients with Renal Insufficiency

A suggested procedure is to transfer approximately
10 mL from the 100 mL of the appropriate infusion
solution to the vial (see list of diluents under
COMPATIBILITY AND STABILITY). Shake well.
Return the resulting 10 mL of suspension to the
remaining 90 mL of the infusion solution.

P a tie n ts w ith c r e a tin in e c le a ra n c e s o f
<5 mL/min/1.73 m2 (<0.08 mL/s/1.73m2) should
not receive PRIMAXIN* unless hemodialysis is
instituted w ithin 48 hours. Both imipenem and
cilastatin are cleared from the circulation during
h e m o d ia ly s is . T h e p a tie n t s h o u ld receive
PRIMAXIN* after hemodialysis and at 12 hour
intervals timed from the end of that hemodialysis
session. Dialysis patients, especially those with
background CNS disease, should be carefully
m o n ito re d ; fo r p a tie n ts on h e m o d ia ly s is ,
PRIMAXIN* is recommended only when the benefit
outweighs the potential risk of seizures (see
PRECAUTIONS). Currently, there are inadequate
data to recommend the use of PRIMAXIN* in
patients undergoing peritoneal dialysis.
TABLE 2
MAXIMUM DOSAGE OF PRIMAXIN’
IN R ELATION TO RENAL FUNCTION

RENAL
FUNCTIO N
M ild
im p a ir m e n t

M o d e r a te
im p a ir m e n t

S e v e re *
im p a ir m e n t

PRIMAXIN* (imipenem and cilastatin sodium for
injection) is cleared by hemodialysis.

DOSAGE AND ADMINISTRATION

D ose
(m g of im ipenem )

Mild

Electrolytes: Decreased serum sodium, increased
potassium, increased chloride.
Renal: Increased BUN, creatinine.

The recommended total daily dosage of PRIMAXIN*
in children and infants 3 months of age and older is
60 to 100 mg/kg of body weight divided into 4 equal
doses given at six hour intervals. The higher
dosages should be used for infants and young
children. The total daily dosage should not exceed
2 g ra m s . C lin ic a l data are in s u ffic ie n t to
recommend an optimum dose for infants and
children with impaired renal function.

C R E A T IN IN E
C LE A R A N C E
mL/min/1.73 m?
(mL/s/1.73 m2)

3 1 -7 0
(0 .5 2 -1 .1 7 )

2 1 -3 0
( 0 .3 5 - 0 .5 0 )

0 -2 0
( 0 - 0 .3 3 )

D O SE
(9)

DO SA G E
INTERVAL
(h)

M AXIM U M
TOTAL
DAILY
D O SA G E
(9)

0 .5

6 -8

1 .5 -2

0 .5

8 -1 2

1 -1 .5

0 .2 5 - 0 .5

12

0 .5 - 1 . 0 * *

P atients w ith c re a tin in e clearance of 6 to
20 mL/m in/1.73 m2 (0.1 - 0.3 mL/s/1.73 m2) should
be treated with 250 mg (or 3.5 mg/kg whichever is
lower) every 12 hours for most pathogens. When
the 500 mg dose is used in these patients, there may
be an increased risk of seizures.
xx The hig h est dose is o nly recommended fo r
infections due to less susceptible organisms
primarily some strains of Ps. aeruginosa.

Repeat, using 10 mL of the diluted suspension, to
ensure complete transfer of the contents of the vial
to the infusion solution.
C A UTIO N : CONTENTS OF VIALS NOT FOR
DIRECT INFUSION.

COMPATIBILITY AND STABILITY
List of diluents
0.9% Sodium Chloride Injection
5% or 10% Dextrose Injection
5% Dextrose Injection w ith 0.02% sodium
bicarbonate solution
5% D extrose and 0.9% Sodium C hloride
Injection
5% Dextrose Injection with 0.225% or 0.45%
saline solution
NORMOSOL-M in D5-W
5% Dextrose Injection with 0.15% potassium
chloride solution
Mannitol 2.5%, 5% and 10%
Reconstituted solutions
Solutions of PRIMAXIN* range from colourless to
yellow. Variations of colour within this range do not
affect the potency of the product.
PRIMAXIN*, as supplied in vials and reconstituted
as above maintains satisfactory potency for four
hours at room temperature and for 24 hours under
refrigeration (4°C). PRIMAXIN* has been found to
be stable in 0.9% Sodium Chloride Injection for
10 hours at room temperature and 48 hours under
refrigeration.

DOSAGE FORMS
AVAILABILITY
PRIMAXIN* is supplied as a sterile powder mixture
in vials con ta in in g imipenem anhydrous and
cilastatin sodium as follows:

When only the serum creatinine level is available,
the following formula (based on sex, weight, and
age of the patient) may be used to convert this value
into creatinine clearance (mL/min). The serum
creatinine should represent a steady state of renal
function.

3514 Ca - 250 mg imipenem equivalent and 250 mg
cilastatin equivalent in vials.

Males:

STORAGE

Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL)

Females:

0.85 x above value.

Dosage in Adults

When using the International System of units (SI),
the estimated creatinine clearance (mL/s) in males
can be calculated as follows:

The recommended daily dose is 1 to 2 g adminis
tered in equally divided doses every 6 to 8 hours
(see Table 1).

(lean body weight, kg) x (140 - age, years) x 1.4736

Dosage in Elderly Patients

and in females the estimated creatinine clearance
(mL/s) is:

(72) x (serum creatinine concentration,/rmol/L)

3516Ca - 500mgimipenemequivalentand500mg
cilastatin equivalent in vials.
The dry powder should be stored at a temperature
below 30° C.

FULL PRODUCT MONOGRAPH
AVAILABLE ON REQUEST
(318-a,7,87)
*®T rademark
MEMBER

The recommended dosage of PRIMAXIN* in elderly
patients with normal renal function is the same as
given for adults above. Renal status of elderly
patients may not be accurately portrayed by
measurement of BUN or creatinine alone. Deter
mination of creatinine clearance is suggested to
provide guidance for dosing in such patients.

(lean body weight, kg)x (140-age, years) x 1.2526
(72) x (serum creatinine concentration, pmol/L)
PRIMAXIN* is cleared by hemodialysis. After each
dialysis session the dosage schedule should be
restarted.
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Diagnosis and M anagem ent of Adrenal Masses:
1987 Du Pont Lecture
Adrenal enlargements were found in
slightly more than 100 patients of
approximately 15 000 who underwent
abdominal computed tomography. A firm
diagnosis was made in 61 patients. Of
these, 34 were screened because of sus
pected metastases from nonadrenal
tumours. Major causes of adrenal
enlargement were metastases (20
patients), nonfunctioning adenomas (15)
and hormonally active masses (9). Fineneedle aspiration biopsy was a useful
diagnostic aid in patients with
metastases. Surgical treatment was
undertaken in 17 patients (three
pheochromocytomas, one Cushing's ade
noma, three Conn's adenomas, four
primary carcinomas, two metastatic car
cinomas, three nodular hyperplasias sus
pected to be part of the multiple endo
crine adenopathy syndrome and one
myelolipoma). Work-up of an adrenal
mass includes a full history and physical
examination, search for possible
nonadrenal primary malignant lesions,
testing for excess adrenal hormone
secretion, computed tomography of the
abdomen and fine-needle aspiration
biopsy in selected patients.

presente une hypertrophie de la surrenale. Un diagnostic ferme a ete pose
chez 61 patients. Parmi ceux-ci, 3 4 ont
ete investigues pour des metastases
soupconnees de tumeurs non surrdnales.
Les principales causes d'hypertrophie de
la surrenale etaient les metastases (20
patients), des adenomes non secretants
(15) et des tumeurs hormonalement acti
ves (9). Une ponction-biopsie a I'aiguille fine
a servi a poser un diagnostic chez les
patients porteurs de metastases. Une
intervention chirurgicale a ete pratiquee
chez 17 patients (trois pheochromocytomes, un adenome de Cushing, trois ade
nomes de Conn, quatre carcinomes primitifs, deux carcinomes metastatiques,
trois hyperplasies nodulaires soupcon
nees d'etre impliquees dans un syndrome
d'adenopathie endocrinienne multiple et
un myelolipome). L'6laboration du dia
gnostic d'une masse surrenale comprend
les antecedents et un examen physique
complet, la recherche de lesions malignes primitives d'origine possiblement
non surrenale, la verification d'une
hypersecretion surrenale, une tomodensi
tometrie de I'abdomen et une ponctionbiopsie a I'aiguille chez des patients
choisis.

Patients and Diagnoses
Between 1983 and 1987, clinical, radi
ologic, histopathologic or cytopathologic
diagnoses of adrenal masses were made
in 61 out of approximately 15 000 patients
who underwent abdominal computed to
mography at the University of Cincinnati
Medical Center and Cincinnati Veterans
Administration Medical Center. Thirtyfour patients underwent computed
tomography for suspected metastases
from a variety cf primary malignant
tumours (Table I). Those in whom
adrenal metastases were not confirmed by
fine-needle aspiration biopsy, underwent
repeat computed tomography over a
period of several months. Metastatic dis
ease was diagnosed if the mass increased
in size in untreated patients or decreased
substantially in size during chemotherapy.
Nonfunctional adenomas and adrenal
hyperplasia were diagnosed by fine-needle
T a b le 1— In d ic a t io n s f o r C o m p u t e d T o m o g r a p h y
In d ic a t io n

From the *Department of Surgery and
tDepartment of Radiology, University of
Cincinnati Medical Center and Cincinnati
Veterans Administration Medical Center,
Cincinnati, Ohio
Presented as the Du Pont Lecture at the
annual meeting o f the Southern Ontario
Surgical Society, Hamilton, Ont., May 22,
1987
t Sponsored as visiting professor, by
Du Pont Canada, Inc., Mississauga,
Ont.
Accepted for publication Sept. 24, 1987
Reprint requests to: Dr. I. Penn, Depart
ment of Surgery, University o f Cincinnati
Medical Center, 231 Bethesda Ave., Cincin
nati, OH 45267, USA

Adrenal masses used to be diagnosed only
when they caused symptoms. At that
stage, malignant tumours were often
incurable, and hormone-secreting
tumours had already caused substantial
morbidity. With the introduction of com
puted tomography we can now visualize
normal adrenal glands and thus detect
and localize abnormal glands.1 In two
series,2-3 computed tomography of the
upper abdomen revealed asymptomatic
adrenal masses in 0.6% and 0.7% of
cases, respectively. The importance of
such masses and the question of further
evaluation and treatment have posed
dilemmas for clinicians. In this report we
describe our experience with 61 patients
with adrenal masses, discovered inciden
tally in most.

34

t h e f o llo w in g p r im a r y
tu m o u rs *
Lung c a n c e r

Sur environ 15 000 patients qui ont subi
une tomodensitometrie, plus de 100 ont

N o . o f p a t ie n t s

S u s p e c te d m e ta s ta s e s fro m

20

C o lo n ic c a n c e r

3

O v a r ia n c a n c e r

2

N o n - H o d g k in 's ly m p h o m a

2

P r o s t a t ic c a n c e r

2

A d u lt W ilm s ' t u m o u r

1

L e io m y o s a r c o m a

1

P a n c r e a t ic c a n c e r

1

P h aryn g ea l c a n c e r

1

C e r v ic a l c a n c e r

1

U n k n o w n s it e

1

H y p e r t e n s io n

6

M u lt ip le e n d o c r in e

3

a d e n o p a th y
U n e x p la in e d w e i g h t lo s s

2

A b d o m in a l t r a u m a

2

F u n g a l in f e c t io n s

2

( s y s t e m ic , p u lm o n a r y )
M a s c u lin iz in g a d r e n o g e n it a l

1

s y n d ro m e
M is c e lla n e o u s a b d o m in a l

11

c o m p la in t s
*1

p a t ie n t h a d 2 p r im a r y t u m o u r s .
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aspiration biopsy or serial computed 14 cases. The diagnosis was confirmed by treated for ovarian cancer, underwent a
tomography. The finding of only normal fine-needle aspiration biopsy in 12, by right adrenalectomy for a suspected
adrenal cells in the aspiration specimens repeat computed tomography in 6 and by metastatic lesion. She became unexpect
was considered compatible with either operation in 2. A 74-year-old man with edly hypotensive when the adrenal gland
diagnosis. Computed tomography was persistent right upper quadrant pain, was removed; a pheochromocytoma was
considered diagnostic if no change in size nausea and vomiting underwent a radi subsequently diagnosed. She made a
occurred on follow-up over a period of cal right nephroadrenalectomy for sus smooth postoperative recovery. Of the
6 months to 2 years. Adenomas appeared pected primary carcinoma of the adrenal, two hypertensive patients treated surgi
as a focal dominant mass in otherwise which was found to be a metastatic cally, one was lost to follow-up and the
normal glands. Hyperplasia was seen as adenosquamous carcinoma, presumably second was normotensive with normal
smooth adreniform or diffuse multinodu from the lung (Fig. 1). He refused radi vanillylmandelic acid levels in the urine
lar adrenal enlargement without a focal otherapy and chemotherapy and was lost 1 year later. The diagnosis was made at
mass.
to follow-up. The second surgical patient autopsy in the fourth patient, an 87-yearConn’s tumour was diagnosed by clin had palliative resection of a metastatic old normotensive man who was found to
ical history, serum biochemical analysis lesion of the adrenal from colonic carci have areas of calciiication on computed
and pathological examination of the sur noma. Several months later widespread tomography (Fig. 3).
gical specimen. Two patients underwent metastases developed.
diagnostic preoperative venous sampling,
Myelolipoma
which was technically unsuccessful in one Nonfunctioning Adenomas
patient found to have aberrant venous
The appearance of a fat-containing
drainage at surgery.
Of the 15 patients with nonfunctioning tumour on computed tomography was
Adrenal myelolipoma was diagnosed adenomas, the lesions were bilateral in 4, considered diagnostic in three of the four
by its characteristic computed tomo the left gland only was involved in 7, the patients (Fig. 4). The fourth patient had
graphic appearance, with areas of the right gland only in 4. The diagnosis was a 4-cm partially calcified soft-tissue dense
tumour having a fat density of - 80 to confirmed by fine-needle aspiration mass and underwent a nondiagnostic fine-100 Hounsfield units (HU). The biopsy alone in five patients, by computed needle aspiration biopsy; the diagno
appearance of an initially high-density tomography alone (1 to 2 years follow sis was made after surgical removal. One
mass (60 to 80 HU), that decreased in up) in three patients and by both proce patient had bilateral lesions.
both size and density over 1 to 3 months dures in seven patients (Fig. 2). One 4-cm
was diagnostic for hemorrhage.
diameter lesion contained a hemorrhagic Adrenal Carcinoma
In patients whose clinical picture war cyst which was confirmed by fine-needle
ranted further investigation, urinary aspiration biopsy.
Three of the four adrenal carcinomas
excretion of 17-hydroxycorticosteroids
were clinically nonfunctional, the fourth
and 17-ketosteroids was measured, in Nodular Hyperplasia
caused masculinization in a woman. At
addition to plasma concentrations of cor
the time of operation one patient had liver
tisol and aldosterone. Catecholamine
Of the five patients with nodular hyper and nodal metastases with tumour
production was evaluated by calculating plasia, two had bilateral lesions. Three thrombus in the inferior vena cava. Oper
the urinary excretion of vanillylmandelic patients had suspected multiple endocrine ation included radical nephroadrenalec
acid, metanephrine and catecholamines, adenopathy — gastrinoma and pituitary tomy, node dissection and removal of the
and the plasma concentrations of tumour in one, the second a pituitary thrombus. Another patient had splenic,
norepinephrine and epinephrine. Other tumour only and hypertension with a sug renal and lymph-node invasion (Fig. 5),
diagnostic tests included angiography, gestive clinical picture in the third. The requiring radical removal of the involved
inferior vena caval venography, ultra diagnosis of nonfunctional nodular structures. Three of the four patients subsonography and adrenal venous sam hyperplasia was made only after removal
pling.
of the affected glands, and all patients
Histopathologic studies were per made smooth recoveries. In the two
formed on surgically removed specimens remaining patients fine-needle aspiration
(17) and autopsy material (1) and biopsy confirmed the diagnosis.
cytopathologic studies were performed on
fine-needle aspiration biopsy specimens Pheochromocytoma
(28). The last test was used mainly in
patients with suspected metastases to the
Only two of four patients with
adrenal glands.
pheochromocytoma were hypertensive.
The lesions involved both glands equally.
Findings
One normotensive patient, previously
The lesions encountered and their
dimensions are listed in Table II. Of the
61 patients 17 (28%) had bilateral lesions
— 9 adrenal metastases, 4 nonfunction
ing adenomas, 2 nodular hyperplasia, 1
myelolipoma and 1 histoplasmosis.
Metastases
The primary malignant tumours that
were metastatic to the adrenal glands
were as shown in Table III. Nine patients
had bilateral lesions. The left adrenal
gland was enlarged in 15 and the right in
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M e t a s t a t i c t o t h e A d re n a l G la n d

Tum our

N o . o f tu m o u r s

Lung c a n c e r

11

C o lo n ic c a n c e r

3

N o n - H o d g k in 's ly m p h o m a

2

O v a r ia n c a n c e r

1

P r o s t a t ic c a n c e r

1

W ilm s ' t u m o u r

1

U nknow n

1

T a b le I I — D ia g n o s is a n d S iz e o f A d r e n a l M a s s e s in 6 1

P a t ie n t s

S iz e o f le s io n , c m

N o . o f p a t ie n t s

Range

M ean

M e t a s t a s e s t o a d r e n a l g la n d

20

1 -

10

4 .8

N o n f u n c t io n in g a d e n o m a

15

1 -

4

2 .5

N o d u la r h y p e r p la s ia

5

1 -

3

—

P h e o c h ro m o c y to m a

4

2 .5 -

8

5

M y e lo lip o m a

4

1 -

10

—

P r im a r y a d r e n a l c a r c in o m a

4

4 .5 -

12

8

3

—

C o n n 's a d e n o m a

3

1 -

A d re n a l h e m o rrh a g e

3

2

-

F u n g a l in f e c tio n

2

3

—

C u s h in g 's a d e n o m a

1

2

—

FIG. 1—Right adrenal mass caused by metastatic adenosquamous
carcinoma presumably of bronchial origin (IVC = inferior vena cava).

FIG. 2—Computed tomography was performed for suspected pan
creatic carcinoma in middle-aged woman. Note left adrenal mass, 3 cm
in dimension, diagnosed as nonfunctioning adenoma since there were
no hormonal abnormalities and no change in computed tom ography
after 1-year follow-up.

FIG. 3—Calcified 5-cm right adrenal pheochromocytoma in normotensive 87-year-old man. Diagnosis was confirmed at autopsy.

FIG. 4—Bilateral myelolipomas in woman with abdominal pain and
abnormal liver function test results. Note fat-density right adrenal mass
(10 cm) and fat-density left adrenal mass (4 cm).

FIG. 5—Carcinoma of left adrenal gland measuring 12 cm in 63-yearold woman with left upper quadrant pain, nausea, vomiting and severe
weight loss. Managed by in-continuity excision of adrenal gland, kid
ney, spleen and lymph nodes.

FIG. 6—Left adrenal mass in 18-year-old hypertensive man. Diag
nosis of C onn’s adenoma was confirmed by venous sampling. Patient
became normotensive after left adrenalectomy.
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sequently suffered widespread metastases
and died 7 to 24 months postoperatively.
The fourth who had a nonfunctioning
4.5-cm adenocarcinoma was well, with a
normal abdominal computed tomogram
more than 16 months after operation.
C onn’s Adenoma
All three patients with Conn’s ade
nomas (Fig. 6) presented with hyperten
sion and hypokalemia. All were treated
surgically, with remission of hypertension
in two. The third required low dosage
antihypertensive medication.
Adrenal Hemorrhage
Adrenal hemorrhage occurred in three
patients; hemorrhage occurred after
abdominal trauma in two and in a third
patient with relapsing polychondritis who
was on long-term corticosteroid therapy.
The density and size changes on serial
computed tomography were considered
diagnostic.
Fungal Infections
Two patients had disseminated fungal
infections, one by histoplasmosis and the
other by blastomycosis. In the former, the
adrenal gland enlargement was bilateral
and in the second it was unilateral with
some calcification. The diagnosis was
confirm ed by fine-needle aspiration
biopsy in both.
Cushing’s Syndrome
This patient’s lesion in the left adrenal
gland was managed by surgical excision.
There was almost complete remission of
the syndrome except for persistent mild
hypertension.

Discussion
High-resolution computed tomography
has made the investigation of adrenal
lesions much safer, eliminating many
invasive and potentially harmful diagnos
tic procedures.4 But, by unearthing
previously unsuspected adrenal masses,
computed tomography creates diagnostic
dilemmas and may fail to detect a lesion
1 cm or less in size4 or an adrenal mass
in children or thin adults who have little
retroperitoneal fat to provide sufficient
contrast.
W ith a radiologically diagnosed
adrenal enlargement, the surgeon faces
two questions — is it hormonally active?
and is it malignant? To answer these ques
tions a careful review of the history, phys
ical and biochemical findings is necessary
to determine whether the patient has
Cushing’s syndrome, primary aldostero
nism, pheochromocytoma or the adreno
108

genital syndrome (with masculinization or
feminization).
In patients with Cushing’s syndrome,
the dexamethasone suppression and
metyrapone tests will determine whether
the underlying cause is in the pituitary
gland or whether an adrenal adenoma or
carcinoma is responsible.5 Great care
must be taken in performing the various
tests and interpreting the results because
they are subject to dietary, pharmacologic
and environmental influences.6 Pheochromocytomas especially are easily
missed as the absence of hypertension
does not exclude the diagnosis in a patient
with an incidentally discovered adrenal
mass.5 In two large series,7,8 20% and
24% of pheochromocytomas, respectively,
were discovered only at autopsy.
However, 131I-meta-iodobenzylguandine
(MIBG) scintigrams show promise in
effectively localizing the tumours, espe
cially multiple and malignant lesions.4 In
addition, iodocholesterol scintigrams
have accurately localized Conn’s ade
nomas in the majority of cases studied.4
Nonfunctional adrenal carcinomas may
be less common than previously thought
and when urinary 17-ketosteroid levels are
measured in such patients, many are
found to be producing excessive amounts
of steroids.5 One of the four primary
carcinomas in our series caused a viriliz
ing syndrome.
More important than the hormonal
investigation is the need to determine if
the lesion is malignant. In our series, 33%
of adrenal enlargements were metastatic
and only 7% primary malignant lesions.
The predominance of metastatic lesions
has been reported by others.2,5 In
patients with known cancers elsewhere in
the body, not all adrenal masses are
metastases, as shown by 15 of 34 patients
in our series who had benign lesions con
firmed by fine-needle aspiration biopsy,
clinical follow-up and serial computed
tomography. A similar finding has been
reported by Belldegrun and colleagues2
who found that 27% of their patients with
known primary carcinomas had unrelated
benign adrenal lesions.
In the absence of metastasis or a func
tional mass one must distinguish between
benign lesions and primary adrenal car
cinomas. Copeland5 emphasized the rar
ity of adrenocortical carcinoma (0.0006%
to 0.00017% annual incidence in cancer
registries) compared with relative fre
quency of benign, clinically silent ade
nomas (1.4% to 8.7% in several autopsy
series). Most cortical adenomas are small
and occur most frequently in the
elderly.6 Some investigators recommend
serial computed tomography for adrenal
masses less than 5 cm in diameter that
have a smooth contour and well-defined
margins.9 Others have recommended
removal of masses larger than 3 to 4
cm,3 3.5 cm,2 or 6 cm.5 In our experience

most benign lesions were 4 cm or smaller
in diameter while primary malignant
tumours were 4.5 cm or larger. The mean
size of adrenal carcinomas in three large
series2,10,11 ranged from 10 to 14 cm and
the smallest tumours from 4 to 1 cm.
Therefore, when a lesion is larger than 4
cm in diameter we advise surgical
removal. For smaller lesions we recom
mend serial computed tomography to
demonstrate lack of growth. If the mass
shows enlargement on follow-up, we
advise operation. If the adrenal lesion is
suspected to be a solitary metastasis in
patients with remote cancers, operation
is also indicated.
Fine-needle aspiration biopsy, a valu
able tool in our study, has been shown to
be diagnostic in 83% to 94% of cases in
selected patients.12-14 We found fineneedle aspiration biopsy to be most
accurate in differentiating metastatic dis
ease from primary adrenal tumours, and
it made possible the diagnosis of fungal
infection of the gland in two patients.
However, it fails as a method of differen
tiating a primary carcinoma from an ade
noma, adenoma from hyperplasia or
hyperplasia from normal adrenal tissue.
The key to its successful use is meticulous
technique using 22-gauge needles and
careful route planning. A “ quick-stain
technique” reduces nondiagnostic biop
sies to a minimum. The specimen is
stained and viewed by the cytopathology
technician in the computed tomography
room. Multiple passes are made until a
good-quality specimen is obtained. Using
a 21- to 23-gauge needle, the incidence of
serious hemorrhage, pneumothorax or
infection is less than 2%.
With the suggested guidelines we
believe that an accurate diagnosis can be
made in most patients. Preoperative
localization allows the surgeon to plan an
approach that combines ease of operation
with low morbidity, avoiding the anterior
transperitoneal route in many cases. In
one series15 using this anterior approach,
18% of patients who underwent left
adrenalectomy required an incidental
splenectomy. We agree with the recom
mendation of others4,15 that the anterior
incision be used for patients with
pheochromocytoma, since approximately
10% have either extra-adrenal tumours or
a malignant lesion not accessible through
a retroperitoneal approach. We also use
the approach for large tumours, but when
extensive en-bloc excision is anticipated
we prefer a thoracoabdominal incision.
For most small lesions we use the
posterior route, which gives good
exposure, particularly of the right adrenal
where the venous drainage frequently
enters the posterior surface of the vena
cava and is less accessible anteriorly.4
For small bilateral lesions, posterior inci
sions are used. Perioperative blood
replacement and postoperative morbidity
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are lower with the posterior approach and
the hospital stay is substantially shorter
after unilateral or bilateral adrenalectomy
than with the anterior incision.15
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Open pelvic fractures are highly lethal lesions, with at least half of such pa
tients dying even in the absence of other injuries. Breaks or joint disruptions
at two different sites occur when a major compressive force is applied to the
bony pelvic “ ring.” Fracture fragments may penetrate the colon or rectum,
thereby further complicating management, but the most common cause of death
after major pelvic fracture continues to be blood loss from small arteries and
veins arising from the hypogastric circulation. Blood at the urethral meatus
after pelvic fracture suggests disruption of the urethra or base of the bladder,
and dictates urethrography prior to attempts at cathether insertion.
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sons de Montreal. Pour renseignements,
s’adresser au secretariat de l’Association:
(514) 849-8887.

Workshop in Liver Surgery
A workshop in liver surgery is sched
uled for Apr. 29, 1988 in Sacramento,
Calif., sponsored by the UC Davis School
of Medicine. Topics covered will include:
current indications and techniques for
hepatic resection and the role of the ultra
sonic dissector in surgery. Information
can be obtained from the UC Davis
School of Medicine, 2701 Stockton Blvd.,
Sacramento, CA 95817; telephone: (916)
453-5390.

14. Berkman w a , Bern a rd in o ME, Sewell CW, et al:
The computed tomography-guided adrenal biopsy. An
alternative to surgery in adrenal mass diagnosis. Cancer
1984; 53: 2098-2103

Postgraduate Course
in General Surgery

15. RUSSELL CF, HAMBERGER B, VAN HEERDEN JA, et al:
Adrenalectomy: anterior or posterior approach? Am J
Surg 1982; 144: 322-324

The Department of Surgery o f the
University of California School of Medi

cine, San Francisco, is holding a course
in general surgery which will offer general
surgeons an intensive overview of
problems encountered in daily practice.
The course will be held Apr. 14-16, 1988.
For registration information write to:
Extended Programs in Medical Educa
tion, Registration Office, Room 575-U,
University o f California, San Francisco,
CA 94143-0766 or call (415) 476-5808.

Annual Surgery Course
of University of Minnesota
Medical School
The University of Minnesota’s Medi
cal School will present its 52nd annual
surgery course, entitled “ Progress in Gas
trointestinal Surgery” , June 15-18, 1988.
For further information contact the
Office of Continuing Medical Education,
University o f M innesota, Box 202,
UMHC, 420 Delaware St. SE, Min
neapolis, MN 55455; telephone (612)
626-5525.
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Dalacin C Phosphate Sterile Solution

(clindamycin phosphate)

Antibiotic
Recommended Applications
Action: Clindamycin exerts its antibacterial effect by causing cessation of protein synthesis and also by
causing a reduction in the rate of synthesis of nucleic acids.
Indications: Dalacin C Phosphate (clindamycin phosphate) is indicated for the treatment of infections
where the oral route is not indicated or feasible.
Dalacin C Phosphate is indicated in the treatment of serious infections due to sensitive anaerobic
bacteria, such as Bacteroides species, peptostreptococcus, anaerobic streptococci, Clostridium
species and micro-aerophilic streptococci.
Dalacin C Phosphate is also indicated in serious infections due to sensitive Gram-positive organisms
(staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci)
when the patient is intolerant of, or the organism resistant to other appropriate antibiotics.
Contraindications: The use of Dalacin C Phosphate (clindamycin phosphate) is contraindicated in
patients previously found to be hypersensitive to this compound, the parent compound, clindamycin, or
clindamycin palmitate. Although cross-sensitization with Lincocin® (lincomycin hydrochloride) has not
been demonstrated, it is recommended that Dalacin C Phosphate not be used in patients who have
demonstrated lincomycin sensitivity.
Until further clinical experience is obtained, Dalacin C Phosphate is not indicated in the newborn (in
fants below 30 days of age), or in pregnant women.
Warnings: Some cases of severe and persistent diarrhea have been reported during or after therapy
with Dalacin C Phosphate (clindamycin phosphate). This diarrhea has been occasionally associated with
blood and mucus in the stools and has at times resulted in acute colitis. When endoscopy has been
performed, some of these cases have shown pseudomembrane formation.
If significant diarrhea occurs during therapy, this drug should be discontinued or, if necessary, con
tinued only with close observation. Significant diarrhea occuring up to several weeks post-therapy
should be managed as if antibiotic-associated.
If colitis is suspected, endoscopy is recommended. Mild cases showing minimal mucosal changes
may respondtosimpledrugdiscontinuance.Moderatetoseverecases.includingthoseshowingulceration or pseudomembrane formation, should be managed with fluid, electrolyte, and protein
supplementation as indicated. Corticoid retention enemas and systemic corticoids may be of help in
persistent cases. Anticholinergics and anti peristaltic agents may worsen the condition. Other causes
of colitis should be considered.
Studies indicate a toxin(s) produced by Clostridia (especially Clostridium difficile) may be a principal
cause of clindamycin and other antibiotic-associated colitis. These studies also indicate that this
toxigenic Clostridium is usually sensitive in-vitro to vancomycin. When 125 mg to 500 mg of vanco
mycin were administered orally four times a day for 5 - 10 or more days, there was a rapid ob
served disappearance of the toxin from faecal samples and a coincidental recovery from the diarrhea.
It should be noted that serious relapses have occurred up to one month after apparently successful
treatment. A relatively prolonged period of continuing observation is therefore recommended.
Precautions: Dalacin C Phosphate (clindamycin phosphate), like any drug, should be prescribed with
caution in atopic individuals. Dalacin C Phosphate must be diluted for intravenous administration.
(See Dosage and Administration)
The use of antibiotics occasionally results in overgrowth of nonsusceptible organisms - particularly
yeasts. Should superinfections occur, appropriate measures should be taken as dictated by the
clinical situation.
As with all antibiotics, perform culture and sensitivity studies in conjunction with drug therapy.
Since abnormalities of liver function tests have been noted occasionally in animals and man, periodic
liver function tests should be performed during prolonged therapy. Blood counts should also be
monitored,during extended therapy.
Dalacin C Phosphate may be used in anuretic patients. Since the serum half-life of clindamycin in
patients with impaired hepatic function is greater than that found in normal patients, the dose of
Dalacin C Phosphate should be appropriately decreased. Hemodialysis and peritoneal dialysisare not
effective means of removing the compound from the blood. Periodic serum levels should be deter
mined in patients with severe hepatic and renal insufficiency.
Adverse Reactions: Local
(a) Intramuscular Injections: Of 404 patients treated with Dalacin C Phosphate (clindamycin
phosphate) intramuscularly (with a solution containing 150 mg/ml), six (1.5%) demonstrated local
reactions as follows: Two complained of pain at the injection site, two demonstrated induration at
the injection site and two developed sterile absesses.
(b) Intravenous Infusions: Of 192 patients treated with Dalacin C Phosphate by intravenous infusion,
14 (7.3%) demonstrated local reactions. Eleven patients developed superficial thrombophlebitis and
one patient developed both superficial and deep thrombophlebitis. The majority of these cases
developed in conjuctionwiththe useofindwelling I.V.cathetersand itisdifficulttoknowhowm uchthe
drug contributed to the irritation. Two patients developed localized erythema, swelling and pain at
the site of the infusion.
Systemic Side Effects: Twenty-eight patients of 596 treated with Dalacin C Phosphate (clindamycin
phosphate) by either the intramuscular or intravenous routes developed systemic side effects as follows:
Number o f Patients
Rash............................................................................................................................................................. 7
Urticaria........................................................................................................................................................ 1
Pruritus......................................................................................................................................................... 1
Fever, Leucocytosis..................................................................................................................................... 1
Nausea, with or without vomiting.............................................................................................................. 1
Diarrhea (See also under "Warnings")........................................................................................................ 4
Hypotension................................................................................................................................................. 1
Hypertension................................................................................................................................................ 1
Shortness of Breath.................................................................................................................................... 1
Superinfection*........................................................................................................................................... 4
Cardiac arrest**.......................................................................................................................................... 1
Bad or bitter taste in mouth........................................................................................................................ 5

*
**

Superinfection is a complication of antibiotic therapy in general and is not necessarily a true side
effect of clindamycin phosphate.
Due to underlying myocarditis in this patient.
y

Clinical and Laboratory Findings: Patients treated during clinical trials of Dalacin C Phosphatj *
(clindamycin phosphate) were followed with clinical laboratory tests, including complete hematology,
urinalysisandliverand kidney function tests. Some of these tests were abnormal initially and returned
to normal during therapy with Dalacin C Phosphate, while others were normal initially and became 4
abnormal,during therapy. Overall evaluation of clinical laboratory values in these patients does not
indicate that Dalacin C Phosphate therapy has a toxic effect on the hematopoietic, hepatic or renal*systems. Transient elevations of serum transaminases have occured in some patients, but other liver
function tests (alkaline phosphatase, serum bilirubin) have not shown any tendency to increase and e.
there have not been clinical signs of drug-induced hepatic toxicity.
Symptoms and Treatment of Overdosage: No cases of overdosage have been reported. No specific
antidote is known. Doses as high as 1200 mg every six hours (4800 mg/day) by infusion forfive days
have been given without adverse effects.
'*
DOSAGE AND ADMINISTRATION
Adults
Intramuscular Injection: 600 mg/day in 2 equal doses.
A
Moderately severe infections: 600 to 1200 mg/day in 2 o r3 equal doses.
Severe infections: 1200 to 2400 mg/day in 2,3 or 4 equal doses. Intramuscular injections of more thaiA
600 mg into a single site are not recommended.
Intravenous Administration: Dalacin C Phosphate (clindamycin phosphate) must be diluted prior to
I V. administration to a dilution of 300 mg in 50 mL of diluent (6mg/mL) or more, and infused in not less
thanlOm inutes. Administration of more than 1200mg in asingle 1 hour infusion isnot recommended. ^
Dalacin C Phosphate should not be injected intravenously undiluted as a bolus.
Moderately severe infections: 900 to 1800 mg/day by continuous drip or in 2 or 3 equal doses, each
infused over 20 minutes or longer.
Severe Infections: 1800 to 2700 mg/day by continuous drip or in 3 or 4 equal doses, each infused ove(_
20 minutes or longer. In life-threatening infections, doses of 2700to 4800 mg/day by continuous drip o r”
in 3 or 4 equal doses each infused over 20 minutes or longer may be given.
Dilution and infusion rates:
Dose
Diluent
Time
300 mg
50 mL
10 min.
**
600 mg
100 mL
20 min.
900 mg
150 mL
30 min.
1200 mg
200 mL
45 min.
Alternatively, drug may be administered in the form of a single rapid infusion of the first dose followed
by continuous I.V. infusion as follows:
To maintain serum
Rapid
Maintenance
clindamycin levels
infusion rate
infusion rate
*
Above 4 mcg/mL
10m g/m in.for30m in.
0.75 mg/min.
Above 5 mcg/mL
15m g/m in.for30m in.
1.00mg/min.
Above 6 mcg/mL
20 m g/m in.for30m in.
1.25 mg/min.
Children: (Overone month of age)
-*
Intramuscular injection: 10 to 15 mg/kg/day in 2 ,3 or 4 equal doses.
Moderately severe infections: 15 to 20 mg/kg/day in 3 or 4 equal doses.
v
Severe infections: 20 to 30 mg/kg/day in 3 or 4 equal doses.
Intravenous Administration:
< Moderately severe infections: 15 to 25 mg/kg/day by continuous drip or in 3 or 4 equal doses, each
infused over 20 minutes or longer.
t
Severe infections: It is recommended that children be given no less than 300 mg/day regardless of body
weight. (Dilute Dalacin C Phosphate Sterile Solution in the same manner as for adults.)
+
Dilution and Compatibility:
4 mL (600 mg) Dalacin C Phosphate when diluted with 1000 mL of the following commonly used in- - y
fusion solutions was found to be physically compatible and demonstrated no significant change in pH
or antimicrobial potency over a period of 24 hours:
.
Sodium chloride injection
f '
Dextrose 5% in water
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Gastroplasty With Distal Gastric Bypass:
a New and More Successful Weight Loss Operation
for the Morbidly Obese
Because of the unacceptable late failure
rates associated with other surgical
procedures for morbid obesity, the
author has performed a new operation —
vertical banded gastroplasty with distal
gastric bypass — on 70 patients. In
seven of these the gastroplasty stoma
had to be debanded. The mean lowest
loss of excess weight was 8 8 % and the
mean final loss of excess weight was
83% for the main group. The postopera
tive complication rate was acceptable
and no late metabolic complications have
been seen.
This operation gives improved weight
loss when compared with gastroplasty or
gastric bypass alone and has none of the
late complications associated with intes
tinal bypass.

A cause du taux inacceptable d’echecs
retardes relies aux techniques chirurgicales courantes pour obesite pathologique,
I'auteur a pratique chez 70 patients un
nouveau type d'operation, une gastroplastie a bandelettes verticales avec deri
vation gastrique distale. Dans sept cas,
les bandelettes du stoma de gastroplastie
durent etre defaites. La perte minimale
moyenne d'exces de poids a ete de 88%
et la perte finale moyenne d'exces de
poids a ete de 83% pour le groupe prin
cipal. Le taux de complications postoperatoires est acceptable et aucune compli
cation metabolique tardive n'a ete
enregistree.
Cette operation augmente la perte de
poids par rapport it la gastroplastie ou a

la derivation gastrique seule et ne cause
aucune des complications tardives reliees
a la derivation intestinale.

Patients and Methods

Although initially a successful weight-loss
procedure in my hands, gastroplasty,
whether horizontal, vertical or vertical
banded, has been associated with an
unacceptable late failure rate. Data com
piled at the University of Alberta H ospi
tal and supported in the literature1-4
show that this failure rate has steadily
increased through the years (Table I5’6).
Weight loss failure is defined as inability
of the patient to lose or maintain a loss
of more than 40% of excess weight.
When the failure o f gastroplasty
became evident some years ago, I began
considering possible alternatives. In my
hands, intestinal bypass in patients fol
lowed up for between 2.8 and 6.8 years
is associated with only a 2.5% failure of
weight loss but a 20% overall failure rate.
Gastric bypass is renowned as a techni
cally difficult procedure and although it
maintains weight loss for longer than gas
troplasty, it was reported in one series to
be associated with a late failure rate of
31.5%.7 The pancreaticobiliary bypass
of Scopinaro,8,9 apparently a very suc
cessful weight loss operation, is also tech
nically demanding and has some o f the
malabsorption problems associated with
intestinal bypass.10,11
In this paper I report a new type of
weight loss operation that combines the
small vertical pouch and reinforced stoma
of gastroplasty with the additional, and
perhaps undefined, benefits of gastric
bypass. I have found it highly successful
T a b le 1— F a ilu re R a t e

From the Department o f Surgery, Univer
sity o f Alberta, Edmonton, Alta.
Accepted fo r publication Sept. 24, 1987
Reprint requests to: Dr. P.A. Salmon,
Department o f Surgery, 2D4. 27 Walter
Mackenzie Health Sciences Centre, Edmon
ton, Alta. T6G 2B7

and associated with few side effects, save
those of gastric restriction.

Vertical banded gastroplasty with dis
tal gastric bypass was performed on 70
patients, followed up for between 1.6 and
4 years. The mean preoperative weight
was 127.2 kg (range from 88.2 to 210.9
kg). The patients met previously estab
lished criteria for selection and were
assessed in the same way as candidates for
intestinal bypass or gastroplasty. They
were assessed postoperatively at 1 month,
3 months, 6 months and every year there
after.
Weight loss for each patient was
recorded on the day of maximum loss
(greatest excess weight loss [GEWL]) and
on the final day of follow-up (final excess
weight loss [FEWL]). These figures show
how profound weight loss has been and
provide an estimate of the stability of
weight loss or any tendency to rapid
regain of weight. Ideal weights were esti
mated from Metropolitan Life Insurance
Company tables; the mean ideal weight
for the group was 60.6 kg (range from
48.6 to 77.3 kg).
Operative Technique

A vertical banded gastroplasty is per
formed using the old TA90 stapler
(United States Surgical Corp., Stamford,
Conn.) with seven staples removed from
the lesser curvature end of the staple clip
to form a stoma. The stoma is reinforced
with a 6-cm segment of 6-cm Impragraft
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(Impra Inc., Phoenix, Ariz.),12 sutured
through the lesser curvature end of the
staple line with 1-0 Prolene. The stoma
is not calibrated with an intraluminal bou
gie or catheter.
The distal gastric bypass (Figs. 1 and
2) is constructed by applying two staple
lines with the new TA90 stapler, running
from the lesser curvature below the gas
troplasty stoma to the greater curvature
at the lower pole of the spleen. A Dennis
clamp is applied above the staple line on
the greater curvature and an appropriate
incision made between clamp and staple
line to accomodate the jejunal anasto
mosis.
The jejunum is picked up at a distance
of between 40 and 60 cm from the liga
ment o f Treitz and divided between
Dennis clamps. The mesentery is opened
and vessels of the arcade are individually
grasped, divided and ligated. An antecolic
gastrojejunostomy is then performed over
clamps after the aseptic technique of
Wangensteen13 and Dennis,14 using inter
rupted 4-0 black silk Lembert sutures.
The rent in the mesentery is closed with
interrupted 4-0 black silk sutures.
A Roux-en-Y enteroenterostomy is
then constructed below the gastroen
terostomy and the mesentery closed. The
nasogastric tube can be passed into the
jejunum but often is only passed through
the gastroplasty stoma.
Postoperative care is as reported previ
ously for gastroplasties.15
Results

Weight Loss
All 70 patients lost at least 40% of
excess weight. Weight loss was rapid and
profound; all, except the ones who were
heaviest, lost maximum weight within the
first 12 to 14 months. Initial weight loss
in 14 patients was either equal to or below
the ideal weight. Subsequently, they
regained a little weight to be near or just
above the ideal.
For the main group (63 patients fol
lowed up 1.9 to 4 years) the mean GEWL
was 88% and mean FEWL was 83%. A
detailed presentation of each patient on
the last day of follow-up is presented in
chronologic weight-loss graphs (Fig. 3).
Patients who underwent debanding had
a mean GEWL of 80% and a mean
FEWL of 72%.

line eventration occurred in two patients
within 18 months. The result in each case
was two stomas, one of standard size and
a second somewhat smaller. The GEWL
was 88% for one patient and 122% for
the second. The FEWL was 67% at 766
days for the former and 100% on day 913
for the latter.
In one patient a 1-mm dehiscence deve
loped in the distal staple line allowing
contrast agent to leak into the distal

Postoperative Complications
There were no major wound infections.
Superficial wound infections occurred in
2% of patients. One patient had an ileal
strangulation 1 year after operation. The
obstruction was due to an adhesive band.
She underwent resection of the involved
gut with primary anastomosis and subse
quently did well. Two patients had an
upper gastrointestinal hemorrhage, one
after 18 months the other after 20
months. Both underwent truncal vagot
omy with suture of a bleeding posterior
wall anastomotic ulcer. Neither patient
has had further difficulties. Two patients
have had minor dyspepsia treated success
fully with H2 receptor blockade. Staple-

DAYS POSTOPERATIVE

DAYS POSTOPERATIVE

Postoperatively seven patients (follow
up 1.6 to 2.9 years) had the gastroplasty
stoma debanded. One was debanded 5
days after operation because of a leak at
the staple line and six were debended later
because of excessive gastric restriction.
Weight losses for this group are treated
separately.

FIG. 1—Gastroplasty with distal gastric
bypass. Distal staple line is well above gastric
antrum at level of lower pole of spleen.
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FIG. 2—Barium outlines esophagus, gas
troplasty pouch (A) and stoma (B), distal gas
tric pouch (C) and gastrojejunostomy (D).
Pouches are not completely filled but staple
lines and gas shadows indicate their extent.

FIG. 3—Chronologic weight-loss graphs.
Each vertical line represents one patient on last
day of follow-up. Top of line is weight at oper
ation, bottom is lowest weight, horizontal
dash is final weight. Circle at bottom
is ideal weight related to height and age
(Metropolitan Life Insurance Company tables).
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defunctioned stomach. This was disco
vered on day 52. By day 549 the excess
weight loss was 98%.
Complete follow-up of serum labora
tory data in all patients did not reveal any
noteworthy abnormality. Results of liver
function tests were all normal at 3 months
and for the remainder of the follow-up
period. No patient had renal stones or
electrolyte abnormalities. There was no
anemia, other than in the two patients
with upper gastrointestinal hemorrhage.
The only serious side effects were
related to gastric restriction and intoler
ance of red meat, which affected 78% of
patients during the first year, but only 7%
by the end of the second year.
Diarrhea is not associated with this
operation. Constipation preoperatively
was improved by operation.
Discussion
The aim of surgery for morbid obesity
is profound and lasting weight loss. Intes
tinal bypass fulfilled these criteria, but
neither gastroplasty nor gastric bypass
alone has totally succeeded, and I no
longer perform gastroplasty alone.
However, gastroplasty with distal gastric
bypass has proved to be unique in that ini
tial weight loss is even more profound
than that achieved with intestinal bypass
and is not associated with metabolic side
effects.
A comparison of my results with those
reported by Reinhold16 for gastric bypass
alone using his simplified method of
evaluation is shown in Table II. Gas
troplasty with distal gastric bypass obvi
ously outperforms gastric bypass, achiev
ing a much more consistent weight loss
over comparable follow-up periods. The
difference may well be related to the last
ing intake restriction imposed by the
lesser curvature vertical gastroplasty and
the banded stoma, a feature less easily
achieved with gastric bypass alone.
The limited intake imposed by the gas
troplasty component is usually well toler
ated. When intractable intolerance
occurred, debanding relieved vomiting
and dysphagia while not fundamentally
altering weight loss.

The addition of distal gastric bypass to
gastroplasty has not, in my hands,
increased the risk of surgery; there were
no deaths attributable to the procedure
and the complication rate was similar to
that of gastroplasty alone. Operating
time, however, increased by one half and
a slightly longer abdominal incision is
necessary. This has not resulted in an
increased need for blood replacement or
rate of wound infection.
The positioning of the gastroen
terostomy stoma more distally has meant
that lengthening the jejunal mesentery is
unnecessary in order to accomplish an antecolic gastroenterostomy. Early in the
series several patients had retrocolic gas
trojejunostomies, but it was soon disco
vered that this was unnecessary so long
as the jejunal limb was made at least 40
cm from the ligament of Treitz. This held
true even in the heaviest patients operat
ed on.
The frequency of acid peptic problems
after gastric bypass alone has been low,
undoubtedly because the small pouch is
made so high on the stomach that little
parietal cell mass is included. I initially
expected that acid peptic problems might
be more frequent after gastroplasty with
distal gastric bypass. That this was not the
case is probably because the proximal gas
troplasty staple lines denervate a substan
tial part of the fundus thereby protecting
the gastroenterostomy. The follow-up is
still relatively short and only further
review will ascertain whether or not
anastomotic ulcers will occur more fre
quently.
Eventration of both proximal and dis
tal staple lines occurred in this series. The
incidence has been small and so far has
had only minimal impact on weight loss.
Undoubtedly the gastric bypass to some
degree ameliorates the effects of proximal
staple-line failure.
Gastroplasty with distal gastric bypass
demands more operating time and is tech
nically more difficult to perform than
either procedure alone. However, the
more profound and lasting weight loss
compared with gastroplasty or gastric
bypass alone and the lack of complica
tions when compared with intestinal

Table II—Comparison of Results of Combined Gastroplasty With
Gastric Bypass and Gastric Bypass Alone16 Using Reinhold's
Classification
No. of patients
Final excess
Reinhold
Salmon
weight, %*
Result
(n = 29)
In - 61)
Reinhold
< 25
Excellent
10
45
34.5
26 - 50
Good
7
15
24.1
51 - 75
Fair
8
1
27.6
76 - 100
Poor
3
0
10.3
> 100
Failure
1
0
3.4
final weight - ideal body weight x ^
‘ Final excess weight ideal body weight

Salmon
73.8
24.6
1.6
0
0

bypass more than compensates for oper
ative time and difficulty. Moreover, many
patients who undergo gastroplasty or gas
tric bypass require reoperation to produce
further weight loss, in itself timeconsuming, expensive and not without
operative risk.
Summary and Conclusions
The results o f a new operation, verti
cal banded gastroplasty with distal gas
tric bypass, have been presented. Seventy
patients underwent operation, 63 achiev
ing a mean greatest excess weight loss of
88% and a mean final excess weight loss
of 83%. Early and late postoperative
complications are of an acceptable level.
No late metabolic complications have
occurred.
The operation gives better weight loss
than gastroplasty or gastric bypass alone
and has none of the late complications
associated with intestinal bypass.
I thank Miss M.O. McArdle who has been
instrumental in achieving the extensive follow
up necessary to compile the complete data
presented in the manuscript and in preparing
the illustrations. Without her efforts this
presentation would have been impossible.
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lleogastrostomy for Morbid Obesity
Jejunoileal bypass procedures for morbid
obesity have been associated with
numerous side effects, due mainly to the
blind-loop syndrome. To overcome this,
the authors describe a new procedure,
ileogastrostomy, that they have per
formed in 50 patients. All had good
weight loss and returned to work.
Patient satisfaction with the operation
was high and self-esteem increased.
There were no deaths or severe compli
cations. Stool frequency and foul-smell
ing stools were still problems but
improved with time.
Stomal ulceration occurred at 3 months
in three patients but resolved within
1 month when treated with H2 blocking
agents and was not encountered later
than 3 months in any patient.
L'operation de derivation jejuno-ileale
pour obesite pathologique a ete rattachee a plusieurs effets indesirables dus
principalement au syndrome de I'anse
borgne. Afin de pallier a ce probleme, les
auteurs decrivent une nouvelle interven
tion, I'ileogastrostomie, qu'ils ont prati
que chez 50 patients. Tous ont connu
une bonne perte de poids et ont repris
leur travail. Le degre de satisfaction des
patients etait dleve et leur confiance en
soi augmente. On n'a constate aucun
deces ou complication grave. Les selles
frequentes et la mauvaise odeur des sel
les constituaient toujours un probleme,
mais celui-ci s'ameliorait avec le temps.
Une ulceration du stoma est survenue
apres 3 mois chez trois patients. Les
ulceres ont cede en moins d'un mois d
un traitement anti-H2. Aucun cas n'a ete
observe passe cette periode de 3 mois.
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Many hundreds of thousands of patients
in North America have undergone
jejunoileal bypass for morbid obesity,
defined as more than 45 kg above the
ideal body weight. Jejunoileal bypass
procedures have varied from the Scott1
operation, which leaves a short length of
jejunum and ileum, to the Salmon2
procedure, which leaves a longer length
of small intestine in continuity, to the
Payne3 operation which leaves a short
length of ileum and a longer length of
jejunum. In the Scott1 and Salmon2
procedures, the blind loop of small bowel
is implanted into the colon at a site of the
surgeon’s preference and with the
Payne3 operation, the blind loop is left
in continuity with the distal ileum.
These operations may cause serious
postoperative problems that include elec
trolyte deficiencies, ranging from
hypokalemia and dehydration to more
subtle and long-lasting changes, resulting
in hyperoxaluria and renal stones. Distur
bance of liver enzymes and function may
lead to liver failure, the patient being at
greatest risk during the first postopera
tive year.
Other notable complications, related to
disturbance of the immune system, result
in rashes and arthralgia. Malabsorption
of food and bile salts can cause steator
rhea, diarrhea and passage of offensive
flatus. There are also many rare, recur
ring side effects that have been well
covered in the literature.
The cause of all these complications
and side effects has in large part been
ascribed to the blind loop syndrome, a
well-known entity in gastroenterology.4’5
Temporary reversal of these complica
tions has been reported — the adminis
tration of antibiotics has “ sterilized” the
blind segment and freed it from the
colonizing bacteria said to cause the
problems.
Despite this, no one has proposed
implanting the blind loop into a more
sterile setting to avoid this syndrome.
Implantation into the colon would result
in colonization of the blind loop due to
the higher colonic pressure and associated
large numbers of bacteria and other
organisms. This could also apply,

although to a lesser extent, to bowel in
continuity with distal ileum.
There are at least two solutions to the
problem. One is a permanent ileostomy
of the blind loop. This procedure has the
disadvantage of requiring a pouch on the
anterior abdominal wall into which drains
between 20 ml and 1 L /d of succus entericus. Although the procedure has been
done in extreme circumstances, it is obvi
ously not desirable from the patient’s
point of view. The alternative is implan
tation of the ileum into the stomach.
Merendino and Thomas6 successfully
substituted a small bowel implant for the
distal esophagus with no subsequent
ulceration. The analogy between this and
ileogastrostomy has merit. Colonization
would be less likely, due to natural
peristalsis o f the bypass loop combined
with the relatively sterile stomach with its
low pH.
Surgical Technique

An end-to-end jejunoileal bypass is
constructed, the proximal jejunum meas
uring 25 cm and the distal ileum 50 cm
(Fig. 1). The proximal end of the residual
blind loop is closed in one layer, the dis
tal end is brought up in front of the colon
and anastomosed high up in the parietal
cell-mass area of the anterior part of the
stomach. A small portion of the stomach
is excised to facilitate the one-layer

FIG. 1—Operative model for ileogas
trostomy.
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anastomosis (Fig. 1). There is no attempt
to close the potential gap in the mesen
tery of the small bowel.
Patients and Method
We studied the results of the first 51
morbidly obese patients who underwent
ileogastrostomy. One patient, a native
Indian, vomited repeatedly when she
returned home and did not eat. Because
of the problem of long-term manage
ment, bowel continuity was restored leav
ing 50 patients to be studied.
All ileogastrostomies were performed
by the same surgeon (R.H.G.). The study
was considered complete when the 50
patients enrolled had been followed up
for a minimum of 1 year. The longest fol
low up was 2.5 years.
Patient height and weight, operative
complications, detailed blood work and
a record of antidiarrheal medication, if
any, were recorded preoperatively, at
monthly intervals postoperatively to 1
year and at 6-week intervals thereafter.
(It was assumed that there were no elec
trolyte disturbances, no nausea and no
need for antidiarrheal medication before
surgery.) In addition, all patients under
went upper gastrointestinal endoscopy 3
months postoperatively, which was
repeated if there was any suggestion of
ulcer. A questionnaire was completed by
all patients and their personal physicians.
Weight was taken to be preoperative
weight divided by ideal weight multiplied
by 100, thus representing the percentage
of the ideal weight.
Potassium deficiency was considered

Table 1— Electrolyte Disturbances
Postop months
Yes, %
No, %
3
15.9
84.0
6
7.1
92.8
12
9.0
90.9
18
0.0
100.0
24
0.0
100.0
Mean
6.4
93.5
Variance
0.3
0.3
X 2 - 1.573 less than 9.488, DF = 4. No
significant differences.

Patient satisfaction was graded on a
scale of 1 (bad) to 10 (excellent).
Statistical analysis used missing data
constraints when some patients were una
ble to answer the questionnaire com
pletely or when a patient was missed at
follow-up.
Statistical results were adjusted so that
non-respondents appeared similar to
respondents. Missing data was substituted
with means and proportions to respon
dent data.
A 5% level was taken as significant
using the x2 test.

present when the serum value was less
than 3.6 mmol/L.
Mildly abnormal liver function was
indicated by a serum a sp a rta te
aminotransferase value of 25 to 35 U /L
(normal 7 to 24 U/L), serum alkaline
phosphatase of 121 to 150 U/L (normal
40 to 120 U/L), serum bilirubin 21 to 25
ixm ol/L (normal 5 to 20 /unol/L) and
serum lactate dehydrogenase value of 120
to 150 U /L (normal 45 to 120 U /L).
Moderately abnormal liver function was
defined by a serum aspartate aminotrans
ferase value of 35 to 70 U /L, a serum
alkaline phosphatase level of 151 to 175
U /L , serum bilirubin 21 to 25 /tmol/L
and serum lactate dehydrogenase of 175
U /L . Severely abnormal liver function
was considered present when levels of
liver enzymes were higher than those in
the moderate group or the serum bilirubin
was greater than 25 /xmol/L. An abnor
mal level of serum protein was that below
60 g/L (normal 60 to 80 g/L) and of
serum albumin below 35 g/L (normal 35
to 48 g/L).
Renal function was considered abnor
mal when the serum creatinine level was
greater than 120 yimol/L (normal 40 to
120 /imol/L) or the serum urea nitrogen
level was 8.1 to 9.8 mmol/L urea (nor
mal 2.5 to 8.0 mmol/L urea).
Iron and folate deficiencies were
recorded when the values were below the
lower limits of normal for the laborato
ries in which they were tested.
Stomal ulcer was present when there
was a deficiency of mucosa with a white
base at or near the ileogastrostomy on
endoscopy.

Results
There were no deaths, and no patients
were lost to follow-up. Some, because of
distance, economic or other reasons,
missed one or more test appointments,
giving rise to a 20% missing data rate for
the time-interval tests; 49 patients were
followed up for 3 months or longer, 48
for 6 months or longer, 48 for 9 months
or longer, 46 for 12 months or longer, 43
for 18 months or longer and 22 for 24
months or longer. The mean follow-up
was therefore 18 months.
Forty-five percent of the total weight
loss occurred in the first 3 months
postoperatively (Fig. 2), with a gradual
reduction of the rate of fall over the next
9 months (18%, 13% and 8%) and
beyond. At 24 months the patients were
125% of ideal weight (range from 100%
to 172%) and all had lost more than 60%
of excess weight.
Mean patient satisfaction was 9.9
(range from 7 to 10). Their assessment of

Table 11-Results in Patients After Ileogastrostomy
Postop time, mo
18
3
Preop

24

9.8
4.9

0
0

Findings
Nausea, %
Severe
Mild
—
Bloating, %
Regularly
2.2
—
Occasionally
Loose bowel
movements, %
Bowel movements, no./d
1.26
Mean
0.3 - 4
Range
Foul-smelling stools, %
0
Regularly
0
Occasionally
—
Need for
antidiarrheal
agent, %
Stomal ulcer, %
Disturbances of liver
function, %
10.9
Mild
—
Moderate
8.3
Potassium
deficiency, %
2.3
Serum protein
abnormality, %

14.3
19
69.7

—

—

r
32
-

p value
NS
< 0.05

—
—
10

< 0.05
< 0.05

6.9
3-20

—

2.9
0.5 - 9
< 0.05

7.3
24.4
40
6.2
35.9
12.8
46.2
21
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—
—
3.2

—

0

8.4
37.5

13.6
0
14.3
4.3

< 0.05
NS
< 0.05

—
—
—

NS

—

NS
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self-esteem was higher for 96.8% of
p atien ts and unchanged for the
remainder; 82.6% were working and
93.7% were able to do more work than
before the operation.
Complications within the first 3 months
included wound infection (6.6%), respira
tory com plications (2.2% ), nausea
(11.1%) and electrolyte disturbances
(15.9%), which resolved completely
within 18 months (Table I).
Table II shows other results. The
postoperative increase in the number of
patients with loose bowel movements had
decreased by 24 months as had the daily
number o f movements. There was no
incontinence.
Although only 3.2% of patients were
taking antidiarrheal medication after 24
months, 9.7% were still taking the medi
cation occasionally.
The number of patients with foul
smelling stools increased markedly after
operation and did not improve with time.
Bloating was also a problem postoperatively, and although the number of
patients who regularly had bloating
decreased with time, 32% still had occa
sional bloating at 18 months. There were
no cases with severe disturbances of liver
function.
Potassium deficiency was present in
8.3% of patients preoperatively, increas
ing to 46.2% at 3 months postoperatively
and decreasing to 14.3% by 18 months.
Possible stomal ulcer was sought
endoscopically and found in 6.2% at 3
months, the number gradually falling to
zero at 6, 12 and 24 months. The ulcer
was always smaller than 3 mm in dimen
sion, occurring at the anastomosis of
ileum and stomach. These patients had
dyspepsia and used acetylsalicylic acid. A
drop in the hemoglobin level, not neces
sitating transfusion, occurred in one
patient. On review of preoperative films
another was discovered to have an ulcer
o f the second part of the duodenum with
stenosis. The stomal ulcers resolved
within 4 weeks of the start of H2 blocker
therapy.
There were no significant differences in
renal function, iron and folate deficiency,
and the frequency of skin lesions or of
joint pains.
Comments
Morbid obesity affects many people in
N orth America, causing loss of income
and self-esteem, and higher morbidity and
mortality than in people of normal
weight. It has many of the characteristics
of a disease and often cannot be remedied
by medical means.
Jejunoileal bypass was a satisfactory
procedure in terms of maintained weight
loss, but was associated with a high inci
dence of serious complications, some
fatal.

By a procedure that avoids the develop
ment of a blind loop syndrome we can
eliminate the most serious complications
and reduce the severity of the less serious
ones to an acceptable level.
The weight loss is as good as the most
successful jejunoileal bypass operations.
Patient satisfaction, increase in self
esteem and ability to work are much bet
ter than we have found with other proce
dures.
Electrolyte disturbances, particularly
potassium deficiency as encountered in
other bypass surgery, are less frequent
and of a lesser degree. A probable expla
nation is that the succus entericus drains
into the stomach where it can be more
readily absorbed than when the blind loop
is inserted into or close to the colon.
The absence of severe liver and renal
disease, and the avoidance of arthritic and
skin complications may be ascribed to the
insertion o f the blind loop into a more
sterile setting.
The residual mild to moderate distur
bance of liver function parallels the
weight loss and may well reflect an
associated tem porary alteration of
metabolism. Iron and folate absorption
were satisfactory.
The increased number, decreased con
sistency and foul odour of stools, which
may be due to lactose intolerance, largely
resolve with time. These problems are,
however, not fully resolved by the surgery
and it may be that the arbitrary lengths
of bowel in continuity need clarification.
Increasing the length of ileum may be
beneficial.
Stomal ulceration is a specific compli
cation of this operation and the one we
most feared. It occurred in only three
patients, on each occasion within the first
3 months, and was treated successfully by
H 2 blockers prescribed for 1 month. The
operation does not appear to produce a
strong ulcer diathesis.
We believe that there may be a place
for ileogastrostomy in patients with com
plications of other bypass surgery due to
the blind-loop syndrome.
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(sterile cefoxitin sodium, MSD Std.)

ANTIBIOTIC
ACTION
In vitro studies demonstrate that the bacteri
cidal action of cefoxitin, a cephamycin derived
from cephamycin C, results from the inhibition
of bacterial cell wall synthesis. Evidence
suggests that the m ethoxy group in the
7a position is responsible for the resistance of
cefoxitin to degradation by bacterial betalactamases.

INDICATIO NS AND CLINICAL USES
TREATMENT
The treatment of the following infections when
due to susceptible organisms:
1 - In tra -a b d o m in a l in fe c tio n s such as
peritonitis and intra-abdominal abscess
2 - G y n e c o lo g ic a l in fe c tio n s such as
endometritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and
Serratia spp.)
5 - Lower respiratory tract infections
6 - Bone and jo in t infections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
should be performed to determine the sus
ceptibility of the causative organism(s) to
MEFOXIN*. Therapy may be started while
awaiting the results of these tests, however,
modification of the treatment may be required
once these results become available.
O rga n ism s p a rtic u la rly a p p ro p ria te fo r
therapy with MEFOXIN" are:
Gram positive
Staphylococci, penicillinase producing and
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing
and non-producing strains)
E. coli
Klebsiella species (including K. pneumoniae)
Proteus, indole positive and negative
Haemophilus influenzae
Providencia species
Anaerobes
Bacteroides fragilis
MEFOXIN* may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
Clinical experience has demonstrated that
MEFOXIN’ can be administered to patients
w h o are a lso re c e iv in g c a rb e n ic illin ,
gentam icin, tobramycin, or amikacin (see
PRECAUTIONS and ADMINISTRATION).
Intravenous Administration
The intravenous route is preferable fo r
patients with bacteremia, bacterial septicemia,
or other severe or life-threatening infections,
or for patients who may be poor risks because
of lowered resistance resulting from such
d e b ilita tin g c o n d itio n s as m a ln u tritio n ,
trauma, surgery, diabetes, heart failure, or
malignancy, particularly if shock is present or
impending.
PROPHYLACTIC USE
MEFOXIN* may be administered perioperatively (preoperatively, intraoperatively and
postop e ra tive ly) to patients undergoing
vaginal or abdominal hysterectomy and ab
dominal surgery when there is a significant
risk of postoperative infection or where the
o ccurrence of postoperative infection is
considered to be especially serious.
In patients undergoing cesarean section, intra
operative (after clamping the umbilical cord)
and postoperative use of MEFOXIN* may
reduce the incidence of surgery related post
operative infections.
Effective prophylactic use depends on the
time of administration. MEFOXIN* usually
should be given one-half to one hour before

the operation. Prophylactic administration
should usually be stopped within 12 hours. It
has been generally reported that continuing
a d m in istra tio n of any a n tib io tic beyond
24 hours fo llow ing surgery increases the
possibility of adverse reactions but, in the
m ajority of surgical procedures, does not
reduce the incidence of subsequent infection.
If signs of postsurgical infection should
appear, specimens for culture should be
obtained for identification of the causative
organism(s) so that appropriate therapy may
be instituted.

CONTRAINDICATIONS
MEFOXIN* is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN* is instituted,
careful inquiry should be made to determine
whether the patient has had previous hyper
sensitivity reactions to MEFOXIN*, cephalo
sporins, penicillins orother drugs. MEFOXIN*
should be given with caution to penicillinsensitive patients.
There is some clinical and laboratory evidence
o f p a rtia l c ro s s -a lle rg e n ic ity betw een
cephamycins and the other beta-lactam anti
b io tic s , p e n ic illin s and cephalosporins.
Severe reactions (including anaphylaxis) have
been re p o rte d w ith m ost b e ta -la cta m
antibiotics.
Pseudomembranous colitis has been reported
with virtually all antibiotics. This colitis can
range from mild to life threatening in severity.
Antibiotics should therefore be prescribed
with caution in individuals with a history of
gastrointestinal disease, particularly colitis. It
is important to considers diagnosis of pseudo
membranous colitis in patients who develop
diarrhea in association with antibiotic use.
While studies indicate that a toxin produced
by Clostridium dillicile is one primary cause of
antibiotic-associated colitis, other causes
should also be considered.
Any patient who has demonstrated some form
of allergy, particularly to drugs, should receive
antibiotics including MEFOXIN* with caution.
If an allergic reaction to MEFOXIN* occurs,
administration of the drug should be discon
tinued. Serious hypersensitivity reactions may
require treatment with epinephrine and other
emergency measures.

PRECAUTIONS
The total daily dosage should be reduced
when MEFOXIN* is administered to patients
with transient or persistent reduction of
urinary output due to renal insufficiency (see
DOSAGE AND ADMINISTRATION) because
high and prolonged serum antibiotic con
centrations can occur from usual doses.
In patients treated with MEFOXIN* a false
positive reaction to glucose in the urine may
occur with Benedict's or Fehling's solutions
but not w ith the use of specific glucose
oxidase methods.
Using the Jaffe Method, falsely high creatinine
values in serum may occur if serum concen
trations of cefoxitin exceed 100 pg/mL. Serum
samples from patients treated with MEFOXIN*
should not be analyzed for creatinine if with
drawn within two hours of drug administration.
Increased nephrotoxicity has been reported
fo llo w in g concom itant adm inistration of
cephalosporins and aminoglycoside antibiotics.
The safety of MEFOXIN* in the treatment of
infections during pregnancy has not been
e s ta b lis h e d . If th e a d m in is tra tio n o f
MEFOXIN* to pregnant patients is considered
necessary, its use requires that the anticipated
benefits be weighed against possible hazards
to the fetus. Reproductive and teratogenic
studies have been performed in mice and rats
and have revealed no evidence of impaired
fertility or harm to the fetus due to MEFOXIN*.
Cefoxitin has been observed in the milk of
nursing mothers receiving the drug.
Prolonged use of MEFOXIN* may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient’s condition
is essential and if superinfection occurs
during therapy, appropriate measures should
be taken. Should an organism become
resistant during antibiotic therapy, another
antibiotic should be substituted.

In children 3 months of age or older, higher
doses of MEFOXIN* (100 m g/kg/day and
a b o ve) have been a sso cia ted w ith an
increased incidence of eosinophilia and
elevated SGOT.

ADVERSE REACTIONS
MEFOXIN* is generally well tolerated. Adverse
re a c tio n s ra re ly req u ire d cessation o f
treatment and usually have been mild and
transient
Local Reactions
Thrombophlebitis has occurred with intra
venous administration. Some degree of pain
and tenderness is usually experienced after
in tra m u s c u la r in je c tio n s using w a te r.
Induration has occasionally been reported.
Allergic
M acu lo p a p u la r rash, u rtica ria , p ru ritu s,
eosinophilia, fever and other allergic reactions
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported
rarely.
Blood
Transient eosinophilia, leukopenia, neutropenia,
hem olytic anemia, and throm bocytopenia
have been reported. Some individuals, particu
la rly those w ith azotemia, may develop
positive direct Coombs tests during therapy
with MEFOXIN*.
Liver Function
Transient elevations in SGOT, SGPT, serum
LDH, and serum alkaline phosphatase have
been reported.
Kidney
Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure
has been rep o rte d ra re ly. The role o f
MEFOXIN* in changes in renal function tests
is d iffic u lt to assess, since fa cto rs pre
disposing to prerenal azotemia or to impaired
renal function have often been present.

TREATMENT OF OVERDOSE
Other than general supportive treatment, no
specific antidote is known. MEFOXIN* can be
eliminated by dialysis in patients with renal
insufficiency.

DOSAGE AND ADMINISTRATION
MEFOXIN* may be administered intravenously
o r in tra m u scu la rly when required. (See
complete monograph on ADMINISTRATION
and RECONSTITUTION.)
TREATMENT DOSAGE
Adults
The usual adult dosage is 1 g o r 2 g of
MEFOXIN* every 6 to 8 hours. Dosage and
route of administration should be determined
by severity of infection, susceptibility of the
causative organisms, and condition of the
patient. The usual adult dosages are shown in
the Table below.
Usual Adult Dosage
T y p e of
in fe c tio n

D a ily
Dosage

F re q u en c y
a n d R o u te

Uncomplicated
forms* of in
fections such as
pneumonia,
urinary tract
infection, soft
tissue infection

3-4 g

1 g every 6-8 h
I.V. or I.M.

Moderately
severe or severe
infections

6-8 g

1 g every 4 h
or
2 g every 6-8 h I.V.

Infections
commonly
needing anti
biotics in higher
dosage (e.g. gas
gangrene)

12 g

2 g every 4 h
or
3 g every 6 h I.V.

"In clu ding patients in whom bacterem ia is
absent or unlikely

Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infections should be maintained
for at least 10 days to guard against the risk of
rheum atic fever or glom erulonephritis. In
staphylococcal and other infections involving
a collection of pus, surgical drainage should
be carried out where indicated.

Adults with Impaired Renal Function
MEFOXIN* may be used in patients with
reduced renal function but a reduced dosage
should be employed and it is advisable to
monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given.
After a loading dose, the following recommen
dations for maintenance dosage may be used
as a guide:
RENAL
FUNCTION

CREATININE
CLEARANCE
mL/min

DOSE

50-30

1-2 g

every 8-12 h

29-10

1-2 g

every 12-24 h

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

Mild>
impairment
Moderate
impairment
Severe
impairment
Essentially
no function

FREQUENCY

In the patient undergoing hemodialysis, the
loading dose of 1 - 2g should be given after
each hemodialysis, and the maintenance dose
should be given as indicated in the Table
above.
Neonates (Including Premature Infants),
Infants and Children (See WARNINGS for
Neonates under ADMINISTRATION in the
complete monograph.)
P r e m a tu r e In fa n ts
w ith B o d y W e ig h ts
A bove 1500 g

20-40 mg/kg every 12 h I.V.

N e o n a te s

01 week of age20-40 mg/kg every 12 h I.V.
20-40 mg/kg every 8 h I.V.
1-4 weeks of age
In fa n ts

1 month to 2 years
of age

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

C h ild r e n

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

In severe infections, the total daily dosage in
infants and children may be increased to
200 mg/kg, but not to exceed 12 g per day.
MEFOXIN* is not recom m ended fo r the
therapy of meningitis. If m eningitis is sus
pected, an appropriate antibiotic should be
used.
A t present there is in s u ffic ie n t da ta to
recommend a specific dosage for children
with impaired renal function. However, if the
administration of MEFOXIN* is deemed to be
essential the dosage should be m odified
consistent with the recom m endations for
adults (see Table above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN* is recommended as follows:
Vaginal or abdominal hysterectomy and
abdominal surgery
2 g administered intram uscularly o r intra
venously just prior to surgery (approximately
one-half to one hour before initial incision).
The second and third 2g doses should be
administered at 2 -6 hour intervals after the
initial dose.
Cesarean Section
The first dose of 2g should be administered
intravenously as soon as the um bilical cord
has been clamped. The second and third
2 g doses should be given intravenously or
intramuscularly four hours and eight hours
after the first dose.

AVAILABILITY
MEFOXIN* is supplied as sterile powder in
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt
Storage
MEFOXIN* in the dry state should be stored
below 30° C.
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Revision of Failed Horizontal Gastroplasty
by Vertical Banded Gastroplasty
Eighteen patients who had undergone
horizontal gastroplasty experienced
postoperative weight gain due to techni
cal failure (large orifice in 10 patients,
staple-line disruption in 7 and a large
pouch in 1). A vertical banded gas
troplasty was used to correct the
problem, with a resulting operative mor
bidity of 38.9% . This included perfora
tion with peritonitis (five patients) and
complete outlet obstruction (two
patients). These complications appear to
result from poor blood supply to the area
of the anastomosis necessary in this
conversion. This study indicates that it is
not safe to use vertical banded gas
troplasty for the failed horizontal gas
troplasty.

Dix-huit patients ayant subi une gastroplastie horizontale ont presente un
accroissement ponderal postoperatoire
du a une dgfaillance de technique
(grande orifice chez 10 des patients, bris
de la ligne des agrafes chez 7 autres, et
une grande poche chez le patient restant). Une gastroplastie en bande verticale fut operee pour corriger leur
probleme, avec un taux de morbidity
operatoire resultante de 38,9% (perfora
tion et pgritonite chez cinq patients, et
obstruction complete chez deux autres).
Ces complications semblent avoir resulte
d'une irrigation sanguine insuffisante de
la region de I'anastomose necessitee par
une telle conversion. Cette etude indique
qu'il est imprudent de recourir a la gas
troplastie en bande verticale dans les cas
de gastroplastie horizontale defaillante.

The currently popular operations used to
treat morbidly obese people are gastric
bypass1’2 and vertical banded gas
troplasty.3 These operations give a good
initial loss of excess weight with minimal
morbidity. The horizontal gastroplasty
with either single4 or double staple
lines5,6 with or without external support
of the stoma6,7 has been much less suc
cessful. As a result horizontal gastroplasty
has been abandoned by most surgeons.
Failure to lose weight or late weight
gain with horizontal gastroplasty is due
to technical problems. The stoma or
pouch can enlarge, and the material used
to support the stoma can migrate into the
gastric lumen. Finally, an opening can
develop in the staple line resulting in poor
weight loss or weight gain. When the
horizontal gastroplasty is revised by
merely reperforming the procedure,
failure for similar reasons is frequent.5
Roux-en-Y gastric bypass has been
reported as the best remedial operation
for the failed horizontal gastroplasty.5
Prospective randomized trials indicate
that gastric bypass provides better results
than horizontal gastroplasty and these
trials advocate gastric bypass as the oper
ation of choice for morbid obesity.8,9
Vertical banded gastroplasty has at
least two potential advantages over
horizontal gastroplasty. The material
used for banding rarely migrates into the
lumen and a small pouch is easily con
structed without sacrificing the blood sup
p ly .10 The conversion of a failed
T a b le 1 - P a tie n t C h a ra c te ris tic s
C h a ra c te ris tic
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horizontal gastroplasty to a vertical
banded gastroplasty, although frequently
suggested as a safe and logical procedure,
has not been reported previously.
This paper presents the combined
experience of the St. Joseph’s Health
Centre in Toronto and the Royal Victoria
Hospital in Montreal with 18 cases of
failed horizontal gastroplasty converted
to vertical banded gastroplasty.
Patients

Of the 18 patients (14 women, 4 men),
8 were from Toronto and 10 from Mont
real. The clinical data are set forth in
Table I.
Horizontal Gastroplasty

The operations performed were slightly
different depending on the patient and the
hospital centre. The technique for the
Toronto procedure was that described by
Gom ez.7 The M ontreal operations
included the Gomez procedure as well as
a number of other horizontal techniques
which placed the stoma at different loca
tions on the horizontal staple line and
used different materials to reinforce the
gastrogastrostomy.6
The patients obtained a mean weight
loss of 34.1 ± 2.5% (± SEM) of their
initial weight down to a mean weight of
91.8 ± 4.4 kg (Table II). Using a clas
sification described previously,6 we
defined a good result as one in which the
patient has lost more than 25% of the ini
tial weight and is within 30% of ideal
body weight, a satisfactory result is used
for a patient who has lost more than 25%
of initial weight but is not within 30% of
ideal body weight and an unsatisfactory
result is a weight loss of less than 25%
of the initial body weight. There were five

T a b le II— O u tc o m e o f H o rizo n ta l G a s tro p la s ty (M e a n ± S E M )
O u tc o m e
P re o p e ra tiv e w e ig h t, kg
A f t e r h o rizo n ta l g a s tro p la s ty , kg
L o w e s t w e ig h t
H ig h e s t w e ig h t
F o llo w -u p b e fo re re vision, m o

M ean

R ange

1 4 0 .8 ± 6 .2

9 5 .5 -

2 0 4 .5

9 1 .8 ± 4 . 4
1 2 0 .3 ± 5 .7
4 5 .1 ± 1 5 .1

6 8 .2 7 2 .7 12 -

1 3 6 .4
1 6 0 .5
68

VOLUME 31, NO. 2, M A R C H 1988 / THE CANADIAN JOURNAL OF SURGERY

good, nine satisfactory and four unsatis
factory results.
The horizontal gastroplasties subse
quently failed in these 18 patients for
several reasons — staple-line disruption
(7 patients), a large orifice due to migra
tion of the material used to maintain a
specific size of stoma (10 patients) and a
poorly positioned orifice (1 patient),
which caused frequent vomiting despite
weight gain. With these problems, the
patients’ mean weight increased to 120.3
± 5.7 kg, representing a gain of 28.5 ±
3.1 kg from their lowest postoperative
weight (Table II). At this point the results
were classified as good in 1 patient, satis
factory in 1 and unsatisfactory in 16

patients. The time taken ( ± SD) for these
problems to develop was 45.1 ± 15.1
months (range from 12 to 68 months)
after surgery.
Vertical Banded Gastroplasty
This operation was performed in a
fashion similar to that described by
M ason.3 The banded area of the gas
troplasty was made below the horizontal
staple line, which usually necessitated an
anastomosis between the upper and lower
gastric pouches in order to provide a
channel along the lesser curvature (Fig.
1). The results of the vertical banded gas
troplasty are presented in Table III. The

postoperative problems associated with
the vertical banded gastroplasty used as
a revision procedure occurred early
postoperatively and were major (seven
patients). Five patients suffered peritoni
tis from a perforation of the stomach at
the anastomosis between the upper and
lower gastric pouches. Four of these had
abscesses drained surgically with no fur
ther problems; however, they were seri
ously ill and required treatment in the sur
gical intensive care unit for several weeks.
In the fifth patient, a gastrocutaneous
fistula developed and did not close for 2
months. Two patients had severe gastric
outlet obstruction requiring further sur
gery to provide adequate drainage from
the gastric pouch. There were no deaths.
The mean weight of these 18 patients at
the time of writing was 87.5 ± 4.7 kg,
which is 37.4 ± 2.6% less than the ini
tial weight. There are 5 good results, 12
satisfactory and 1 unsatisfactory result
(Table IV) at a mean follow-up after ver
tical banded gastroplasty of 13.9 ± 6.4
months (±SD ).
Discussion

F1G. 1—Failed horizontal gastroplasty corrected by vertical banded gastroplasty : A = dou
ble row of horizontal staples, B = reinforced gastrogastrostomy of horizontal gastroplasty,
C = double row of vertical staples, D = reinforced pouch outlet of vertical gastroplasty. Insertion
of gastrogastrostomy (E) was required to complete vertical banded gastroplasty.
Table Ill-O u tc o m e of V ertical Banded G astro plasty for Failed
Horizontal G astroplasty (M e an + SEM )
Outcom e
W eight before vertical banded
g astro p lasty, kg
Current w e ig h t, kg
Loss from initial w eight, %
Follow up a fte r vertical banded
gastroplasty, mo

M ean

Range

1 2 0 .3 ± 5 .7

7 2 .7 - 1 7 0 .5

8 7 .5 ± 4 .7
3 7 .4 ± 2 .6
1 3 .9 ± 6 .4

5 8 .2 - 1 2 6 .4
1 0 .4 - 6 2 .8
6 - 2 6

T ab le IV— Results of G astro plasty Procedures
Horizontal g as troplasty, class
Result
Good
S atisfa cto ry
U nsa tisfacto ry

Best

Failed

V ertical banded
gastroplasty

5
9
4

1
1
16

5
12
1

The patients presented in this paper had
an initial favourable response to horizon
tal gastroplasty, but because of staple-line
disruptions or orifice enlargement, all
regained most of their weight. This failure
o f horizontal gastroplasty is now well
established. In a review of 5470 gastric
partitioning operations, weight gain was
the most frequent cause of failure in 5%
to 20% of patients.11 Technical failure
rates as high as 62% have been reported
for horizontal gastroplasty.12 The techni
cal failures relate primarily to stomal size
or disruption of the staple line. Despite
reinforcement of the gastrogastrostomy
as emphasized by Gomez13 and o f the
staple line as emphasized by Brolin and
R av itch ,14 there are still several
reports5’9,15’'* o f horizontal gastroplasty
failures. It is important to have a long and
complete patient follow-up. In the 18
patients reported here, there were some
failures as early as 1 year, but others
occurred as late as 68 months after
horizontal gastroplasty.
The vertical banded gastroplasty is cur
rently popular because a small pouch is
easily constructed, the orifice o f the new
gastric pouch can be externally supported
and the polypropylene mesh rarely
migrates through the thicker wall on the
lesser curvature of the stomach. This
operation presently has acceptable
results,3’17-19 although long-term evalua
tion is only now being reported.10’20 It is
accepted but not proven as a suitable
primary procedure for the surgical ther
apy of morbid obesity.
As a secondary procedure, especially
for failed horizontal gastroplasty, verti
cal banded gastroplasty cannot be recom-
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Examinations
T h e e x a m in a tio n s o f th e R o y a l C o lle g e
are he ld in S e p te m b e r o f e a c h y e a r. C a n 
d id a te s w is h in g to s it fo r th e e x a m in a 
t io n s sh o u ld n o te th e fo llo w in g :
1. E v e ry c a n d id a te fo r a d m is s io n to th e
e x a m in a tio n s m u s t s u b m it a n a p p li
c a t io n fo r a s s e s s m e n t o f tra in in g .
2. C a n d id a te s in tra in in g in C a n a d a
s h o u ld ap p ly fo r p re lim in a ry a s s e s s 
m e n t o f tra in in g at le a s t o n e y e a r
b e fo re th e d a te on w h ic h th e y e x p e c t
to s it fo r th e e x a m in a tio n s , th a t is to
s a y n o t later th a n S e p te m b e r 1 o f th e
p re c e d in g year. C a n d id a te s w h o have
had train in g o u ts id e o f C a n a d a sh o u ld
s u b m it th eir in itia l a p p lic a tio n fo r
a s s e s s m e n t a t le a s t 1 8 m o n th s
b e fo re th e y e x p e c t to s it fo r th e e x a 
m in a tio n s , th a t is b y M a r c h 1 o f th e
p r e c e d in g y e a r. O n ly c a n d id a t e s
w h o s e a s s e s s m e n t o f c r e d e n t ia ls is
c o m p le te w ill b e a c c e p te d to s it fo r
th e e x a m in a tio n s .
3 . C a n d id a te s w h o d e s ire to s it fo r an
e x a m in a tio n , h a v in g c o m p lie d w ith
th e a b o v e re q u ire m e n t o f p re lim in a ry
a s s e s s m e n t o f tra in in g , m u s t n o tify
th e R o y a l C o lle g e in w r itin g o f th e ir
in te n t b e fo re F e b ru a ry 1 o f th e y e a r
o f th e e x a m in a tio n . U p o n r e c e ip t o f
th is n o tic e o f in te n t, th e e v a lu a tio n
o f th e c a n d id a t e 's p e r f o r m a n c e
d u rin g tra in in g w ill be a d d e d to th e
p r e v io u s ly c o m p le te d a s s e s s m e n t o f
c re d e n tia ls . E a c h c a n d id a te w ill th e n
r e c e iv e n o tific a tio n a s to e lig ib ilit y
to g e th e r w ith an a p p lic a tio n fo rm fo r
a d m is s io n to th e e x a m in a tio n to be
c o m p le te d and retu rn e d .
4 . T h e fo llo w in g d o c u m e n ts m a y be
o b ta in e d fro m th e R o y a l C o lle g e
o ffic e :
(a) A p p lic a tio n fo r m s fo r a s s e s s m e n t
o f tra in in g ;
(b) G e n e ra l in fo rm a tio n b o o k le t on
tra in in g re q u ire m e n ts a n d e x a m i
n a tio n s ;
(c) S p e c if ic re q u ire m e n ts fo r tra in in g
an d re g u la tio n s re la tin g to th e
e x a m in a tio n s o f e a c h s p e c ia lty .
R e q u e s ts sh o u ld in d ic a te th e s p e 
c ia lt y o r s p e c ia ltie s o f in te r e s t to
th e a p p lic a n t;
(d) L is tin g o f s p e c ia lty tra in in g p ro 
g ra m s in C a n a d a a c c re d ite d b y
th e R o y a l C o lle g e .
5 . A d d r e s s a ll e n q u ire s to:

Dr. R.F. Maudsley, Director,
Office of Training and Evaluation,
The Royal Colieqe of Physicians
and Surgeons of Canada,
74 Stanley,
Ottawa, Canada
KIM 1P4.
(613) 746-8177.
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mended on the basis of our experience.
It was associated with a 28% incidence
of pouch perforation with peritonitis and
an 11 % incidence of gastric obstruction
requiring further surgical correction.
These complications are considerably
higher than those reported in the lit
erature, and the perforation rate with
peritonitis is the highest presently
reported.3'5,8’17,18’20 M ason and col
leagues21 had previously given a rate of
6.1% with horizontal procedures, and the
highest reported rate for gastric bypass is
4.0% .8'9’17'21 The frequency of perfora
tion is increased when the operations are
remedial, with a previously reported inci
dence of 6.9% for revised horizontal gas
troplasties.5,21 The reason for these
major complications of perforation and
stomal stenosis appears to be inadequate
blood supply to the pouch (Fig. 1).
Mason’s group21 and other investigators
have indicated that this complication is
due to the precarious blood supply of the
upper pouch after two operations. In par
ticular, the horizontal and vertical staple
lines are associated with poor blood sup
ply where they interesect. Stomal scarring
is probably secondary to a localized leak
or poor healing due to inadequate blood
supply.
Conversion to a gastric bypass proce
dure from horizontal gastroplasty can
also be dangerous if, in so doing, the sur
geon must use vertical staple lines to cre
ate a smaller pouch. In creating the
smaller pouch similar problems can the
oretically be encountered by compromis
ing the blood supply to the fundic pouch.
The results of the vertical banded
procedure in terms of weight loss in this
group of patients were not uniformly
good. Thus, from the standpoint of
weight loss, the vertical banded gas
troplasty as a revision procedure for the
failed horizontal gastroplasty was less
than ideal.
Patients with failed horizontal gas
troplasty with a small gastric pouch are
most appropriately treated with Roux-enY gastric bypass. Sugerman and Wolper5
have reported a loss of 66 ± 18% of
excess weight with gastric bypass for
failed gastroplasty that was comparable
to the 69 ± 17% obtained when gastric
bypass was a primary procedure. This
conversion can be difficult and was
associated with problems in 21 of the 34
patients.5 If the gastric pouch is large or
the patient has an unacceptable result
after gastric bypass, the intestinal bypass
of Cleator and Gourlay described in this
issue of the journal (pages 114 to 116)
may be considered. In their procedure an
end-to-end jejunoileal bypass is done with
25 cm of jejunum anastomosed to 50 cm
of ileum. The bypassed segment is
drained into the upper stomach. Diar
rhea, metabolic problems and bypass
enteritis were not a problem after this

operation, which leaves a long distal seg
ment in circuit. Bacterial reflux into the
bypassed segment is minimized by
drainage into the stomach.
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Adverse Effect of Blood Transfusions on
Patient Survival After Resection of Rectal Cancer
Studies have shown that the number of
units of blood transfused perioperatively
in patients operated on for colonic
cancer has a progressively strong nega
tive influence on survival.
The present study, involving 198
patients with rectal cancer, was done to
determine if perioperative blood transfu
sions had any prognostic significance.
Multivariate regression analysis was
applied to these patients, operated for
cure of Dukes' stage A, B or C disease.
Other variables analysed were age, sex,
preoperative hemoglobin, albumin and
lymphocyte values and the timing of
transfusion.
Perioperative deaths, pre- and post
operative immunodepression, neopla
sia in situ, nonresections and stage D
disease were excluded.
It was found that the number of units
of blood transfused perioperatively had a
negative effect on patient survival, that
was independent of the other analysed
variables.
It is suggested that blood transfusion
perioperatively exerts an immunosup
pressive effect on patients with rectal
cancer.

Les analyses de regression multivariees ont ete appliquges a ces patients
operes pour cure d'un cancer rectal, de
stade A, B ou C de Dukes.
Les autres variables etudiees ont ete
I'age, le sexe, les taux preoperatoires
d'hemoglobine et d'albumine, la numera
tion lymphocytaire et le moment des
transfusions (pre, per ou postoperatoire).
Les criteres d’exclusion ont ete les
deces perioperatoires, les etats
d'immuno-depression pre et postoperatoires, les cancers in situ, les interven
tions & visees non curatives et les
stades D.
Les resultats ont montre que le
nombre d'unites de sang transfuse en
perioperatoire avait un effet negatif sur
la survie des malades et que cet effet
deletere etait independant des autres
variables etudiees.
Ceci suggere que les transfusions san
guines perioperatoires, exercent un effet
immuno-depresseur sur les malades
atteints d'un cancer rectal.

perioperative blood transfusions on the
survival of 198 patients operated on for
rectal cancer in our institution.
Patients and M ethods

The medical records of 446 patients
who underwent surgery for rectal cancer,
between 1951 and 1971 at the hopital
Notre-Dame in Montreal were reviewed.
Exclusion criteria were death within 1
month of operation (31 patients), immunodepressive conditions such as previ
ous neoplasia, diabetes, recent tubercu
losis, previous or current chemotherapy,
radiotherapy or corticotherapy (70),
postoperative adjuvant therapy (17), diag
nostic or palliative procedure (154),
insufficient data (5) and Dukes’ stage D
disease (116).
Rectal cancer was defined as disease
located below the rectosigmoid angle.
Of primary concern was the number of
units of whole blood or packed red cells
that each patient received perioperatively.
The patient population was grouped as
either transfused or not transfused. The
Evidence is increasing that blood trans number of transfusion units was divided
fusions impair the host immune system into subsets of 0, 1 to 5, 6 to 10 and 11
by mechanisms that are not fully under or more units, or studied on an individual
Des etudes anterieures ont montre que le
stood. This is used to advantage in organ basis. The timing of transfusion was also
nombre d'unites de sang transfuse en
transplantation, as demonstrated by classified—preoperative (within 3 months
periode perioperatoire, ont une influence
numerous studies of kidney allografting. before the operation), peroperative, and
fortement negative sur le pronostic vital
Graft survival is greatly improved after postoperative (within 1 month after sur
des malades ayant subi une resection
preoperative blood transfusion, the gery). Other analysed variables were age,
intestinale pour cancer colique.
benefit seemingly proportional to the sex, preoperative values of hemoglobin
(g/L) and serum albumin (g/L), total
La presente etude a ete conduite sur
number of units administered.1-20
198 malades souffrant de cancer rectal
However, it has been shown recently lymphocyte count, Dukes’ stage (A, B
pour determiner si les transfusions peri
that perioperative blood transfusions and C) of the disease and type of opera
operatoires avaient une signification
have a deleterious effect on host tion (abdominoperineal resection, an
pronostique.
resistance to infection and cancer recur terior resection, pull-through or surgical
rence, with decreased survival after polypectomy).
Population distribution for each vari
tumour resection.21-31
In a previous retrospective study,21 able was studied by the x2 test and
analysing the outcome of 281 patients analysis of variance. Correlation between
operated on for colorectal cancer, we variables was submitted to the Pearson
showed that the number of perioperative test. Distribution of the variables was
From the *Department o f Surgery and
t Department of Medicine, Transplantation blood transfusions had a highly signifi studied in accordance with a specific
Unit, Hopital Notre-Dame, University de
cant proportional negative effect on the criterion such as Dukes’ stage, type of
Montreal, Montreal, PQ
survival of patients treated for colonic surgery, transfused versus nontransfused
cancer, regardless of the other variables patients, number of blood units given and
Accepted for publication Aug. 11, 1987
studied. This negative effect was not timing of transfusion.
Reprint requests to: Dr. Jacques Corman,
Survival was defined as the time from
found when the 74 patients with rectal
Department of Surgery, Transplantation
resection to last follow-up or death. In the
tumours were analysed separately.
Unit, Hopital A Dame, CP 1560, Sta
We present data on the influence of analysis, death was a factor only when it
tion C, Montreal, PQ H2L 4K8
121
VOLUME 31, NO. 2, MARCH 1988 / THE CANADIAN JOURNAL OF SURGERY

was due specifically to rectal cancer; other
causes of death were classified as cases
lost to follow-up.
Mantel-Cox log-rank tests were used to
compare single group and subgroup vari
ables and to draw actuarial survival
curves. Simultaneous influence of all
covariables was tested by Cox’s multivar
iate regression analysis when the number
of blood units was studied on an
individual basis.

perineal resection was performed in 172
(87%) patients, 10 (5%) had an anterior
resection, 13 (6.5%) a pull-through oper
ation and the remaining 3 (1.5%) patients
underwent surgical polypectomy.
The exact number and timing of trans
fusions are shown in Table I.
Distribution o f Variables According
to Specific Criteria
Age, sex and preoperative albumin
levels were equally distributed in all
groups studied (Tables II to V).
When comparing the variables for
Dukes’ stage, we found that the total lym
phocyte count was differently distributed
in classes A, B and C (Table II). Distri
bution of the resection types, taken
individually, was not statistically differ
ent in this group (p = 0.09). However,
when comparing the variables for the type
of surgery (Table III), we found that more
abdominoperineal resections were per
formed, compared with all other types of
operations taken together, when the stage
was more advanced (p = 0.04).
When the distribution of variables was
studied in transfused and nontransfused

Findings

After application of the exclusion
criteria 198 of the 446 patients were avail
able for study.
The 198 patients (102 men, 96 women)
had a mean age of 59.8 ± 10.6 years. The
mean hemoglobin level, determined
preoperatively in 190 patients was 124 ±
22 g/L. The mean serum albumin level
determined in 120 (61%) patients was
16.2 ± 14.2 g/L and the lymphocyte
count in 181 (91%) patients was 2.0 ±
0.98 x 109/L. Dukes’ stages were
almost equally represented with a slight
predominance of stage B (37%) over
stages A (33%) and C (30%). Abdomino

T a b le 1 -U n its o f Blood T ra n s fu s e d P e rio p e ra tive ly
T im in g o f
tra n s fu s io n

U n its tra n s fu s e d

N o o f p atien ts
(% o f to ta l group)

P e rio p e ra tive ly *
T ra n s fu s e d
N o t tra n s fu s e d
P re o p e ra tive ly*
T ra n s fu s e d
N o t tra n s fu s e d
P e ro p e ra tive ly
T ra n s fu s e d
N o t tra n s fu s e d
P o sto p e ra tive ly*
T ra n s fu s e d
N o t tra n s fu s e d

T o ta l

M ea n ± SD

187 (94)
7 (4)

905

4 .7 ± 3.2

37 (19)
157 (79)

105

2.9 ± 2.2

188 (95)
10 (5)

582

3.1 ± 1.3

89 (45)
105 (53)

230

2.6 ± 2.8

' E x a c t no. o f u n its tra n s fu s e d d eterm ined in 194 (9 8 % ) patien ts

T a b le

II—D istrib utio n

patients, 100% of those with pull-through
procedures, 98% with abdominoperineal
resections, 80% with anterior resections
and 33% who had surgical polypectomies
were transfused (p = 0.0001). However,
the stage of the disease was not a factor
in the need for transfusion and, as
expected, there was a striking difference
in the number of units transfused since
seven patients did not receive blood
(Table IV).
Again, when considering the number of
units transfused, we noted that patients
who underwent a pull-through operation
received proportionately more units of
blood than those who had an
abdominoperineal or anterior resection of
the rectum (p = 0.00001) (Table V).
Preoperative hemoglobin values were
statistically different according to the
number of blood units administered
(p = 0.0003). However, the Pearson
test indicated a strong and significant
linear correlation between the preopera
tive hemoglobin level and the number of
transfusions preoperatively (r = 0.5,
p = 0.001) but weak and not significant
ones for peroperative transfusions
(r = 0.06, p = 0.1) and postoperative
Finally, in the subsets relating to the
amount of blood transfused, most of the
patients who received 1 to 10 units of
blood were transfused during the operation and the majority who received more
than 10 units were transfused postoperatively (Table V).
Survival
Omitting the transfusion variable, we
round, as expected, a significant
(p = 0.00001) difference with respect to
survival (log-rank test) in the follow-up
of Dukes’ stages A, B and C rectal
cancers, at 10 years — 77%, 42% and
23% respectively (Fig. 1).

o f V a ria b le s A c c o rd in g to Dukes' S tage*
S tage

Va riable

A (n = 65)

S ex
M ale
Fem ale
T y p e o f resectio n
Abdom ino p erineal
A n te rio r
P u ll-th rou gh
P o lyp e c to m y
Age, yr
P reo p hem oglobin, g/Lt
Preo p album in, g/ Lt
P reo p lym p h o c yte s ,
109/Lt
T ra n s fu s io n s , u n its
P erio p
P re o p t
Pero p
P o s to p f

x

±

'F ig u re s are m ean s
sta n d a rd d eviation.
t D a ta m issing: hem oglob in
8, album in

122

-

-

B (n -

73)

C (n = 60)

p value

0.2

30
35

43
30

29
31

5 9 .6
126
16
2 .2 4 8

52
4
6
3
±
±
±
±

11
19
14
1.262

6 0 .6
122
14
1.73 0

63
4
6
0
±
±
±
±

10.4
26
13
0 .56 2

57
2
1
0
±
±
±
±

4 .3
0 .2 8
2 .9
1.1

±
±
±
±

2.8
0.97
1.8
1.6

5.1
0 .7 7
2 .6
1.5

±
±
±
±

3.7
1.5
1.3
2.5

78, lym p h o c yte co u n t

= 17, pre

and posto p tra n sfu sio n

59.3
124
19
2.04 8

±

0.09
10.5
17
14
0 .9 3 3

4 .5
3.1
0 .5 2 ± 1
3 .2 ± 1.8
0 .8
1.9

±

0.8
0.5
0.3
0.01
0.39
0.07
0.3
0 .1 4

= 4.
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On the other hand, log-rank compari
son of survival according to the different
resection types or transfused versus nontransfused patients did not demonstrate
any statistical differences (Figs. 2 and 3).
However, actuarial survival was signifi
cantly (p = 0.0008) different according
to the number of blood units patients
received during the perioperative period.
At 10 years, for subgroups transfused
with 0, 1 to 5, 6 to 10 and more than 10
units, survival was 86%, 53%, 31% and
14% respectively (Fig. 4).
When multivariate adjustment for the
seven main variables studied simultane
ously (Cox’s regression analysis) was

applied to the population, the following
three variables had a significant predic
tive value on patient survival: preopera
tive hemoglobin level (p = 0.001),
Dukes’ stage (survival was better for stage
A compared with stages B and C
[p = 0.0001] and for stage B compared
with C [p = 0.001]) and the number of
blood units transfused (p = 0.03) (Table
VI).
Finally, in an attempt to determine if
the timing of transfusion had any
influence on survival, we found that the
number of peroperative blood transfu
sions was statistically significant
(p = 0.002) when com pared w ith

Table III--Distribution of Variables According to Type of
Resection*
Type of resection
Other
Abdominoperineal
(n - 172)
(n - 26)

p value
Variable
Sex
91
11
Male
0.3
81
15
Female
Dukes' stage
A
52
13
0.04
63
10
B
57
3
C
60 ± 10.3
58 ± 12.9
0.5
Age, yr
0.4
124 ± 22
120 ± 24
Preop hemoglobin, g/Lt
19.1 ± 14.2
Preop albumin, g/Lt
15.9 ± 14.2
0.3
Preop lymphocytes, * 109/Lt
1.914 ± 0.733
2.013 ± 1.015
0.6
Transfusions, units
4.5 ± 2.8
5.4 ± 5.1
0.4
Periop
0.9
Preopt
0.5 ± 1.2
0.5 ± 1.5
0.7
2.9 ± 1.5
2.8 ± 2.5
Perop
1 ± 1.8
2 ± 3.2
0.1
Postopt
'Figures are means ± SD.
tData missing: hemoglobin - 8, albumin - 78, lymphocyte count - 17, pre and postop transfusion
- 4.

Variable

Table IV--Distribution of Variables According to Transfused
Versus Nontransfused Groups*
Nontransfused
Transfused
(n = 7)
(n - 191)

p value

Sex
4
98
Male
3
1.0
93
Female
Dukes' stage
62
3
A
1
0.4
72
B
3
57
C
Type of resection
3
169
Abdominoperineal
2
8
Anterior
0
0.0001
13
Pull-through
2
1
Polypectomy
0.6
63.1 ± 16.3
59.7 ± 10.4
Age, yr
0.4
131 ± 13
123 ± 22
Preop hemoglobin, g/Lt
19.2 ± 18
0.6
16.4 ± 14
Preop albumin, g/Lt
1.738 ± 0.429
0.5
Preop lymphocytes, x 109/Lt
2.009 ± 0.995
Transfusions, units
—
4.8 ± 3.2
Periop
0.0001
0.56 ± 1.3
Preopt
3 ± 1.6
Perop
—
1.2 ± 2.1
Postopt
'Figures are means ± SD.
tData missing: hemoglobin - 8, albumin - 78, lymphocyte count - 17, pre and postop transfusion
= 4.

preoperative (p = 0.58) and postopera
tive units transfused (p = 0.73).
Discussion

The effects of blood transfusion on
host immunocompetence are o f growing
interest. The effects on renal transplan
tation, cancer surgery and host bacterial
infections have been summarized in an
excellent review by G eorge and
Morello.32
The immunosuppressive effect of
whole blood is used as a routine tool to
enhance allograft survival of transplanted
cadaver kidneys2-12,15,16,18 and is pro
portional to the number of units of
whole blood or packed cells adm i
nistered.9,13,14,17,19,20
On the other hand, there is a growing
suspicion that blood transfusion may
have an adverse effect on the outcome of
patients operated on for cancer and on
the rate of concomitant bacterial infec
tions. Retrospective studies have shown
this to be so in patients operated on
for colorectal cancer,22,25-27 lung tu 
mours,23,28 breast cancer29 and soft-tissue
sarcomas.30 Prospective studies have
shown that in patients with penetrating
abdominal trauma and in those who
undergo elective colorectal operations,
significantly more infections occurred in
recipients of blood even after adjustment
for other risk factors.24,31
In a recently published retrospective
analysis21 of 281 patients operated on for
cure of a Dukes’ stage A, B or C colorec
tal cancer, we concluded that the num
ber of units of blood transfused perioperatively had a strong negative influence on
patient survival regardless of the other
analysed risk factors. However, this
adverse effect could not be demonstrated
when patients with rectal cancer were
studied separately, although they received
more blood units than those operated on
for colonic cancer.
We hypothesized that the timing of
transfusion was important or the biologic
behaviour of rectal cancer differed from
that of colonic cancer as suggested by
Wolmark and colleagues33 and Foster
and colleagues26 or more simply that the
number of cases studied was not large
enough to reach valid statistical conclu
sions.
This prompted us to enlarge our series
of rectal cancer patients transfused and
not transfused.
The present study shows that regard
less of the stage of the disease, the type
of surgery, the preoperative hemoglobin
level and the other variables, the number
of blood units transfused during the peri
operative period has a negative effect on
patient survival (Table VI).
Other risk factors singularly important
are the stage of the disease and the
preoperative hemoglobin level (Table VI).

VOLUME 31, NO. 2, M A R C H 1988 / THE CANADIAN JOURNAL OF SURGERY

123

It should be noted, however, that the
Pearson test indicated a strong and sig
nificant correlation only between the
preoperative hemoglobin level and the
number of transfusions given preoperatively not between peroperative and
postoperative blood units administered.
The data also indicate that the timing
of transfusions may be important since
the num ber of units administered
peroperatively had a prognostic value
(p = 0.002). On the other hand, it should
be noted that most (95%) of the patients
were transfused peroperatively (Table I),
and, o f a total of 905 units of blood, 582
were administered during the operation.
It could be argued that the number of
units transfused relates to the type of
resection, and the form of surgery like
wise is related to the stage of the disease.
Hence, the influence of the number of
blood units administered could be related
to the Dukes’ stage. Actually, the mean
number o f transfusions was almost the
same, regardless of Dukes’ stage or the
type of surgery. The patients receiving the
most blood units (six and more) were
those who underwent a pull-through
procedure, even though those operations
were performed mostly for Dukes’ A and
B disease. The opposite should have been
the case if the transfusion influence was
really related to the stage of the disease
through the type of resection.
It is well known that for equivalent
stages, rectal cancer has a worse progno
sis than colonic cancer. This has been
attributed to a difference in biologic
behaviour between the two.26’33 On the
other hand, more blood transfusions are
needed during the surgery for rectal than
for colonic cancer. We are currently
studying a population of patients oper-

FIG. 1—Survival for Dukes’ stage A (65 patients), B (73 patients) and C (60 patients) rec
tal cancers (log-rank analysis) shows significant difference (p = 0.00001); 10-year survival rates
for stages A , B and C are 77%, 42% and 23% respectively.

FIG. 2—Survival for abdominoperineal (AP, 172 patients) versus other types (O, 26 patients)
of rectal cancer resection. Log-rank analysis showed no significant difference (p = 0.4).

Table V—Distribution of Variables According to Number of Blood Units Transfused*
0
(n - 7)

Variable
Sex
Male
Female
Dukes' stage
A
B
C
Type of resection
Abdominoperineal
Anterior
Pull-through
Polypectomy
63
Age, yr
131
Preop hemoglobin, g/Lt
19
Preop albumin, g/Lt
1.738
Preop lymphocytes, x 109/Lt
Transfusions, units
Preopt
Perop
Postopt
‘ Figures are means ± SD.
tData missing: hemoglobin - 8, albumin -
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Blood transfused, units
1 to 5
6 to 10
(n = 131)
(n - 45)

>10
(n - 11)

4
3

70
61

20
25

5
6

3
1
3

47
45
39

10
19
16

3
7
1

3
2
0
2
±
±
±
±

118
6
6
1
60 ± 9.7
128 ± 24
16 ± 13
2.071 ± 1.087

41
1
3
0
58.8 ± 11.5
112 ± 24
12.7 ± 13
1.786 ± 0.668

6
1
4
0
±
±
±
±

0.2 ± 0.7
2.5 ± 1
0.5 ± 0.9

1.5 ± 1.8
4 ± 1.7
1.8 ± 1.5

-

-

16.3
13
18
0.429

bb.1
115
28
2.181

p value

0.7
0.2

0.00001
11.6
20
17
0.910

1.3 ± 1.9
5.5 ± 2
7.2 ± 3.8

0.2
0.0003
0.1
0.3
0.00001

78, lymphocyte count = 17, pre and postop transfusion - 4.
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ated on for colonic and rectal cancer to
determine if the negative transfusion
effect can account for the inferior prog
nosis of the rectal tumour, generally
attributed to its localization.
Whatever the mechanism of this
deleterious transfusion effect it is tempt
ing to correlate it to the same immuno
logic effect that enhances allograft sur
vival in renal transplantation.34-36

Randomized prospective studies using
whole and leukocyte-free or autologous
blood are needed to prove that
hypothesis.
We thank Francine Fugere, Johanne Trahan
and Guy Jean for their technical assistance in
compiling the data. The statistical analysis was
done by Les Services a la recherche JTD Inc.,
Montreal.

FIG. 3—Survival for transfused (T, 191) versus nontransfused (NT, 7) patients with rec
tal cancer. Log-rank analysis showed no significant difference (p = 0.09).

FIG. 4—Comparison by log-rank analysis o f survival by number of blood units received
(determined in 194 patients) (p = 0.0008). Ten-year survival rate for patients not transfused
(7) and those receiving 1 to 5 units (131), 6 to 10 units (45) and more than 10 units (11) was
86%, 53%, 31% and 14% respectively.
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Analysis of a Protocol
for an Autologous Blood Transfusion
Program for Total Joint Replacement Surgery
This retrospective study analysed an
autologous blood transfusion program for
total joint replacement surgery. A group
of 99 patients receiving autologous
blood transfusion was compared with a
control group of 55 patients. One-unit
phlebotomies were done 14 and 7 days
before surgery. The whole blood was
transfused intraoperatively. Preoperative
hemoglobin values were within the normal
range for all patient groups except the
female autologous blood group for which
the mean value was 122 ± 11.3 g/L.
Due to perioperative hemodilution, the
postoperative hemoglobin values were
substantially lower than preoperative
values for all groups. Mean intraopera
tive blood loss was similar for the
autologous and control groups (650 to
750 ml). IMo adverse reactions were
associated with the autologous transfu
sions and 7 4 % of the autologous group
received autologous blood only. From
this analysis a 3-week, three-unit
preoperative collection was proposed for
future use. A standardized protocol will
allow logistical ease and implementation
of the program for various surgical
procedures.
Cette 6tude retrospective se penche sur
un programme de transfusion de sang
autologue utilise lors des arthroplasties
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totales de la hanche. Un groupe de 99
patients qui ont recu une transfusion de
sang autologue a ete compare a un
groupe temoin de 55 patients. Des phle
botomies d'une unite de sang furent pratiquees 14 et 7 jours avant I'intervention. Des transfusions de sang entier
furent effectuees durant I'operation.
L'hemoglobinemie preoperatoire s'est
reveiee a I'interieur des limites de la normale pour tous les groupes, sauf pour
les femmes du groupe recevant du sang
autologue, dont la valeur moyenne s'etablissait a 122 ± 11.3 g/L. A cause de
I'hemodilution peroperatoire, I'hemoglobinemie postoperatoire etait beaucoup plus
basse que la mesure preoperatoire, et
ceci pour tous les groupes. La deperdi
tion sanguine moyenne durant I'operation
a ete semblable pour le groupe ayant
recu du sang autologue et pour le groupe
temoin (de 650 a 750 ml). Aucune reac
tion indesirable n'a ete reliee aux transfu
sions de sang autologue et 7 4 % de ce
groupe n'ont recu que du sang autolo
gue. A partir de cette analyse, une collecte de trois unites de sang repartie sur
3 semaines est suggeree pour I'avenir.
Un programme standardise offrira une
flexibilite logistique et permettra la mise
en oeuvre de ce programme pour diverses interventions chirurgicales.

The first reports of the use o f autologous
blood transfusion for orthopedic surgery
were by Miller,’ in 1885, for a hip ampu
tation and by Duncan,2 in 1886, for a leg
amputation. The transfusion method was
intraoperative blood salvage and reinfu
sion, which is one o f three clinically
applicable forms of autotransfusion, the
others being preoperative blood collection
and storage, and hemodilution and
autotransfusion.

Recently, preoperative blood collection
and storage has been used in elective total
joint replacement surgery.3"8 In these
reports, blood storage has been as fresh
whole blood,4’6 a mixture of fresh whole
blood and frozen packed cells,5,8 a mix
ture o f fresh whole blood and frozen
whole blood,3 and all units as frozen
whole blood.7 The protocol for autolo
gous transfusion was either individualized
or only partly standardized to a pre-set
schedule. The number o f units collected
per patient therefore varied greatly within
each report. No reported programs have
standardized all o f the following: the
number o f units to be collected preoperatively, the preoperative timing o f the
phlebotomies, the storage o f the collected
units as fresh whole blood and the rou
tine intraoperative transfusion o f the
collected units of blood. Analysis o f a
program designed with these four stan
dardizations and of logistic ease for
patients, surgeons, consulting physicians,
anesthetists and blood-bank personnel
would provide useful information for
future planning for autologous blood
transfusion programs. At the Calgary
General Hospital, preoperative storage o f
two units of whole blood to be transfused
intraoperatively has been in effect since
1977 for patients scheduled to undergo
total joint replacement. This retrospective
study analyses the autologous transfusion
program for elective total joint surgery
from 1982 to 1986 inclusive.
Program Design and Methods
This program was designed as a stan
dardized protocol for logistic ease.
• Having decided to undergo surgery,
patients are invited to participate in the
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autologous transfusion program if they
weigh more than 45 kg and have no his
tory of ischemic heart disease, cerebrovas
cular accident or chronic anemia.
• The family practitioner or internist
assesses the patient and affirms that the
hemoglobin level is greater than 120 g/L.
• The examining physician sends the
director of the blood bank a letter verify
ing medical clearance and requests
arrangements be made for phlebotomies
at the hospital hematology clinic approx
imately 14 and 7 days before the sched
uled surgery (the second phlebotomy is
always done more than 72 hours before
the scheduled surgery).
• Patients are instructed to take iron
and vitamin B supplements from the time
of the first phlebotomy (ferrous gluconate
300 mg orally three times daily and Stress
Caps T orally daily).
• The units of whole blood are typed
and screened and stored with citrate phos
phate dextrose adenine - 1 (CPDA-1)
solution as a preservative at 4°C in the
hospital blood bank.
• When the patient is admitted for sur
gery the collected autologous blood is
cross matched.
• The autologous whole blood is trans
fused intraoperatively, and if for some
reason it is not transfused it is discarded.
This program is designed to permit an
interval of 1 month from initial consent
to completion of surgery. From 1982 to
1986 inclusive, 99 patients who underwent
total joint replacement surgery (95 total
hip and 4 total knee) were in the autolo
gous transfusion program. One surgeon
performed the operation in 87 of these
patients. During the same period, the
same surgeon performed 55 total joint
replacements on patients who were not in
the autologous transfusion program.
They were used as a control group: they
included patients eligible for the autolo
gous transfusion program but inadver
tently not so informed, patients who did
not meet the appropriate hemoglobin,
weight and medical history criteria,
patients whose altered operation sched
ule did not permit the right timing for the
phlebotomies and patients whose blood
clotted at the time of phlebotomy or

whose antecubital veins were too small.
Both groups of patients were compared
as to sex, age, preoperative and postoper
ative hemoglobin levels, estimated
intraoperative blood loss, transfusion
morbidity and total transfusion require
ments.
Comparison of preoperative and post
operative hemoglobin levels was consi
dered of questionable value. A change in
hemoglobin could be due to perioperative
hemodilution. To study this further, the
preoperative hemoglobin levels were used
in a calculation to correct for any change
in hematocrit from preoperative to post
operative samples (Table I). An apparent
change would show the calculated
hemoglobin value equal to the actual
measured postoperative hemoglobin
value. The calculated hemoglobin was
equal to preoperative hemoglobin multi
plied by postoperative hematocrit and
divided by the preoperative hematocrit.
Estimated mean intraoperative blood
loss plus the standard deviation of this
mean plus an estimated 100 ml postoper
ative loss was used in estimating the
potential blood transfusion requirements
of the surgical procedure. With standard
normal population statistics, the mean
plus the standard deviation of the mean
equals a value equal to or greater than
that of 84% of the population. Likewise,
the mean plus two standard deviations
equals a value that will be greater than or
equal to that in 97.7% of the popula
tio n .9 These statistics were used in
predicting the blood requirements for
patients in the study. The Student’s /-test
was used to analyse differences in the
findings. The significance level used was
p = 0.01.

Table II--Autologous and
Age,
No.
Group
Autologous
42
Male
57
Female
Control
21
Male
34
Female
Differences were not significant.

Findings
The sex and ages of the patients in the
two groups are shown in Table II.
Hemoglobin values were obtained for
all patients preoperatively and on the day
after surgery. Preoperative hemoglobin
values were within the limits of the nor
mal for the hospital (male 135 to 180 g/L ,
female 125 to 164 g/L) except in the
group of women who had autologous
transfusions, whose values were below the
normal range (Table I). Preoperative and
postoperative hemoglobin values for the
control group were significantly higher in
all patients than for the autologous
group. Postoperative hemoglobin values
for both sexes o f both groups were sig
nificantly (p < 0.01) lower than the
preoperative values (Table I). The calcu
lated hemoglobin value was not signifi
cantly different from the measured
postoperative hemoglobin within any
group. The hemoglobin of any patient
who received only the intraoperative
autologous transfusions tended to return
to preoperative values (determined by the
hematocrit or hemodilution) during the
hospital stay (Fig. 1).
Intraoperative blood loss, ranging from
650 to 750 ml, was similar for both sex
and group (Table I).
Transfusion reactions (increased tem
perature) occurred in only two patients;
one who received autologous and
homologous transfusions and in a patient
who received homologous transfusion
alone. In the autologous group, 3% did
not receive autologous blood; 5%
received only one unit of autologous
blood (only one unit collected or given)
(Table III). Ninety-one percent of patients

Control Groups: Ages
yr (mean + SD)

Age range, yr

64 ± 9.1
62 ± 12.2

37 - 78
26 - 87

67 ± 9.6
70 ± 12.1

54 - 83
35 - 84

Table I—Autologous and Control Groups: Hemoglobin and
Estimated Blood Loss (Mean ± SD)
Hemoglobin, g/L
Calculated*
Postop

Blood loss, ml
Preop
Group
Autologus
650 ± 238
122 ± 13.84
124 ± 11.8
138 + 9.3
Male
750 ± 311
115 ± 11.94
112 ± 13.3
122 ± 11.3
Female
Control
650 ± 224
127 ± 15.5
129 ± 15.5
144 ± 17.14
Male
700 ± 33
118 ± 12.6
119 ± 12.14
134 ± 14.1t
Female
‘ Calculated hemoglobin - preoperative hemoglobin x postoperative hematocrit + preoperative hematocrit.
tFor 1984 patients only.
^Significantly higher than autologous group values, p < 0.01.
All calculated hemoglobin values not significantly different from postoperative values within a group. All blood loss estimates not significantly different.
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blood loss of approximately 650 to 750
ml in major orthopedic surgery. Age
alone does not appear to exclude patients
from entering the program as 30% were
more than 70 years old, and other
investigators3-8'10 have not applied age
restrictions. In addition, blood donations
by healthy people aged 66 years and older
are carried out without any difference in
immediate or short-term reactions when
compared with donors 55 to 65 years
old.11 Both men and women had signifi
cantly (p < 0.01) lower hemoglobin levels
preoperatively than the control group;
however, the difference between the con
trol and autologous group values was
equal to (women) or less than (men) the
drop in hemoglobin noted in healthy sub
jects who underwent a one-unit phlebot
omy followed by iron supplementation
and reassessment of their hemoglobin
level at 2 weeks.10 Therefore, even with
the second phlebotomy 7 days after the
first, in this study patients were able to

in the autologous group received the two
units of whole blood while in hospital and
26% received extra packed-cell transfu
sions during their hospital stay. Conse
quently, requirements were met with
autologous blood only in 74% of
patients. Also, in the autologous group,
transfusion requirements were met with
two units or less of either autologous or
homologous transfusions in 74%, with
three units or less in 82% and with four
units or less in 95% (Table III). The
results were similar for the control group.
The average number of units given in the
autologous group was 2.48 compared
with 2.25 for the control group.
Discussion

This retrospective study demonstrated
that an autologous transfusion program
designed to have two units of whole blood
available for intraoperative transfusion is
feasible and sustains an intraoperative
Example 1. - Postoperative Hemodilution

Example 2. - Postoperative Hemoconcentration

FIG. 1—In-hospital hemoglobin levels for patients receiving only intraoperative autolo
gous blood, x = measured hemoglobin value, o = hemoglobin value corrected for hemodilution
by using hematocrit.

maintain their hemoglobin levels equally
well. It is well known that repeated phle
botomies of greater frequency and larger
total volume than we report cause no
adverse effects if sufficient time elapses
to allow correction of the hemoglobin
level, and the patient is provided with ade
quate iron supplementation.12’13 Phlebot
omy can stimulate red-cell production
three to five times that of normal.12
Therefore, in this study, the cause of the
lower preoperative hemoglobin level in
the autologous group compared with the
control group could be due partially to
insufficient time for optimal hematopoi
esis or to inadequate iron supplementa
tion, which was based solely on patient
compliance. The 2 weeks from initial
phlebotomy to surgery are inadequate for
complete recovery of hemoglobin levels
especially from two phlebotomies. The
literature suggests that 3 weeks are ne
cessary for hemoglobin to return to
the pre-phlebotomy value.10 Patients
depositing between 1 and 10 units of
blood preoperatively, over a period of 2
to 20 weeks have shown no significant
difference in preoperative hematocrit
compared to a control group of patients
who did not deposit blood.3
The postoperative drop in hemoglobin
value could be due to either transfusion
of blood that had less hemoglobin per
blood cell or hemodilution from intra
venous fluids. The former would not be
a significant factor in the autologous or
homologous transfusions; therefore,
hemodilution was thought to be the cul
prit. The hemodilution was also demon
strated by the trend for hemoglobin and
hematocrit levels to return to preopera
tive values during the patient’s hospital
stay. Intravenous fluid hemodilution
takes time to correct, the interval depend
ing on the concentration of sodium,14
which may be increased if saline was used
intraoperatively.
In our autologous transfusion pro
tocol, the preoperative hemoglobin level
is essentially maintained, in the majority
of patients, both during the surgery and
postoperatively, by the intraoperative
transfusion of two units of whole blood.

Table III—Autologous and Control Groups: Transfusion Data
Units transfused
Group
Autologous
Autologous
blood only
(cumulative
frequency, %)
All transfusions
(cumulative
frequency, %)
Control
Packed red cells
(cumulative
frequency, %)

128

0

1

2

3

4

5

6

3 (3)

5 (5)

91 (100)

2 12)

2 (4)

69 (74)

18 (82)

13 (95)

4 (99)

1 (100)

4 (7)

6 (19)

30 (73)

7 (85)

5 (95)

1 (96)

2 (100)

Mean
units/
patient
2.48

2.25
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This quantity could replace an average
blood loss of 650 to 750 ml for the total
joint procedures in both the autologous
and control groups. Mean blood loss plus
the standard deviation of the mean plus
100 ml postoperative loss equals a twoto three-unit volume for all groups. The
oretically, in 84% of patients three units
or less should replace blood lost, as con
firmed by the data of this study.
The intraoperative blood loss of 650 to
750 ml in our series is markedly lower
than that reported in the literature for
other autologous blood transfusion
studies in total joint replacement.3' 5 As
well, the others also had a lower percen
tage of patients receiving only autologous
blood. In this study, patients in the
autologous group having total joint sur
gery required less autologous blood and
less added homologous transfusion per
patient and at the same time met the
transfusion requirements of a higher per
centage of patients by autologous trans
fusion alone than any reported work for
total joint surgery.
The number of units to be collected
should be determined on the basis of
blood loss for a particular procedure. A
3-week interval from initial phlebotomy
to surgery would help in restoring the
patient’s hemoglobin to a normal level
preoperatively by increased erythropoiesis, assisted by iron medication. Using
CPDA-1 as a preservative, blood may be
stored for 35 days making it possible to
collect five units of autologous blood
preoperatively. In analysing our protocol,
a change to a 3-week, three-unit preoper
ative collection, while maintaining the
oral iron and B vitamin supplementation,
could allow 84% of patients to receive
only autologous blood. If prudent guide
lines for further transfusions were estab
lished, a statistical estimate of 97.7%
(mean ± SD) of patients could receive

only autologous blood; that is, the statis
tics of four units or less could perhaps be
achieved with three units.
In assessing the need for n&.isfusions,
we noted that the average total units of
transfusion per patient was higher for the
autologous than the control group, solely
owing to the fact that the control group
did not routinely receive two units of
blood intraoperatively.
Febrile transfusion reactions were
observed in 2 (2.47%) of 81 patients
receiving a homologous transfusion. An
autologous transfusion program, met by
autologous blood alone, would eliminate
these reactions and other potential post
transfusion complications, such as hepa
titis, acquired immune deficiency syn
drome, toxoplasmosis and cytomegalovi
rus infection.
Conclusions
An autologous transfusion program is
feasible if the protocol is standardized for
the number of units to be collected
preoperatively for a specific procedure,
preoperative collection times, the storage
of these collected units as fresh whole
blood and routine intraoperative transfu
sion of the collected units of blood. The
logistics with this protocol are simple for
patients, surgeons, consulting physicians,
anesthetists and blood-bank personnel.
Standardization of a program also
ensures no mistake as to who introduces
the autologous program to the patient,
what guidelines are used to exclude
patients from the program, who does the
medical assessment of the patient, who
assesses the phlebotomies, on which days
the phlebotomies are done, what sup
plementation the patient should take, the
in-hospital arrangements for intraopera
tive transfusion and the use of nontransfused autologous blood.

The protocol for the autologous pro
gram in this study was completely success
ful for 74% of patients who received only
autologous blood. Using as guidelines the
calculated blood loss of the total joint
procedure and the time needed for
increased hematopoiesis to correct the
loss by phlebotomy, it is concluded that,
for total joint replacement, a 3-week, threeunit preoperative collection protocol
would improve the percentage of patients
receiving only autologous blood as well
as the preoperative hemoglobin level and
the ongoing erythropoiesis at the time of
surgery.
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Relationship Between Deep-Vein Thrombosis
in the Calf and Fatal Pulmonary Embolism
Deep-vein thrombosis of the lower limb
is common, yet the importance of iso
lated calf deep-vein thrombosis is poorly
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understood and the treatment is con
troversial.
This retrospective study documented
that 13% of fatal pulmonary emboli
originated only from calf deep-vein
thrombosis. This rate is similar to that in
another study (15% ), suggesting that
isolated calf deep-vein thromboses do
produce fatal pulmonary emboli.
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La thrombose veineuse profonde d'un
membre inferieur est frequente. N6an-
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moins, on comprend mal ('importance
d'une thrombose veineuse isolee du mollet et son traitement fait I'objet de dis
cussion.
Cette etude retrospective montre que
13% des embolies pulmonaires fatales
originaient d'une thrombose veineuse
profonde du mollet. Ce taux est semblable a celui d’une autre etude (15% ), ce
qui indique que les thromboses veineuses profondes du mollet produisent
effectivement des embolies pulmonaires
fatales.
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Lower limb venous thrombosis usually
occurs in patients treated primarily for
unrelated conditions. It is a common
complication of orthopedic procedures
and can be fatal. Thromboses in the veins
o f the proximal thigh or pelvis are consi
dered dangerous,1-3 and most physicians
advocate anticoagulant th erap y ,4
whereas many physicians believe that
asymptomatic calf deep-vein thrombosis
(discovered on routine follow-up for
unrelated conditions, commonly ortho
pedic) is unimportant and needs no treat
ment.5 This study was conducted to
investigate the source of thrombosis in
cases of fatal pulmonary embolism.
Method
A retrospective chart review was con
ducted of patients who died of pulmonary
embolism at the Ottawa General and
Ottawa Civic hospitals over a 5-year
period. All were admitted to hospital for
problems other than venous thrombosis,
the embolism occurring as a complica
tion. Only deaths considered to be caused
by pulmonary embolism were studied.
Cases in which autopsy findings failed to
identify the cause o f death or location of
the deep-vein thrombosis were excluded.
Results
Pulmonary embolism was listed as the
cause of death on the charts of 152
patients; in 70 of these, autopsy was done,
and 59 registered autopsies failed to rev
eal the source of embolism. Autopsy find
ings confirmed pulmonary embolism as
the cause of death and identified the
source of embolism in 23 patients, who
formed the basis for this study. Sites of
thrombi were: pelvic veins 7, thigh veins
13 and calf veins 3.
Discussion
Lotke and colleagues3 stated that
deep-vein thrombosis in the calf, whether
large or small, is unlikely to produce
symptomatic emboli, and therefore anti
coagulation is unnecessary. They also
stated that thrombi limited to the calf
rarely form emboli.3 This is contrary to
the statement by Browse and Thomas1
that emboli can arise from any thrombus
and the calf, being the most common site
for thrombus, is therefore the most com
mon source of emboli. However, they
believed that lethal emboli originated in
the femoroiliac segments. In the opinion
o f Lowe,4 calf thrombi are important
and “ thrombi proximal to the popliteal
vein or greater than 5 cm in length in the
calf are significant because of immediate
risk of embolism and long term possibil
ity of venous h y p e rte n sio n .. .the
remainder, clots of less than 5 cm in
length in the calf veins are ‘not signifi
cant’ and may be observed by continu
ing I125 scanning” . These were arbitrary
130

criteria. Hirsh and associates6 believed
that if one chooses not to treat a calf
deep-vein thrombosis then the patient
must be followed up clinically as 20% of
such thromboses extend into the thigh.
This concept is supported by others.1'4-7’8
But are clots confined to the calf veins
capable of producing pulmonary emboli,
especially fatal pulmonary emboli? Harris
and colleagues2 stated, “ there is substan
tial evidence that it is the thrombi that
form in the veins of the thigh or iliac
region that are the principal sources of
major pulmonary emboli” . This remark
leaves open the possibility of a small per
centage originating only in calf veins, as
does the conclusion reached by Moser and
LeMoine9 that calf deep-vein thrombosis
poses a low risk of embolism. McKenna
and colleagues10 in a prospective study
of patients scheduled to undergo total
knee replacements used iodine-125labelled fibrinogen scanning and phlebo
graphy to show isolated calf vein
thrombi in 10 patients, 6 of whom
had pulmonary emboli documented on a
lung scan. In another study of 30 total
knee replacements, 16 patients had venographic evidence of thrombosis, resulting
in three pulmonary emboli. In these three,
the thromboses were located in the calf
veins and only one extended into the
popliteal and fem oral veins.11 The
authors stated that their study showed
“ an association between thrombosis of
the calf veins... and pulmonary embolism
in patients who have had total knee
replacements” .
Are some emboli from calf veins fatal?
Browse and Thomas1 stated “ the effect
of an embolus depends both upon its size
and the cardiovascular state of the
patient. Undoubtedly size is the most
important factor in a fit person, but one
or many small emboli can have a very
serious effect on the pulmonary circula
tion, especially if the heart is weak; hence
the potential danger of calf thrombosis
must not be ignored.” Very large emboli
straddle the pulmonary artery bifurcation
and cause rapid clinical deterioration.
Slightly smaller emboli blocking one pul
monary artery or a secondary lobar artery
result in less rapid changes. Multiple small
pulmonary emboli produce pulmonary
hypertension leading gradually to cardiac
failure or fatal arrhythmia. Sevitt and
Gallagher12 performed autopsies in 74
cases of death from pulmonary embolism
to investigate the size (length and
diameter) and number of the pulmonary
emboli and also to locate the origin,
which was: the iliofemoral veins in 61, the
inferior vena cava in 2 and the calf veins
in 11 cases. The rate of fatal pulmonary
emboli from thrombi in the deep veins of
the calf in this study was 15% (11 of 74),
a figure remarkably close to the 13% (3
of 23) found in our series. Most deep-vein
thromboses are asymptomatic so the

likelihood of an associated fatal pulmo
nary embolism still remains unanswered.
Most pulmonary emboli are asympto
matic. The majority of symptomatic pul
monary emboli are not fatal and in those
that are, only 13% to 15% originate in
the veins of the calf.
In my opinion the patient at most risk
of a fatal pulmonary embolism from
deep-vein thrombosis in the calf is the
elderly patient with limited cardiorespira
tory reserve in whom a small embolism,
or multiple small emboli, can trigger a
fatal arrhythmia. If there is no contrain
dication, full heparinization for 1 week
followed by oral anticoagulation for 3
months is recommended. Low-dose Cou
madin, as suggested by Harris and
colleagues2 is a safe alternative.
Until the exact rate of fatal pulmonary
emboli arising from isolated calf deepvein thrombosis is known, one cannot
compare the risk of heparinization with
that of observation; nevertheless, these
veins must be recognized as a source of
fatal pulmonary emboli.
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Correction
The November 1987 issue of the Jour
nal contains an error in the article by Dr.
M. Robinette. On page 407, in Case 1,
under discussion, the sentence “ Ureteral
‘danger areas’ are: the inferior mesenteric
vessels (during ligation), the ovarian fossa,
the rectovesical pouch, the ureterosacral
ligaments . . .” should read “ Ureteral
‘danger areas’ are: the inferior mesenteric
vessels (during ligation), the ovarian fossa,
the rectovesical pouch, the uterosacral liga
ments . .
We apologize to Dr. Robinette
and to our readers for this error.
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Thoracic Outlet Syndrome
With Congenital Pseudarthrosis of the Clavicle:
Treatment by Brachial Plexus Decompression,
Plate Fixation and Bone Grafting
Although a number of cases of congeni
tal pseudarthrosis of the clavicle have
been described in the literature, they pro
vide little direction for the treatment of
this condition when it is associated with
thoracic outlet syndrome. The authors
describe their experience with such a
case in a 20-year-old woman. Symptoms
of pain in the ulnar distribution of the
right forearm and discoloration of the
hand with abduction of the extremity
had developed over 3 years. The radial
pulse was obliterated by abduction of
the arm. Exploration of the brachial
plexus revealed a constricting band aris
ing from the distal fragment of the clavi
cle running to the first rib which,
together with the mass of the pseudar
throsis, comprised the thoracic outlet.
The patient was successfully treated by
division of the fibrous band, reduction of
the clavicle, internal fixation with a plate
and iliac crest bone grafting. At follow
up the patient had a full range of motion
in the shoulder and was asymptomatic.

Meme si on retrouve un certain nombre
de cas de pseudarthrose congenitale de
la clavicule dans la litterature, on y
decouvre peu de directives quant au traitement de cette affection lorsqu'elle est
associee a un syndrome du defile
thoraco-brachiale. Les auteurs ddcrivent
comment ils ont fait face d un cas semblable chez une femme de 20 ans. Sur
une periode de 3 ans, elle vit apparaitre
une douleur dans la region cubitale de
I'avant bras droit, accompagnee d'une
decoloration de la main avec abduction
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de I’extremite. Le pouls radial disparaissait a I'abduction du bras. A I'exploration
du plexus brachial, on a observe un
retrecissement partant du fragment distal
de la clavicule et allant jusqu'a la pre
miere cote; cette bande, ajoutee a la
masse de la pseudarthrose, venant
entourer la traversee thoraco-brachiale.
La patiente fut traitee avec succes par
division de la bande fibreuse, reduction
de la clavicule, fixation interne a I'aide
d'une tige et greffe osseuse de la Crete
iliaque. A I'examen de controle, la
patiente avait recouvre une pleine ampli
tude des mouvements de I'epaule et etait
asymptomatique.

In 1984 Bargar and colleagues1 reported
the first case of thoracic outlet syndrome
associated with congenital pseudarthro
sis of the clavicle. A 28-year-old woman
had complete relief of her symptoms fol
lowing resection of the pseudarthrosis and
the middle 3 cm of her clavicle. Wood2
reported a patient who had subclavian
vein thrombosis secondary to a congeni
tal pseudarthrosis of her right clavicle,
also treated by claviculectomy. The
patient had a good functional result.
Cases of thoracic outlet syndrome
associated with ununited clavicular frac
tures have been reported by WatsonJones,3 Ghormley and associates4 and
Pipkin.5 In Pipkin’s case the patient had
fractured her clavicle at ages 4 and 7 years
and vascular compromise developed sud
denly 32 years later.
Many unsolved issues surround both
the etiology and treatment of congenital
pseudarthrosis of the clavicle. Since
Fitzwilliams6 first described congenital
pseudarthrosis of the clavicle in 1910, 83
unilateral right-sided cases, 10 bilateral
cases, 4 left-sided cases (two associated
with dextrocardia, one with a large cer
vical rib and one unspecified) have been
reported in the literature.7-19 However,
medical literature provides little direction
for the treatment of congenital pseudar
throsis of the clavicle when it is associated

with thoracic outlet syndrome. We
recently treated such a patient in one stage
by brachial plexus exploration and
decompression combined with plating
and bone grafting of the clavicular
pseudarthrosis. To our knowledge this
method of treatment, which was success
ful, has not previously been reported.
Case Report
A 20-year-old woman, who was right
handed, presented to the Upper Extremity
Clinic with right upper limb complaints. Dur
ing the previous 3 years she had experienced
aching discomfort about her right shoulder and
pain along the ulnar aspect of her right hand
and forearm; the pain was burning in nature
and aggravated by carrying luggage or lifting
the arm above 90°. The dorsum o f her hand
became discoloured at times. Motor weakness
or loss of sensation had not occurred. She was
aware that her right clavicle was foreshortened,
with a swelling in its middle third; her parents
had been informed, in the patient’s early child
hood, that the mass was caused by a congeni
tal pseudarthrosis of the clavicle. Since the
mass was painless and did not present a cos
metic or functional deformity, no treatment
was indicated at that time.
On examination there was a 2-cm decrease
in the sternoacromial distance on the right com
pared with the left, and a firm, slightly tender
mass was present over the middle third of the
right clavicle. The two clavicular ends were pal
pable with the sternal portion lying superior
to the acromial segment. Movement was
elicited at the site of the pseudarthrosis. Pas
sive or active abduction of the right shoulder
to 90° decreased radial artery pulsation and
resulted in cyanosis on the dorsum of her hand
and a burning pain along the ulnar aspect of
the hand and forearm. There was no audible
bruit in the supraclavicular or axillary region.
Full range of motion was present in both the
glenohumeral joint and cervical spine. An xray film confirmed the presence of a pseudar
throsis in the middle third of the clavicle (Fig.
1).

With the clinical confirmation of thoracic
outlet syndrome associated with congenital
pseudarthrosis of the clavicle neither arteriog
raphy nor venography was performed. We
decided to explore the brachial plexus with the
objective of decompressing the thoracic out-
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let. We also wished to treat the clavicular
pseudarthrosis in such a manner that brachial
plexus compression would not recur and shoul
der strength would be maintained.
Through a transverse incision over the clavi
cle the proximal (sternal) end of the bone was
found to lie above the distal (acromial) aspect
and was directed posteriorly into the brachial
plexus, decreasing the size of the thoracic out
let. There was a thick fibrous band arising from
the medial tip of the acromial fragment, attach
ing to the first rib and further constricting the
thoracic outlet. The brachial plexus was decom
pressed by excision of the fibrotic band and
reduction of the clavicle; it was not necessary
to remove the first rib. The sclerotic ends of
the pseudarthrosis were trimmed, removing the
covering fibrocartilage. A chevron-type cut was
made in the distal (acromial) fragment to key
into a reverse cut in the sternal fragment; both
ends were cut back to bleeding bone. Good sta
bility was obtained by a contoured eight-hole
3.5-mm DC plate (Synthes [Canada] Ltd., Mis
sissauga, Ont.) that was applied to the superior
aspect of the clavicle. Iliac bone graft was

packed about the plate and at the pseudarthro
sis site. Postoperatively, the woman wore a
Velpeau-type support for 6 weeks after which
time the shoulder was mobilized with phys
iotherapy supervision. Two years postopera
tively there was solid union of the pseudarthro
sis and resolution of the thoracic outlet
syndrome (Fig. 2). The patient had a full range
of abduction and forward flexion (Fig. 3).

Discussion

Congenital pseudarthrosis of the clavi
cle is rare.7’8,10'13'14'19 It can be distin
guished from birth traum a,8 which
presents as a painful greenstick fracture
that shows evidence of callus formation
and usually heals. The lesion is a painless
transverse mobile pseudarthrosis and may
occasionally be part of the spectrum of
the syndrome of cleidocranial dysostosis.
Congenital pseudarthrosis of the clavicle
is not related to congenital pseudarthro
sis of the tibia,20 nor is it associated with

neurofibromatosis. In contrast, congen
ital pseudarthrosis of the tibia is
associated with neurofibromatosis in 40%
of cases21 and can present with varying
degrees of severity including a pre
fracture state consisting of bowing,
medullary canal sclerosis, diaphyseal con
striction or cystic changes.20 Pseudar
throsis in the clavicle generally heals
rapidly with excision and bone
grafting.8' 10'12,13'15'17’18
The etiology of congenital pseudarthro
sis of the clavicle is obscure. Because of
the predominance of right-sided lesions
(or left-sided lesions associated with dex
tro card ia), Lloyd R oberts and
colleagues14 suggested that “ the lesion is
sometimes due to pressure upon the
developing clavicle by the subclavian
artery which is normally at its highest
level on the right side” . They speculated
that this pressure may prevent ossification
of the middle third of the clavicle. Other
anatomic variations, such as vertically
positioned or elevated first ribs or the
presence of a cervical rib, may push the
subclavian artery against the middle third
of the clavicle, the area where congenital
pseudarthrosis occurs. In the developing
fetus, the impact of arterial pulsation may
cause resorption of bone. Others7 have
suggested that the condition results from
a failure of fusion of the two ossification
centres of the clavicle, but this was not
proven by embryologic studies.10
Most authors advocate nonoperative
treatment for congenital pseudarthrosis
of the clavicle unless there is intolerable
pain or a serious cosmetic deformity. Sug-

FIG. 1—Anteroposterior view showing congenital pseudarthrosis of right clavicle. Prox
imal (sternal) fragment lay superiorly and was directed posteriorly, compromising and constricting
thoracic outlet.

FIG. 1—Postoperative anteroposterior view 1 year after debridement of pseudarthrosis,
reduction of clavicle, application of 3.5-mm DC plate and autogenous iliac crest bone grafting.
Clavicle has united.
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FIG. 3—(a) Patient 1 year postoperatively.
Brachial plexus was explored through trans
verse incision along clavicle, (b) Patient had
full range of shoulder motion, no pain, nor
mal strength and no further symptoms or signs
of thoracic outlet syndrome.
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gested treatm ents for sym ptom atic
patients have included observation,11'13'19
excision o f the pseudarthrosis combined
with bone grafting,7’9'12’15'16’18 internal
fix a tio n w ith an in tra m ed u lla ry
p j n i, 4 ,i o ,i3 ,i6 ,2 i ancj partial1 and total
claviculectom y.3
Our patient, who was asymptomatic
for many years, presented with symptoms
related to the developm ent o f thoracic
outlet syndrome in association with con
genital pseudarthrosis o f the clavicle. This
association has previously been reported
only twice in the medical literature.1'2 A
fibrous band arising from the medial tip
o f the distal (acromial) fragment to the
first rib constricted the brachial plexus.
The proximal (sternal) fragment was
directed posteriorly into the brachial
plexus, further reducing the size o f the
thoracic outlet.
In our opinion internal fixation o f the
fragments using a plate was important
both to prevent redisplacement o f the
fragments into the brachial plexus and to
encourage sound union o f the clavicle.

The bone was o f sufficient quality to per
mit excellent fixation using 3.5-mm cor
tical screws. Intramedullary nailing would
have been difficult due to sclerosis o f the
bone ends. We believe the results we
obtained with reconstruction of the clavi
cle are superior with respect to cosm esis
and strength to those that would have
been p o ssib le w ith cla v icu lecto m y .
W ood2 has reported m ild weakness o f
the pectoral girdle follow ing claviculec
tom y. We wished to avoid shoulder weak
ness in our young, active patient.
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Multiple Giant Fibroadenomas
in an Adolescent Female Breast
Fibroadenomas are the commonest
breast masses requiring surgery in the
adolescent female, but multiple and giant
tumours are rare. This case report
describes the history and management
of a teenager who had multiple giant
fibroadenomas in one breast, eventually
requiring mastectomy and recon
struction.
The literature is reviewed. Tumours in
this age group are almost always benign,
even the giant and phyllodes tumours.
Malignant tumours are extremely rare.
Management should involve excision
with skin reduction if necessary. The
breast should be preserved if at all pos
sible.
Les fibro-adenomes sont les tumeurs
mammaires qui, chez I’adolescente,

From the Department o f Surgery, Health
Sciences Centre Hospital, University o f
British Columbia, Vancouver, BC
Accepted fo r publication Nov. 23, 1987
Reprint requests to: Dr. U. Kuusk,
410 - 2150 West Broadway, Vancouver, BC
V6K 4L9

necessitent le plus souvent la chirurgie;
les tumeurs multiples et les tumeurs
geantes sont rares. On decrit ici les ante
cedents et le traitement d'une adolescente porteuse de fibro-adenomes geants
multiples du sein qui, eventuellement,
necessiterent une mastectomie et une
operation de reconstruction.
La literature medicale est passee en
revue. Ches les femmes de cet age, les
tumeurs sont presque toujours benignes,
meme les tumeurs geantes et les
tumeurs phyllodes. Les tumeurs malignes
sont extremement rares. Le traitement
implique excision et chirurgie de reduc
tion lorsque ceci est necessaire. Le sein
est conserve lorsque cela est possible.

The adolescent female with a breast mass
represents only a sm all proportion o f
patients seen in general surgical practice.
Although fibrocystic problems do occur,
fibroadenomas are the comm onest surgi
cal condition in the area. Generally, the
diagnosis is simple, as is the surgery.
H owever, giant and multiple tum ours,
although quite uncom m on, can present
serious management problems.

Case Report
A 14-year-old girl was seen regarding a left
breast mass that she discovered herself. She had
never taken oral contraceptives nor been preg
nant. Menarche was at 12 years of age. Nee
dle biopsy of the mass (2 cm in diameter) in
the upper breast confirmed a fibroadenom a.
She was seen 3 months later and now had two
masses, 1.5 cm and 3.5 cm in dimension, in
different quadrants of the left breast. A month
later when admitted for scheduled biopsy the
entire left breast was swollen with superficial
venous dilatation, redness and increased
warmth. Five tumours were palpable in the
breast, and the two larger ones were removed
using a superior circumareolar incision. On
pathological examination these were found to
be pericanalicular fibroadenomas. When seen
2 months postoperatively, a number of new
masses had developed and 1 year later about
half the breast was occupied by tum our.
Tumour growth then seemed to have stopped
for 2 years and no masses developed in the right
breast.
She was lost to follow-up for a year, but
when seen again at the age of 17 years the left
breast had become greatly enlarged and pain
ful, with countless masses. It was almost twice
the size of the right breast. There was redness,
thinning of the skin and persistent venous dila-
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tation. The nipple was now considerably lower
than that on the right breast (Fig. 1).
A subcutaneous mastectomy was performed
with the immediate implantation by a plastic
surgeon of a subpectoral tissue expander for
reconstruction. Pathological examination
showed that the breast was almost completely
replaced by innumerable fibroadenomas (Fig.
2), mainly pericanalicular (Fig. 3), variable in
type and up to 5 cm in size. The nipple-areolar
skin was banked in the labia for further use.
She had no recurrent problems when seen 6
months later at which time a permanent sili
cone prosthesis was inserted.

Discussion
This patient represents an interesting
problem in breast disease. With the
advent of conservation in breast cancer
surgery, fewer mastectomies are being
performed. In this case mastectomy
would seem a mutilating procedure for
benign disease. However, with the pain,
weight and the total involvement of the
breast, there was no alternative. In
general, almost any tumour of the adoles
cent breast can be removed with a rim of
normal tissue, thus preserving most of the
breast tissue, avoiding recurrence and
providing acceptable cosmesis.

FIG. 1—Appearance of enlarged, nodular
breast just before mastectomy.

Fibroadenomas are the commonest
tumours in adolescent breasts, and at least
25% are bilateral.1 A few of these, less
than 5%,2 are giant tumours. In the
literature, the definition of a giant tumour
varies from one having a diameter greater
than 5 cm to a mass weighing more than
500 g; less than 50 such tumours have
been reported. At one time, a giant
tumour was classified as a cystosarcoma,
but this diagnosis is no longer valid as
most of these tumours are benign and
most are fibroadenomas. In one series
and literature review of phyllodes
tumours of the breast, from 1927 to
1954,3 none were shown to behave in a
malignant fashion. Juvenile fibroade

FIG. 3—Photomicrograph of representative
fibroadenoma showing pericanalicular pattern
(hematoxylin and eosin, original magnification
x 400).

noma is different pathologically from that
of the adult, being more floridly glandu
lar and usually larger. These tumours can
grow rapidly over a period of months,
with superficial venous dilatation, redness
and warmth;3 the cause is unknown, but
it is not suggestive of an underlying malig
nant condition. Hormonal influences
have been postulated but not proven. In
general, even for giant tumours, conser
vation of the breast has been recom
mended if at all possible. Removal of
giant tumours with a skin reduction, using
a Makissok-type mammoplasty, has been
suggested, thereby reducing breast defor
mity from redundant skin.4
Multiple giant tumours have been
reported by Gogas and colleagues,5 Sandison and Walker,2 Ashikari and col
leagues,6 Wulsin3 and Nambiar and
Kutty;7 they are uncommon with no
more than 10 cases being described. Dis
tinguishing these cases from virginal
hypertrophy clinically may be difficult
because the latter may present as a nodu
lar breast and also be unilateral.
However, superficial venous dilatation
occurs only with the large fibroadenomas,
not in virginal hypertrophy.6 Diffuse
fibroadenomatosis presents in a fashion
similar to multiple fibroadenomas and is
also difficult to distinguish from virginal
hypertrophy. Only one case in the litera
ture has described bilateral multiple
fibroadenomas in an adolescent (18 years
old) serious enough to require bilateral
mastectomy.2 Also, there is only one
case report of a subcutaneous mastec
tomy and silicone implant for a giant
fibroadenoma in an adolescent,6 the
treatment of choice if mastectomy is
necessary.
In widely spaced, rather than con
fluent, multiple fibroadenomas, separate
removal of each tumour can result in
unsightly breast scarring but this may be
preferable to a mastectomy; each case
needs individual planning.
All cases of unusual pathologic fea
tures, such as phyllodes tumours, call for
appropriate consultation to avoid
unnecessarily extensive surgery of the
breast in these young women.
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Action
In vitro studies indicate that the bacterial action of CLAFORAN (cefotaxime sodium)
a sem i synthetic cephalosporin antibiotic, results from in hibition of cell wall
synthesis.

Indications and Clinical Uses
T re a tm e n t: CLAFORAN (cefotaxime sodium) may be indicated for the treatment
of in fections caused by susceptible strains of the designated micro-organisms
in the diseases listed below.
L o w e r re s p ira to ry tra c t in fe c tio n s : pneum onia and lung abscess caused by
Streptococcus pneumoniae (formerly Diplococcus pneumoniae), other streptococci
(excluding enterocci, e.g. S. taecalis), Straphylococcus aureus (penicillinase and
non-penicillinase producing), Escherichia coli, Hemophilus influenzae, (including
am p icillin resistant strains) and unspecified Klebsiella species.
U rin a ry tra c t in fe c tio n s : caused by Escherichia coli, unspecified Klebsiella
species (including K pneumoniae), Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated gonor
rhea caused by N. gonorrhoeae including penicillin resistant strains.
B a c te re m ia / S e p tic e m ia : caused by Escherichia coli, unspecified Klebsiella
strains and Serratia marcescens.
S k in in fe c tio n s : caused by Staphylococcus aureus (penicillinase and non
penicillinase producing, S. epidermidis, Group A streptococci, Escherichia coli,
Proteus mirabilis and indole positive Proteus.
In tra -a b d o m in a l in fe c tio n s : caused by Escherichia coli, and unspecified Kleb
siella species.
G yn e co lo g ica l in fe c tio n s : including pelvic inflammatory disease, endometritis
and pelvic cellulitis caused by E. coli, Group A streptococci and Staphylococcus
epidermidis, anaerobic bacteria including unspecified Peptococcus and Peptostreptococcus strains and some strains of Bacteroides fragilis. In several cases although
clin ica l cures were achieved, bacteriological follow up was not available.
Clinical experience with CLAFORAN in anaerobic infections is limited. CLAFORAN
has been used with some success in wound and intra-abdominal infections against
som e strains of unidentified Bacteroides and anaerobic cocci.
CLAFORAN has been shown to be active against some strains of Pseudomonas.
In the treatment of infections encountered in im munosuppressed and granulo
cytopenic patients, results of therapy with CLAFORAN have not been impressive.
CLAFORAN should not be considered in the treatment of enterococcal infections,
i.e. Streptococcus taecalis.
S pecim ens for bacteriologic culture should be obtained prior to therapy in order
to isolate and identify the causative organisms and to determine their suscep
tib ilitie s to CLAFORAN. Therapy may be instituted before results of susceptibility
studies are known; antibiotic treatment should be re evaluated once these results
becom e available.
P ro p h yla ctic U s e : The administration of CLAFORAN perioperatively (preoperatively, intraoperatively and postoperatively) may reduce the incidence of certain infec
tions in patients undergoing elective surgical procedures (e.g. abdominal or vaginal
hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified
a s contaminated or potentially contaminated.
In patients undergoing caesarian section w ho are considered to be at increased
risk of infection, intraoperative (after clamping the umbilical cord) and postoperative
use of CLAFORAN may also reduce the incidence of certain postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage
and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation
by mechanical cleansing as well as with a non absorbable antibiotic (eg. neomycin)
is recommended.
If there are signs of infection, specim ens for culture should be obtained for iden
tification of the causative organism so that appropriate therapy may be instituted.

infection occurs, therapy should be discontinued and appropriate measures taken.
A lthough CLAFORAN rarely produces alterations in kidney function, evaluation
of renal status is recommended, especially in severely ill patients receiving high
doses.
Patients w ith markedly im paired renal function should be placed on the special
dosage schedule recommended under Dosage and Administration, because nor
mal dosage in these individuals is likely to produce excessive and prolonged serum
antibiotic concentrations.
Positive direct Coomb’s test is known to develop in individuals d u rin g treatment
w ith the cephalosporin group of antibiotics, including cefotaxime sodium .
In laboratory tests a false positive reaction to glucose may occur w ith reducing
substances but not with the use of specific glucose oxidase m ethods.

Adverse Reactions
The m ost frequent adverse reactions with their frequency of occurrence a re :
H yp e rs e n s itiv ity (1.8%): Rash, pruritus, fever. L oca l (5%); Injection site inflam 
mation with intravenous administration. Pain, induration and tenderness after in
tram uscular injection. G a stro in te stin a l (1.7%): C olitis diarrhea, nausea and
vom iting. Symptoms of pseudomembranous co litis can appear d uring or after
CLAFORAN treatment. H e m ic a nd L ym p ha tic S yste m ( < 1 % ) : M ild, reversi
ble leukopenia, granulocytopenia and thrombocytopenia have been reported. Some
patients developed positive direct Coomb's test during treatment w ith CLAFORAN.
G e n ito u rin a ry S ystem ( < 1% ): Moniliasis, vaginitis. Liver ( < 1 % ): Transient
elevations in SGOT, SGFT, serum LDH and serum alkaline phosphatase levels
have been reported. K id ne y ( < 1 % ): Increased serum creatinine and BUN have
occasionally been observed. C e n tra l N e rvo us S ystem (0.2% ); Headache.

Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with CLAFORAN, no
specific information on symptom s or treatment is available. Treatment of over
dosage should be symptomatic.

Dosage and Administration
CLAFORAN (cefotaxime sodium ) may be administered intram uscularly or in
travenously after reconstitution (see Table with recommended mode of reconstitution
according to route of administration).

Reconstitution
For In tra m u s c u la r U s e : CLAFORAN should be reconstituted with Sterile Water
for Injection or Bacteriostatic Water for Injection in accordance w ith the volum es
recommended in the following table.

Reconstitution Table

Intramuscular

Guidelines for Dosage of CLAFORAN (cefotaxime sodium)
Daily Dose
Type of Infection

(g)

Frequency and Route

Uncomplicated
Gonorrhea

1

1 g IM (sing le dose)

Uncomplicated
infections

2

1 g every 12 hours
IM or IV

Moderately
severe to severe
infections

3-6

1-2 g every
8 hours IM or IV

Very severe
infections (e.g.
septicemia)

6-8

2g every
6-8 hours IV

Life-threatening
infections

up lo 12

2 g every
4 hours IV

To prevent postoperative infection in contaminated or potentially contaminated
surgery, recommended doses are as follows.
(a) 1 g IM or IV administered V 2 to I V 2 hours p rio r to the initial surgical incision
to ensure that adequate antibiotic levels are present in the serum and tissues
at the start of surgery
(b) 1 g IM or IV administered 11/2 to 2 hours following the first dose; for lengthy
operative procedures, additional intraoperative doses may be adm inistered, if
necessary, at appropriate intervals (IV 2 to 2 hours) during surgery

Warnings

(c) 1 g IM or IV administered within 2 hours following com pletion of surgery

Before therapy with CLAFORAN is instituted, it must be carefully determined whether
the patient has had previous hypersensitivity reactions to cefotaxime,
cephalosporins, penicillins or other drugs CLAFORAN should be given with caution
to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including
CLAFORAN should be administered w ith caution to any patient who has
demonstrated some form of allergy, particularly to drugs. If an allergic reaction
to CLAFORAN occurs, the drug should be discontinued and the patient treated
w ith the usual agents (e.g. epinephrine, antihistamine, pressor-am ines or
corticosteroids).
Pseudomembranous colitis has been reported with the use of cephalosporins
(and other broad spectrum antibiotics); therefore, it is im portant to consider its
diagnosis in patients who develop diarrhea during the administration of CLAFORAN.
T h is colitis can range from m ild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as CLAFORAN, alters the nor
m al flora of the colon and may p erm it overgrowth of Clostridium difficile or other
Clostridia. It has been established that a toxin produced by Clostridium difficile
is one primary cause of antibiotic-associated colitis.
M ild cases of colitis may respond to discontinuation of CLAFORAN and replace
ment with a suitable specific antibiotic. Moderate to severe cases should be manag
ed with fluid, electrolyte and protein supplementation as indicated. When the colitis
is not relieved by discontinuance of CLAFORAN administration or when it is severe,
an antibiotic specifically effective in antibiotic-associated pseudomembranous colitis
(e.g. vancomycin) or ether suitable therapy may be indicated. Other possible causes
of colitis should also be considered (see A v e rs e Reactions).

The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period.

Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped.
The second and third doses should be given as 1 g IM or IV at 6 and 12 hours
after the first dose.

Neonates, Infants, and Children
The following dosage schedule is recom m ended:
N eonates:

0-1 week of age
1-4 weeks of age

50 m g / kg IV q 12 h
50 m g / kg IV q 8 h

infants and children (1 m onth to 12 years): For body weights le ss than 50 kg,
the recommended daily dose is 50 to 100 mg / kg IM or IV of b o d y weight divid
ed into 4 to 6 equal doses, or up to 180 m g / kg / day for severe infections.
For body weights 50 kg or more, the usual adult dosage sh ou ld be used.
The maximum daily dosage should not exceed 12 grams.
Administration of CLAFORAN should be continued for a m in im u m of 48 to 72
hours after the patient defervesces or after evidence of bacterial eradication has
been obtained; a m inim um of 10 days of treatment is recom m ended for infec
tions caused by Group A beta-hemolytic streptococci in order to guard against
the risk of rheumatic fever or glomerulonephritis; frequent bacteriologic and clinical
appraisal is necessary d uring therapy of chronic urinary tract infectio ns and may
be required for several m onths after therapy has been com pleted; persistent in
fections may require prolonged treatment. Doses less than tho se recommended
should not be employed.

Precautions

Dosage for Patients with Impaired Renal Function

CLAFORAN (cefotaxime sodium) should be prescribed with caution in individuals
w ith a history of lower gastrointestinal disease, particularly colitis.
The safety of CLAFORAN in pregnancy has not been established. Consequently,
use of the drug in pregnant women requires that the likely benefit from the drug
be weighed against the possible risk to the mother and fetus.
Use of CLAFORAN in women of child bearing potential requires that the anticipated
benefits be weighed against the possible risks.
Cefotaxime is excreted in hum an milk in low concentrations. Caution should be
exercised when the drug is administered to nursing mothers.
Prolonged use of CLAFORAN may result in the overgrowth of nonsusceptible
organisms. Constant evaluation of the patient's condition is essential. If super

In patients with estimated creatinine clearance of less than 20 m L / m in / 1.73m2
the dose of CLAFORAN should be halved (see Precautions).
If serum creatinine values alone are available, the following fo rm u la (based on
sex, weight, and age of the patient) may be used to convert these values into
creatinine clearance.
M a le s : Weight (kg) x (140 - age) Females: 0.85 x above value
72 x serum creatinine

Administration
In tra m u s c u la r: CLAFORAN should be injected well within the body of a relatively

Approximate
Available
Vol. (mL)

Approx. Average
Concentration
(mg/mL)

2
3
5

2.2
3.4
6.0

230
300
330

‘ shake to dissolve.
For d ire c t in tra v e n o u s in je ctio n (b o lu s ) a nd / o r c o n tin u o u s in tra v e n o u s
in fu s io n ; 500 m g, 1 and 2 g vials should be reconstituted w ith at least 10 mL
of Sterile Water for Injection. Reconstituted solution may be further diluted with
50 to 1000 m L of the fluids recommended for IV infusion.

Reconstitution Table

Intravenous

Volume to be
Added to
Vial (mL)*

Approximate
Available
Vol. (mL)

Approx. Average
Concentration
(mg/mL)

500 mg viallO
1 g vial
2 g vial

10.2
10
10

50
10.4
11.0

95
180

Adults
The dosage of CLAFORAN should be determined by susceptibility of the causative
organisms, severity of the infection and condition of the patient.

Volume to be
Added to
Vial (mL)*

500 m g vial
1 g vial
2 g vial

Dosage

CLAFORAN is contraindicated in patients w ho have shown hypersensitivity to
cefotaxime sodium, the cephalosporin or the penicillin groups of antibiotics.

Contraindications

large m uscle such as the upper outer quadrant of the buttock (i.e. gluteus maximus); aspiration is necessary to avoid inadvertent injection into a blood vessel.
In tra v e n o u s : The intravenous route is preferable for patients w ith bacteremia,
bacterial septicemia, or other severe or life-threatening infections, or for patients
who may be poor risks because of lowered resistance resulting from such
debilitating conditions as malnutrition, traum a, surgery, diabetes, heart failure,
or malignancy, particularly if shock is present or im pending.
For bolus adm inistration a solution containing 1 or 2 g of CLAFORAN can be
injected over a period of 3 to 5 minutes. Using an in fusion system, it m ay also
be given over a longer period of time through the tub in g system by w h ich the
patient may be receiving other intravenous solutions. Butterfly* or scalp vein type
needles are preferred for this type of infusion. However, during infusion of the
solution containing CLAFORAN, it is advisable to discontinue tem porarily the ad
ministration of other solutions at the same site.
Reg'd TM of Abbott Laboratories.

'shake to dissolve.
S o lu tio n s fo r IV I n fu s io n : CLAFORAN is com patible w ith the follow ing infu
sion flu id s :
- Sterile Water for Injection
- 0.9% NaCI injection
- 5 % dextrose injection
- 0.9% NaCI and 5 % dextrose injection
- 0.45% NaCI and 5 % dextrose injection
- 0 .2% NaCI and 5 % dextrose in jection
- Sodium Lactate injection
- 5 % dextrose and 0.15% KCI injection
- Plasma-Lyte 56 Electrolyte Solution in 5 % dextrose injection
- Ringer's injection
- Lactated Ringer's solution
- Lactated Ringer’s with 5 % dextrose injection
CLAFORAN is also compatible with lignocaine 1%.
A solution of 1 g of CLAFORAN in 14 m L of Sterile W ater for Injection is isotonic.
S ta b ility o f S o lu tio n
S to ra g e : S olutions of CLAFORAN range from light yellow to amber, depending
on concentration and the diluent used. The solutions tend to darken depending
on storage conditions and should be protected from elevated tem peratures and
excessive light.
"R e g 'd TM of Baxter-Travenol Laboratories.
CLAFORAN reconstituted in the original vial as described under Reconstitution
maintains satisfactory potency for 24 hours at room tem perature (25°C) and for
48 hours under refrigeration (0-5°C). O nly freshly prepared reconstituted solu
tions may be further diluted with 50 to 1000 m L of the recom m ended infusion
fluids in V ia fle x " intravenous bags. S uch solutions m aintain satisfactory poten
cy for 24 hours at room temperature (25°C) and for 72 hours under refrigeration
(0-5°C). Any unused solutions should be discarded.
CLAFORAN reconstituted with 1% lignocaine m aintains satisfactory potency for
up to 24 hours at room temperature and 48 hours under refrigeration (reference
to lignocaine restrictions is advisable).
CLAFORAN solutions exhibit m axim um stability in the pH 5-7 range.
S p e c ia l In s tr u c tio n s : Parenteral drug products sh ou ld be inspected visually
for particulate matter and discoloration p rio r to adm inistration. S olutions of
CLAFORAN range from light yellow to amber, depending on concentration and
diluent used. The dry powder as well as solutions tend to darken, depending
on storage conditions.
In c o m p a tib ilitie s : Solutions of CLAFORAN m ust not be adm ixed with
am inoglycoside solutions. If CLAFORAN and am inoglycosides are to be ad
ministered to the same patient, they m ust be adm inistered separately and not
as a mixed injection.
Solutions of CLAFORAN should not be prepared w ith diluents having a pH above
7.5 such as Sodium Bicarbonate Injection.

Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder,
in vials containing 500 mg, 1.0 and 2.0 g of cefotaxime sodium (expressed as
acid on a dry basis).
S to ra g e ; CLAFORAN in the dry state should be stored at room temperature,
protected from light and heat.
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Membres du College royal, veuillez expedier a: College royal des medecins et
chirurgiens du Canada, 74 Stanley, Ottawa, O nt. KIM 1P4.
Subscribers please mail to: Information Systems, Canadian Medical Associa
tion, PO Box 8650, Ottawa, Ont. K1G 0G8.
Abonnes, veuillez expedier a: Systeme de diffusion d’informations, l’Association medicale canadienne, CP 8650, Ottawa, O nt. K1G 0G8.

CLASSIFIED ADVERTISING
As a further service to its readers the Canadian Journal o f Surgery is pleased to accept suitable classified advertisements. The deadline is 1 month before issue
date. Regular classified rates (for each insertion): $42.00 for the first 40 words or less, additional words 55C each (additional $16.00 for frame). Special Display
under 75 words, 2%" x 2" $105.00. $6.00 charge (first insertion only) for CJS box numbers. Display rates available on request.
Copy should be mailed to the Canadian Journal o f Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.

MICROSURGICAL COURSE — The Department of

Surgery, McMaster University, Hamilton, Ontario,
is now offering one week, on-going courses in
microsurgery, using animal facilities and video
tapes. These courses are for anyone interested in
small vessel anastomosis, nerve repairs, vas and
fallopian tube reconstructions. The laboratory is
organized to guide you through the basic microsurgical techniques to more advanced tasks with the
help of an assistant on a one-to-one basis. Please
call: Dr. A. Thoma, (416) 523-0019 for further in
formation.

—S88-09

CLINICAL BURN FELLOWSHIP: ON - Available
July 1, 1988 for six months or twelve months.
Regional Adult Burn Centre treating 120 patients
per year, clinical research. New ultramodern burn
centre, very well staffed, extensive research fund
ing. Please contact: Dr. Walter J. Peters, Ste. 224,
Turner Wing, Wellesley Hospital, 160 Wellesley
St. E., Toronto, ON M 4Y 1J3.
-S 8 8-1 2
CHIEF, DIVISION OF ORTHOPEDICS: ON - The

Ottawa Civic Hospital, a 922-bed teaching and
research facility closely associated with the
University o f Ottawa Faculty of Health Sciences
is seeking a new Chief for the Division of Ortho
pedic Surgery. The Division has 86 beds, 8 staff
members and a Royal College Training Program.
Spinal surgery has been a major clinical and
research focus. A regional trauma program is

136

planned and will be an area for future develop
ment. The hospital is expanding its basic and clin
ical research activities and applicants should have
a strong academic background. In accordance
with Canadian immigration policies, initial prefer
ence for this position will be given to Canadian
citizens and permanent residents of Canada.
Applicants should reply with their curriculum vitae
and the names of three references to: Dr. J.D.
Grimes, Vice President, Clinical and Research
Administration, Ottawa Civic Hospital, 1053
Carling Ave., Ottawa, ON K1Y 4E9.
-S 8 8 -1 6
ORTHOPEDISTS: US — Fargo Clinic — MeritCare,
one of the nation's largest multispecialty clinics,
is seeking several additional orthopedists. The
present department of five will be expanded to
meet the needs of our community as we complete
construction of the comprehensive orthopedic and
rehabilitation facility. Two PA's and a family phy
sician assist in musculoskeletal evaluations. Ad
ditional training in pediatrics, spine, and sports
medicine welcome but not required. Competitive
compensation and benefits. Tri-college communi
ty of 130 000 near western Minnesota lakes
region. Call: Dr. Dave Wiest or Dr. Chuck Ander
son, 1-800-437-4010 or send cv in confidence to:
Dr. Anderson, Box 2067, Fargo, ND 58123.
-S 8 8-1 3

GENERAL SURGEON: NWT -

required for ex
panding northern community. One active surgeon

on staff. Expansion of surgical work will occur
with opening of new hospital shortly. This post is
both challenging and lucrative. The city has ex
cellent facilities and schools. Please forward en
quiries to: Family Medical Clinic, PO Box 1559,
Yellowknife NWT X1A 2P2.

-S 8 8 -0 6

GENERAL/THORACIC SURGEON: US - Well es
tablished group in Philadephia area community
hospital is seeking a BC/BE associate to provide
general/thoracic surgery (no open heart). Please
send cv to: Box S 116 CJS
-S 8 8 -1 5

RESIDENCY IN
C A R D IO V A S C U LA R
A N D THO RAC IC SURGERY
Opening available July 1, 1988 and 1989 for threeyear training program in busy adult (600) and pedriatric (1 50) cardiac surgery program including arrhyth
mia surgery, heart and heart/ lung transplantation, and
vascular and thoracic surgery. Outstanding facilities
and fully accredited program at a major Canadian
university. ABS certification or eligibility required. If
not graduate of North American medical school,
MCCQE required. Please reply to:
Patricia A. Penkoske, MD
Department of Surgery
Room 2D2.09 Walter MacKenzieCenter
University of Alberta
Edmonton, AB

T6G 2R7
Tel: (403) 432-8057

S88-01
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is virtually lint free and non-ffaying to minim ize the risk
o f potential infections and foreign reactions
that could enhance scar form ation1;
adheres less to wounds and causes less disruption
of exposed and friable dermal capillary beds';
provides a drier wound site because it is 56%
and 26% more absorbent than 8 & 12 ply cotton gauze
sponges respectively1;
is more economical in use than cotton gauze sponges
and has shown overall sponge savings of 10 to 25% and more
in Canadian hospitals, not including savings
on non-adhering dressings, combine pads, post-op sponges
and nursing time.
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NU GAUZE* sponges are totally
Canadian made, are used
in the majority of Canadian
hospitals and exported
to many countries.
9

T

Reference: 1. Birdsell DC, Davidson JSD: A Report on Clinical Trials of NU GAUZE*
Rayon Sponges, Including In Vitro and In Vivo Comparisons with Conventional Cotton Gauze
Sponges. July 1986,

(J

I)
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•Trademark of Johnson & Johnson 'Johnson & Johnson 1986

...n o w comes the
Even Greater Stapler

■Soft, supple, flexible
• Resists kinking
• Yields secure knots
•Strong

Ultra Light Compact
disposable skin stapler
Automatically released staples
Improved staple visibility
Proven reliability
Allows for excellent accuracy
Quality stapler supplied inexpensively

the manageable monofilament.

F O R A DIFFpRENC
YOU CAN FEEL

THE SMOOTH ONE

NEWPRE-CYD1

|(ChlorhexidineGluconate)

ew Pre-Cyde is the only
germicidal antiseptic hand
wash that combines all the
effectiveness of chbrhexidine
with a gentle emollient to
sooth the skin

N

DEXON* PLUS
Excellent knot security plus superior handling
and smoother tissue passage.

Pre-Cyde Is safe, virtually
non-irritating,1and has a
pleasant emollient...for a
difference you can feel

quality professional products from
DAVIS+GECK
Cyanamid Canada Inc.

A TRADITION OF INNOVATION
Atria North, 2255 Sheppard Avenue East, Willowdale, (Ontario) M2J 4Y5

‘ Registered Trademark of Cyanamid Canada Inc.

